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Abstract 
The nuclear lamina is a filamentous network of B-type and A- type lamins that is 
part of the nuclear envelope and supports nuclear architecture in metazoans. 
Mutations in A-type lamins have been linked to a myriad of pathological conditions 
called laminopathies. Lamina-associated polypeptide 2α (LAP2α) is a mammalian 
nucleoplasmic chromatin-associated protein that binds to A-type lamins in the 
nuclear interior. This nucleoplasmic complex of lamin A and LAP2α has been 
implicated in the regulation of retinoblastoma protein-mediated cell cycle 
progression in tissue progenitor cells. In this study I analyzed the in vivo effects of 
disease-causing mutations in lamin A and in LAP2α using mouse models and 
patient cells.  
K32 mutations in A-type lamins cause severe congenital muscular dystrophy in 
humans and a muscle maturation defect in LmnaΔK32/ΔK32 knock-in mice. On a 
molecular level, mutant K32 lamin A/C protein was significantly reduced and 
mislocalized to the nucleoplasm. To test the hypothesis that an abnormally 
regulated pool of nucleoplasmic lamins in LmnaΔK32/ΔK32 mice may contribute to the 
disease phenotype, LAP2 was additionally deleted in these mice. In the double 
mutant mice the LmnaΔK32/ΔK32- linked muscle defect was not affected. Mutant lamin 
A/C was able to interact with LAP2, but unlike wild-type lamin A/C, loss of LAP2α 
did not affect its nucleoplasmic localization. However, like in wild type mice, loss of 
LAP2 in LmnaΔK32/ΔK32 mice impaired the regulation of tissue progenitor cells. The 
findings of this study suggest that the LAP2-linked functions of nucleoplasmic 
lamin A/C in the regulation of tissue progenitor cells are not affected in 
LmnaΔK32/ΔK32 mice and that a LAP2-independent assembly defect of K32 lamin 
A/C is predominant for the mouse pathology. 
The P426L mutation in LAP2α was identified in a patient to segregate with the 
Emery-Dreifuss Muscular Dystrophy phenotype. The P426L mutation in LAP2α did 
neither interfere with binding to lamin A/C nor did it affect lamin A/C expression and 
localization in primary patient fibroblasts and muscle biopsies. Interestingly, patient 
fibroblasts contained reduced pRb protein level and showed impaired cell cycle 
regulation in vitro. These data indicate that the P426L LAP2α mutation may affect 
the function of LAP2α in the pRb-mediated cell cycle control of tissue progenitor 
cells, which may in turn contribute to the disease phenotype. 
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Zusammenfassung  
Die Kernlamina ist ein fibrilläres Netzwerk, das als Teil der Kernhülle neben 
anderen Aufgaben vorwiegend für die Stabilität des Zellkerns sorgt. Seine 
Hauptkomponenten sind A-Typ Lamine (neben B-Typ Laminen), die verschiedene 
Krankheiten, sogenannte Laminopathien, verursachen können, sollten sie von 
Gendefekten betroffen sein. Das Lamina-assoziierte Polypeptid 2α (LAP2α) ist ein 
nukleoplasmisches Membranprotein, das den Teil der A-Typ Lamine bindet, der 
sich im Zellkerninneren befindet. Diese sogenannten intranukleären Komplexe (aus 
Laminen und LAP2α) spielen in der Regulierung der Zellzyklusprogression von 
Gewebsvorläuferzellen eine Rolle, die vom Retinoblastoma-Protein bestimmt wird. 
Um die von Mutationen in einem der beiden Bindungspartner oder durch das 
Fehlen von LAP2α verursachten in vivo Effekte näher zu bestimmen, analysierte ich 
insbesondere zwei Mutationen: Die Mutation K32 in A-Typ Laminen (unter 
Verwendung eines Doppelmutanten- Mausmodells)  und die Mutation P426L in 
LAP2α (unter Verwendung von Patientengewebsproben und primären Zellen). 
Die Mutation K32 in A-Typ Laminen verursacht eine schwere kongenitale 
Muskeldystrophie im Menschen und einen Muskel-Maturationsdefekt im transgenen 
LmnaΔK32/ΔK32 knock-in Mausmodell. Auf molekularer Ebene war das mutierte 
Protein signifikant reduziert und misslokalisierte ins Zellkerninnere anstatt an die 
Zellkernperipherie. Um die Hypothese zu testen, dass ein anormal regulierter Pool 
von Intranukleärkomplexen zum Krankheitsbild  der LmnaΔK32/ΔK32  Mäuse beitragen 
kann, löschten wir zusätzlich LAP2α aus, indem wir Lap2α-/- Mäuse mit 
LmnaΔK32/ΔK32  Mäusen kreuzten. In den daraus resultierenden Doppelmutanten war 
der auf der K32 Mutation basierende Muskeldefekt unverändert. Lamin ΔK32 
bewahrte seine Fähigkeit, an LAP2α zu binden; Seine intranukleäre Lokalisation 
wurde aber nicht - im Kontrast zum Wild-Typ Lamin - von LAP2α beeinflusst. 
Andererseits führte das Fehlen von LAP2α in LmnaΔK32/ΔK32 Mäusen zu einer 
veränderten Regulierung von Gewebsvorläuferzellen, genauso wie im Wild-Typ. 
Zusammenfassend lässt sich sagen, dass ein von LAP2 unabhängiger 
Assemblierungsdefekt des K32 Proteins für den Phänotyp bestimmend ist, obwohl 
die mit LAP2 in Zusammenhang stehenden Funktionen in der Regulierung der 
Vorläuferzellen nicht beeinträchtigt werden.  
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Die Mutation P426L in LAP2α wurde erst kürzlich entdeckt und segregiert mit einem 
Emery-Dreifuss Muskeldystrophie Phänotyp. Die Mutation wirkte sich weder 
störend auf die Fähigkeit von LAP2α aus, an Lamine zu binden, noch 
beeinträchtigte es die Expression oder Lokalisierung von Lamin A/C in primären 
Patienten- Fibroblasten oder Muskelbiopsien. Interessanterweise verfügen 
Patienten- Fibroblasten über weniger Retinoblastoma Protein und zeigten eine 
verminderte Zellzyklusregulierung in vitro. Diese Daten weisen darauf hin, dass die 
P426L Mutation die zuvor festgestellte Funktion LAP2αs in der pRb-bestimmten 
Regulierung der Zellzyklusprogression von Gewebsvorläuferzellen beeinflusst, was 
wiederum zum Krankheitsbild beitragen könnte. 
 
 
 
1 
 
  
Introduction 
 
  
 
 
 
2 
 
  
  
 
 
 
3 
 
  
The functional architecture of the eukaryotic nucleus 
In a eukaryotic cell, the nucleus is an essential organelle.  It stores genetic 
information and it is involved in the regulation of gene expression during 
development and differentiation, thereby defining the function and identity of the 
specific cell type in the organism. Nuclear architecture is important for nuclear 
function. Two major compartments, the nuclear envelope and the nucleoplasm, 
which contains chromatin, soluble nuclear substances and structural sub-
compartments contribute to the functional organization of the nucleus (Pederson 
2011). 
The nuclear envelope as depicted in Figure 1 consists of the outer nuclear 
membrane (ONM), the inner nuclear membrane (INM), the nuclear pore complexes 
(NPCs) and the nuclear lamina. The INM and ONM are joined at the periphery of 
each nuclear pore complex and build one continuous membrane system. The outer 
nuclear membrane is continuous with the endoplasmic reticulum (ER). The 
perinuclear space between ONM and INM, is an extension of the ER lumen. 
Despite their continuity the membranes are biochemically distinct. The double 
membrane system of the nuclear envelope serves as a barrier between the nucleus 
and the cytoplasm, allowing gated transport of macromolecules, including RNA and 
proteins, through the NPCs. Reviewed in (Burke and Stewart 2006; Stewart, Roux 
et al. 2007) 
 
Figure 1: Nuclear envelope organization 
(adapted from (Burke and Stewart 2006)) 
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Underlying the INM is a meshwork of intermediate filaments - called the nuclear 
lamina - attached to it through interactions with a multitude of integral membrane 
proteins. The nuclear lamina was originally described in ultra-structural studies as a 
fibrous component of the nucleus resistant to extraction by salt and detergents 
(Dwyer and Blobel 1976).  
The lamina provides structural support for the NE, determines largely the shape of 
the interphase nucleus, serves as an anchor point for NPCs (Gerace and Burke 
1988) and associates with chromatin both directly and indirectly by interaction with 
NE proteins of the LAP2 family discussed later, barrier-to-autointegration factor 
BAF, lamin B receptor LBR and HP1 (Foisner and Gerace 1993) and reviewed in 
(Zastrow, Vlcek et al. 2004; Broers, Ramaekers et al. 2006; Burke and Stewart 
2006) . In order to perform these functions, lamins are considered to possess a 
dynamic rather than an inflexible, rigid structure. 
Recently, a range of diseases generally termed the laminopathies have revived 
interest in the nuclear lamina and added to the view that the lamina is involved in 
more cellular processes than originally thought, particularly in regulatory activities. 
 
The nuclear lamins 
The nuclear lamins building up the nuclear lamina are type V intermediate filaments 
exclusively found in the nucleus and can be grouped in A and B-type lamins based 
on biochemical, structural and dynamic properties, sequence homologies and 
expression patterns. 
 
A-type lamins 
In man, A-type lamins originate from a single gene transcript encoded by the LMNA 
gene at 1q21.2-q21.3, alternatively spliced into Lamin A, Lamin C, Lamin AΔ10 and 
Lamin C2, reviewed in (Burke and Stewart 2006).  Lamin A and C are the major 
products and appear incorporated in the lamina in approximately equal amounts. 
Lamin AΔ10 (missing the 5’ end of exon 10 (Machiels, Zorenc et al. 1996)) and 
Lamin C2 are minor products, Lamin C2 being specific to the male germ line and 
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containing an alternate amino terminal domain arising from a separate start site 
encoding six unique amino acids (Alsheimer, von Glasenapp et al. 2000). With the 
exception of Drosophila melanogaster, A-type lamins are found in vertebrates only.  
A-type lamins are absent in mouse and human embryonic stem cells and re-
expressed after loss of pluripotency, first in embryonic endoderm, yolk sac and 
trophoblast. Subsequently, myoblasts start the expression of A-type lamins at the 
beginning of tissue differentiation in mouse at day E12.0 (Stewart and Burke 1987; 
Constantinescu, Gray et al. 2006). In many other tissues, lamin expression cannot 
be detected until after birth (Rober, Sauter et al. 1990). 
 
B-type lamins 
The human B-type lamins are encoded by two unlinked genes, LMNB1 at 5q23.3-
q31.1 encoding for Lamin B1 and LMNB2 at 19p13.3 encoding for Lamin B2 
(Hoger, Krohne et al. 1988; Hoger, Zatloukal et al. 1990). Lamin B3 is a splice 
variant of Lamin B2 and is expressed in mammalian male germ cells (Furukawa 
and Hotta 1993). B-type lamins are ubiquitously expressed throughout development 
and at least one type of B-type lamins is present in most cells. In contrast to A-type 
lamins, B-type lamins can be found in all metazoan cells. 
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Structure and posttranscriptional processing of lamins 
Like all other intermediate filaments, lamins consist of an α-helical rod domain, a 
globular amino-terminal head and a carboxy-terminal tail domain (Figure 2), 
reviewed in (Burke and Stewart 2006; Dechat, Gesson et al. 2010). As lamins are 
found exclusively in the nucleus, a nuclear localization signal (NLS) is located right 
after the rod domain (Loewinger and McKeon 1988).  
 
 
Figure 2: Structural domains of A-type lamins 
(adapted from (Dechat, Gesson et al. 2010)) 
 
 
Moreover, they contain a structural motif similar to an S-type immunoglobulin (Ig) 
fold and a CAAX box (C is cystein, A any amino acid with an aliphatic side chain, X 
any amino acid) at the C-terminus, which is important for their posttranscriptional 
processing. In prelamin A the CAAX motif is the CSIM sequence, in lamin B1 CAIM 
(Dhe-Paganon, Werner et al. 2002; Krimm, Ostlund et al. 2002). 
Posttranscriptional modification at this domain starts with farnesylation of the 
cystein, followed by removal of the –AAX by ER-associated endoproteases 
(Zmpste24 acting likely on prelamin A, and Ras-converting enzyme (Rce1) acting 
on Lamin B). Finally, the methyltransferase Icmt methylates the isoprenylated 
cystein. Farnesylation and carboxy-methylation make the lamins more hydrophobic 
and facilitate their tight interaction with the INM. Lamin A but not Lamin B 
undergoes a second endoproteolytic processing step by Zmpste24, removing 15 
amino acids from the C-terminus including the farnesylgroup to produce mature 
lamin A (reviewed in (Burke and Stewart 2006; Rusinol and Sinensky 2006; Dechat, 
Gesson et al. 2010)).  
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As a consequence of the loss of the farnesyl group, A-type lamins can more freely 
localize within the nucleus; In fact, a minor fraction of A-type lamins can be found 
inside the nucleoplasm where it is considered to perform specific functions. 
(Reviewed in (Burke and Stewart 2006; Rusinol and Sinensky 2006; Dechat, 
Gesson et al. 2010))  
Lamins form parallel coiled-coil dimers that further assemble in a head-to-tail 
fashion to form polar protofilaments (Stuurman, Heins et al. 1998). In vitro, higher 
order structures are built by anti-parallel association of protofilaments, including ca. 
10-nm filaments and paracrystalline structures (Ben-Harush, Wiesel et al. 2009). 
Lamin-interacting proteins 
 
Due to their intermediate-filament nature, lamins have been long believed to merely 
fulfill structural functions such as providing mechanical stability and shape to the 
nucleus. Recent findings and an ever growing number of interaction partners 
demonstrate that peripheral and nucleoplasmic lamins are implicated in many 
essential cellular processes such as transcription, DNA replication, cell cycle 
progression, and chromatin organization. These functions are mediated by a 
plethora of lamin interaction partners at the nuclear periphery and in the 
nucleoplasm (reviewed in (Zastrow, Vlcek et al. 2004; Wilson and Foisner 2010). 
Binding affinities of lamin interactions vary considerably and are often regulated in a 
cell cycle and cell type-specific manner. While some proteins are known to bind to 
lamins directly and relatively stable in the nuclear interior or at the nuclear envelope 
(see below), others feature a more transient interaction, like PCNA, c-Fos, 
retinoblastoma (pRb) and Oct-1, probably as a mean of their regulation (reviewed in 
(Wilson and Foisner 2010)). 
Figure 3 depicts binding partners of nucleoplasmic lamins with confirmed binding 
regions in the lamin polypeptide. These proteins are involved in gene expression, 
signaling and cell cycle control (continuous frames), chromatin organization 
(dashed frames) or other processes (dotted frame).  Arrows indicate the binding 
partners pRb and LAP2α, which will be described in greater details as they are of 
particular interest to the study described in the thesis. 
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Figure 3: Confirmed binding sites within Lamin A/C 
(adapted from (Dechat, Gesson et al. 2010)) 
 
 
At the nuclear periphery lamins interact with a multitude of integral membrane 
proteins of the INM (Schirmer and Foisner 2007). One major group of lamin-
interacting factors predominantly at the nuclear periphery but also in the nuclear 
interior is the LEM-domain protein family (LEM stands for LAP2, Emerin, MAN1). 
This growing family of unrelated nucleoplasmic and inner nuclear membrane 
proteins is characterized by a shared structural motif of around 45 amino acids, 
termed the LEM domain, which interacts with BAF (barrier-to-autointegration 
factor), an essential chromatin-associated and DNA cross-linking protein shown to 
act as a transcriptional co-repressor.  
Six lamina-associated-polypeptide 2 (LAP2) isoforms, emerin, MAN1, LEM2 and 5 
and ANKLE 1 and 2 are known LEM proteins in mammals.  There are also 
Drosophila -specific proteins of this family, otefin and Bocksbeutel α/β (reviewed in 
(Wagner and Krohne 2007)).  
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The LEM-domain protein family: LAP2  
The LAP2 protein family comprises six alternatively spliced products derived from a 
single gene, LAP2 or TMPO, named LAP2 α, β, γ, δ, ε, and ζ (depicted in Figure 4). 
Only the three first isoforms have been described in humans (Harris, Andryuk et al. 
1994). 
 
 
Figure 4: Structural organization and functional domains of LAP2 isoforms 
Numbers denote the position of amino acids in human protein sequences.  
(adapted from (Dechat, Vlcek et al. 2000; Dechat, Gesson et al. 2010)) 
 
 
With the exception of isoforms α and ζ, LAP2 proteins contain a C-terminal 
transmembrane domain and a lamin B binding region that targets these proteins to 
the INM (Furukawa, Fritze et al. 1998). Furthermore, all LAP2 isoforms contain a 
highly conserved N-terminal region which contains the BAF-interacting LEM domain 
(see above) and a DNA-binding LEM-like domain. LAP2 α, β, and γ are the 
predominantly expressed isoforms. While LAP2α and β are mainly present in highly 
proliferative tissues and growing cultures, LAP2γ and other isoforms are up-
regulated in differentiated tissues. The biological functions and expression patterns 
of the smaller LAP2 isoforms are still largely unknown (reviewed in (Dechat, Korbei 
et al. 2000; Schirmer and Foisner 2007)).  
LAP2β is the largest INM-localized LAP2 isoform and binds lamin B exclusively. It 
also directly interacts with transcriptional regulators like GCL (germ-cell-less, (Nili, 
Cojocaru et al. 2001)) and epigenetic modifiers including HDAC3 (Somech, Shaklai 
et al. 2005), contributing to transcriptional repression by induction of histone H4 
deacetylation. LAP2β was also reported to bind HA95, a chromatin protein involved 
in DNA replication (Martins, Marstad et al. 2003).  
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LAP2ζ, the smallest member of the LAP2 family, was reported to be involved in 
transcriptional regulation. As it lacks both a transmembrane domain and a nuclear 
localization signal, it localizes to the cytoplasm where it binds BAF, restricting its 
availability in the nucleus and inhibiting BAF- and LAP2β-mediated gene repression 
(Shaklai, Somech et al. 2008). 
LAP2α is the largest and most distantly related isoform with a size of 693 amino 
acids. It contains a unique C-terminus and lacks a membrane-spanning domain. 
Consequently, it differs from other LAP2 isoforms in terms of cellular localization, 
expression pattern, binding preferences and supposed functions. X-ray 
crystallography of the α-specific C-terminal tail has revealed a dimeric structure with 
a previously unseen central four-stranded coiled-coil organization (Bradley, Jones 
et al. 2007). 
The unique C-terminus of LAP2α also accounts for other isoform-specific features: 
The binding of Lamin A/C, rather than to lamin B, is mediated by residues 616-693 
(Dechat, Korbei et al. 2000). As LAP2α is exclusively located in the nuclear interior, 
it is thus interacting with a specific pool of A-type lamins in the nuclear interior 
(intranuclear or nucleoplasmic A-type lamins) that are not integrated in the 
peripheral nuclear lamina. These nucleoplasmic lamins are more mobile than 
peripheral lamins, suggesting dynamic binding to chromatin and/or an altered 
assembly pattern (Moir, Yoon et al. 2000).   
Interestingly, the nucleoplasmic pool of A-type lamins is dependent on LAP2 and 
is tightly regulated during the cell cycle and differentiation. Lamins A/C in the 
nuclear interior are lost in proliferating fibroblasts and in epidermal progenitor cells 
when LAP2α is genetically eliminated in mice (Naetar, Korbei et al. 2008). The loss 
of intranuclear lamins can be rescued by reintroduction of LAP2α, but not by a 
LAP2α mutant deficient in lamin A/C binding. Similarly, human fibroblasts 
undergoing si-RNA mediated knockdown of LAP2α showed a decrease in 
nucleoplasmic lamins (Pekovic, Harborth et al. 2007). Moreover, also in myoblast 
differentiation the loss of nucleoplasmic lamins goes hand in hand with a down-
regulation of LAP2α (Markiewicz, Ledran et al. 2005). These findings suggested 
that LAP2α is essential and sufficient to target and/or stabilize A-type lamins in the 
nuclear interior (Dechat, Gesson et al. 2010). 
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Lamins and LAP2α in cell cycle control 
The tumor suppressor retinoblastoma protein (pRb) is a major transcriptional 
regulator of G1- to S-phase transition, an irreversible event committing proliferating 
cells to further cell division. In its active (hypophosphorylated) repressive state, pRb 
binds to the transactivation domain of E2F transcription factors and represses E2F 
activity and thus expression of E2F-target genes required for G1–S-phase 
transition, thereby arresting cells in the cell cycle and/or promoting transition to 
quiescence, senescence or differentiation, reviewed in (Giacinti and Giordano 2006; 
Boban, Braun et al. 2010). pRb hyperphosphorylation (by several cyclin–Cdk 
complexes) releases and activates E2F transcription factors, thereby promoting 
progression into S-phase. Dephosphorylation of pRb occurs at the end of M-phase 
and is probably mediated by PP (protein phosphatase) 1 or PP2A. (Yan and 
Mumby 1999) 
LAP2α and lamin A have been shown to bind directly to retinoblastoma protein 
(pRb) in its hypophosphorylated, active form (Markiewicz, Dechat et al. 2002). In 
cells lacking A-type lamins, pRb is destabilized and proteolytically degraded 
(Johnson, Nitta et al. 2004; Nitta, Jameson et al. 2006; Nitta, Smith et al. 2007). 
Moreover, the phosphorylation-dependent repressor activity of pRb was reported to 
be impaired in lamin A-deficient cells (Van Berlo, Voncken et al. 2005).  In addition, 
LAP2α - likely in complex with nucleoplasmic lamins - was shown to be involved in 
E2F/pRb target gene repression and pRb-mediated proliferation control in tissue 
progenitor stem cells in regenerating tissues. Thus the LAP2-lamin A complex in 
the nuclear interior may regulate cell cycle progression and differentiation in an 
E2F/pRb dependent manner (Dorner, Vlcek et al. 2006; Naetar, Korbei et al. 2008). 
Further insights from the Lap2α-/- mice and implication in diseases will be discussed 
in the sections “mouse models of the laminopathies”. 
 
The LEM-domain protein family: Emerin 
Emerin is another member of the LEM-domain protein family. It is a 254 amino acid 
long integral membrane protein of the INM ubiquitously expressed in both 
mitotically active and terminally differentiated or post-mitotic cells (Lattanzi, 
Ognibene et al. 2000).  It was first described as a product of the human EMD (STA) 
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gene located at Xq28, whose deficiency is associated with the X-linked form of 
Emery-Dreifuss Muscular Dystrophy (Bione, Maestrini et al. 1994).  
Emerin binds directly to A-type lamins as well as to B-type lamins in vitro 
(Clements, Manilal et al. 2000; Lee, Haraguchi et al. 2001) and colocalizes with 
these proteins in vivo (Manilal, Nguyen et al. 1998).  A-type lamins are particularly 
important for emerin localization, as loss of A-type lamins in cells caused a 
mislocalization of emerin to the endoplasmic reticulum (ER) (Sullivan, Escalante-
Alcalde et al. 1999). Inversely, lamin C grossly mislocalizes to the nuclear interior in 
skin fibroblasts obtained from emerin-null patients while lamin A retains its position 
at the lamina (Markiewicz, Venables et al. 2002). 
Emerin also binds to a variety of nuclear factors including transcription repressors 
(GCL and Btf), an mRNA splicing regulator and barrier-to-autointegration factor 
(BAF) and to a conserved chromatin- and DNA-binding protein, reviewed in 
(Holaska and Wilson 2006). Emerin was also associated with Wnt signaling as it 
binds to β-catenin and has a role in regulating (inhibiting) its transcriptional function 
by restricting its accumulation in the nucleus (Markiewicz, Tilgner et al. 2006). 
Furthermore, emerin binds nuclear myosin 1c (NM1) directly (Holaska and Wilson 
2007) and is required for mechanotransduction (Rowat, Lammerding et al. 2006).  
It was also shown to bind directly to globular (G-) actin (Fairley, Kendrick-Jones et 
al. 1999) and cap the pointed ends of filamentous (F-) actin in vitro. Emerin has 
therefore been proposed to be involved in actin dynamics (Holaska, Kowalski et al. 
2004).  
Pull-down studies identified an emerin-binding transcription factor, Lim domain only 
(Lmo7), which controls the expression of emerin and inhibits muscle specific genes 
like Pax3 and MyoD during myoblast proliferation (Holaska, Rais-Bahrami et al. 
2006; Dedeic, Cetera et al. 2011).  
 
Insights from Emd-/- mice and implications for diseases will be discussed in the 
sections “mouse models of the laminopathies” and “EDMD”, respectively. 
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The LEM-domain protein family: MAN1 
MAN1 is an integral membrane protein of the INM encoded by the LEMD3 gene on 
human chromosome 12q14. It is ubiquitously expressed and contains a C-terminal 
tail with two membrane- spanning domains and a RNA recognition motif (RRM), 
which faces the nucleoplasm like the N-terminal LEM domain (Lin, Blake et al. 
2000). 
MAN1 binds to both types of lamins and is part of a protein platform regulating 
cellular signaling pathways mediated by TGF-β and BMP (Konde, Bourgeois et al. 
2010). It binds directly to downstream components of TGF-β and BMP-pathways 
Smads2 and 3 (part of the receptor regulated R-Smads) (Lin, Morrison et al. 2005), 
but not Smad4, resulting in the inhibition of R-Smad phosphorylation, 
heterodimerization with Smad4 and nuclear translocation, and consequently 
repression of transcriptional activation of the TGF- β, BMP2, and activin-responsive 
promoters (Pan, Estevez-Salmeron et al. 2005). 
Moreover, loss-of-function mutations in MAN1 resulting in enhanced TGF-β activity 
were reported to cause osteopoikilosis, Buschke–Ollendorff syndome and 
melorheostosis (Hellemans, Preobrazhenska et al. 2004). 
 
Nesprin and SUN proteins 
Nesprins (nuclear envelope sprectrin repeat proteins) are giant proteins of the 
nuclear envelope and the cytoskeleton. Four genes (SYNE 1–4) encoding nesprins 
1–4 have been identified so far. They are characterized by a long spectrin-repeat 
rod domain linked to a C-terminal transmembrane KASH (Klarsicht-ANC-Syne-
Homology) sequence which mediates nuclear membrane localization at the ONM 
and N-terminal domains mediating interactions with cytoskeletal proteins, such as 
the actin-binding paired calponin-homology region (Mellad, Warren et al. 2011). 
Smaller isoforms of nesprin-1 and nesprin-2 were also found in the INM, where they 
interact with Lamin A/C and emerin (Mislow, Holaska et al. 2002). 
Nesprins and other KASH-domain proteins in the ONM associate with the INM SUN 
(Sad1p-UNC84) domain proteins Sun1 and Sun2 within the perinuclear space and 
form a physical link between the nucleoskeleton and cytoskeleton (LINC) complex. 
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(Razafsky and Hodzic 2009).  Nesprins were also found to be mutated in Emery-
Dreifuss muscular dystrophy (Zhang, Bethmann et al. 2007) and cerebellar ataxia 
(Dupre, Bouchard et al. 2007). 
 
Lamins in gene expression and signaling  
Besides binding to retinoblastoma protein (pRb) described earlier, lamins also 
interact with other transcription factors and regulators, such as the transcription 
factors cFos, Oct-1, SREBP1, MOK2, the tumor suppressor ING1 as well as cyclin 
D3 and protein kinase C a (PKCa) and JIL-1 kinase (Bao, Zhang et al. 2005; 
Mariappan, Gurung et al. 2007; Han, Feng et al. 2008), reviewed in (Zastrow, Vlcek 
et al. 2004; Wilson and Foisner 2010)). 
The transcription factor AP-1 (activator protein 1) is activated by various signals like 
growth factors or cytokines and regulates cell proliferation, differentiation and 
apoptosis. It consists of c-Fos and c-Jun heterodimers. The binding of c-Fos to A-
type lamins tethers it to the nuclear periphery, inhibiting its heterodimerization with 
c-Jun and thereby suppressing AP-1-dependent transcription. Phosphorylation of c-
Fos by ERK1/2 at the nuclear lamina releases c-Fos from the nuclear envelope and 
mediates rapid AP1 activation, responsible for early transcriptional response to 
mitogenic signals. Interestingly, also ERK1/2 was shown to bind to lamins, likely 
functioning as a molecular switch for AP1-1 regulation (Ivorra, Kubicek et al. 2006; 
Gonzalez, Navarro-Puche et al. 2008), reviewed in (Boban, Braun et al. 2010). 
Similarly, association of the transcription factor Oct-1 with lamin B sequesters it at 
the nuclear envelope, limiting access to the target genes it represses, many of 
which are involved in the response to oxidative stress (Malhas, Lee et al. 2009). 
Also farnesylated prelamin A was shown to influence transcription by binding to the 
adipogenesis-involved transcription factor SREBP1 (sterol-regulatory-element-
binding protein 1) and thereby decreasing the active pool of SREBP1. This 
inactivation of SREBP1 and subsequent impairment of adipogenesis was 
suggested to be disease causing in many lipodystophies featuring overexpression 
of prelamin A (Lloyd, Trembath et al. 2002; Maraldi, Capanni et al. 2008). 
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The tumor suppressor ING1 (inhibitor of growth) binds directly to lamin A/C which 
was found to be important for its nuclear localization and function. Moreover, ING1 
protein interacts with core histones, histone deacetylases and histone 
acetyltransferases and mediates epigenetic regulation (Han, Feng et al. 2008).  
A mayor pathway affected by lamin A is the Notch signaling pathway, required for 
the differentiation of mesenchymal stem cells. Lamin A binds to and thereby 
inactivates SKIP (Ski-interacting protein), a co-activator of Notch dependent target 
genes. In progeria cells, enhanced osteogenesis and decreased adipogenesis was 
reported due to up-regulated Notch signaling, caused by lamin A variants that fail to 
bind SKIP (Scaffidi and Misteli 2008).  
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The nuclear lamina from a medical point of view 
The collective term ‘nuclear envelopathies’ is used to describe diseases caused by 
defects in components of the nuclear envelope and the nuclear lamina, 
encompassing disease-causing mutations in 14 genes as outlined and summarized 
in Table 1 and reviewed in (Burke and Stewart 2002; Worman and Bonne 2007; 
Worman, Ostlund et al. 2010). The diseases are highly variable in terms of 
hereditary mechanism, severity, age of onset, progression and tissue involvement, 
and once more highlight the many functions of the nuclear envelope. 
Table 1: Diseases associated with the nuclear envelope 
 (Burke and Stewart 2002; Worman and Bonne 2007; Worman, Ostlund et al. 2010) 
Gene Protein Disease 
EDM (STA) Emerin 
X-linked EDMD and 
cardiomyopathy 
LMNA Lamin A/C Laminopathies 
ZMPSTE24 
(FACE-1) 
Prelamin A endoprotease RD and progeroid disorders 
LAP2 (TMPO) Lamina-associated polypeptide 2 Cardiomyopathy 
LMNB1 Lamin B1 
Adult-onset dominant 
leukodystrophy 
LMNB2 Lamin B2 
Acquired partial 
lipodystrophy 
LBR Lamin B receptor 
Pelger-Huet anomaly 
(heterozygous) 
Greenberg skeletal 
dysplasia (homozygous) 
MAN1 MAN1 Sclerosing bone dysplasia 
AAAS ALADIN Triple A syndrome 
TOR1A Torsin A DYT1 dystonia 
LIS1 Lisencephaly Lisencephaly 
SYNE1&2 Nesprin-1, 2 Cerebellar ataxia, EDMD 
NUP155 Nuclear pore component 
Atrial fibrillation and sudden 
cardiac death 
MATR3 Matrin 3 (nuclear matrix protein) 
Autosomal dominant distal 
myopathy 
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The laminopathies 
As mutations in the LMNA gene are the most common, also the term laminopathies 
arose and is now frequently used to summarize this major subclass of 
envelopathies; they are further divided into primary and secondary laminopathies, 
depending on the mutated gene, LMNA itself or FACE-1, encoding the enzyme 
responsible for post-translational lamin processing described before. 
The 458 reported mutations and 281 variants (in September 2012 on 
http://www.umd.be/LMNA/, the mutation database created to more easily report and 
follow mutations and clinical phenotypes) are spread randomly over the 12 exons of 
the LMNA gene with no mutational hotspot or an established link between the site 
of the mutation and the phenotypic outcome, severity, or type of disease.  
Figure 5 shows the latest reviewed and annotated mutations in Lamin A/C (Dechat, 
Gesson et al. 2010). 
 
 
Figure 5: Disease causing mutations in Lamin A/C 
(adapted from (Dechat, Gesson et al. 2010)) 
 
Consequently, also the tissue affected by the respective LMNA mutation is used for 
further classification: skeletal and cardiac muscle, white adipose tissue and/or 
skeleton and peripheral nerves. Systemic involvements like the premature aging 
syndromes are classified as systemic laminopathies. An increasing number of 
diseases with overlapping pathologies in different tissues is termed overlapping 
laminopathies. Especially the latter group suggests a real continuum within all the 
different types of laminopathies. (Reviewed in (Burke and Stewart 2006; Worman 
and Bonne 2007; Worman, Ostlund et al. 2010)) 
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Striated muscle involvement 
Emery-Dreifuss Muscular Dystrophy (EDMD) 
Emery Dreifuss muscular dystrophy (EDMD) was described in 1966 (Emery and 
Dreifuss 1966) as a relatively benign independent muscular dystrophy, featuring a 
specific conduction defect not present in patients suffering from Becker or 
Duchenne muscular dystrophy (Ellis 2006).  
The following triad of symptoms is a hallmark of this disease (Helbling-Leclerc, 
Bonne et al. 2002; Ellis 2006): 
(1) Early joint contractures of Achilles tendons, elbows, and post-cervical muscles 
(often before significant muscle weakness can be observed). 
(2) Childhood onset of slowly progressive muscle weakness and wasting, usually 
with a scapuloperoneal distribution. 
(3) Adult-onset cardiac disease characterized by conduction defects, (ranging from 
sinus bradycardia, prolongation of the PR interval on electrocardiography to 
complete heart block), arrhythmias, and cardiomyopathy. 
The gene locus of X-linked EDMD was mapped to Xq28 (EMD or STA gene), 
encoding for a single membrane spanning protein of predicted molecular mass of 
29 kDa, which was named emerin (Bione, Maestrini et al. 1994) and is now known 
as a member of the LEM protein family (see above).  A few years later, researchers 
discovered an autosomal form of EDMD linked to defects in the LMNA gene 
encoding for lamin proteins A and C, making EDMD the first reported laminopathy 
(Bonne, Di Barletta et al. 1999). 
 In 2007, sequence variants in SYNE1 and SNYE2 genes encoding nesprin 1 and 2 
proteins were identified in EDMD patients (Zhang, Bethmann et al. 2007). These 
proteins bind both emerin and lamin A/C and link - together with SUN proteins - the 
nucleoskeleton with cytoskeletal networks. Recently, also mutations in the FHL1 
(four and a half LIM domains) gene have been reported to be causative for the 
EDMD phenotype in six families (Gueneau, Bertrand et al. 2009). FHL1 belong to a 
protein family containing four and a half LIM domains (Lin-11, Isl-1, Mec3), defined 
by the possession of a highly conserved double zinc finger motif. Diverse cellular 
roles have been attributed to the LIM domain proteins as regulators of gene 
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expression, cytoarchitecture, cell adhesion, cell motility and signal transduction, and 
most interestingly, as mediators of communication between the cytosolic and the 
nuclear compartments (Kadrmas and Beckerle 2004). Three major isoforms (A, B, 
C) are obtained by alternative splicing. The main isoform FHL1A is predominantly 
expressed in striated muscles, whereas the two other less abundant isoforms 
FHL1B and FHL1C are expressed in striated muscles and in brain and testis, 
respectively (Lee, Li et al. 1999; Ng, Lee et al. 2001). 
The frequency of EDMD is estimated at 1/100 000 for the X-linked form but is 
unknown for the autosomal dominant inheritance and includes merely a couple of 
cases for the autosomal recessive form. Also sporadic mutations account for a  big 
proportion of AD-EDMD cases (Helbling-Leclerc, Bonne et al. 2002). Furthermore, 
more than 50% of EDMD patients cannot be associated to mutations in the genes 
mentioned above, strongly suggesting the existence of other causative lamin-linked 
genes to be discovered, one of the candidates being TMPO, the gene encoding for 
LAP2. 
 
Dilated Cardiomyopathy with conduction defect (DCM-CD or CMD1A) 
Dilated cardiomyopathy is characterized by cardiac dilatation and reduced systolic 
function, and is the outcome of a mixture of acquired and inherited disorders 
accountable for more than half of all required heart transplantation in young 
children.  
Mutations in LMNA, in cardiac myosin-binding protein C (MYBPC) and many other 
genes can be disease causing. All cardiomyopathy-linked mutations found in LMNA 
cause heritable, progressive conduction system disease (sinus bradycardia, 
atroventricular conduction block, or atrial arrhythmias) and dilated cardiomyopathy. 
Heart failure and sudden death occur frequently, but no skeletal muscle features 
such as joint contractures and muscle deficit are reported (Fatkin, MacRae et al. 
1999; Burkett and Hershberger 2005). 
Intriguingly, a DCM causing mutation in the TMPO or LAP2 gene (c.2068C  T; 
p.R690C) was located in the C-terminal domain of the LAP2α protein, a region 
known to interact with lamin A/C. Consequently, the lamin binding capacity of this 
mutant LAP2α was impaired (Taylor, Slavov et al. 2005).  
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Limb-girdle muscular dystrophy type 1B (LGMD1B) 
Limb-girdle muscular dystrophy (LGMD) constitutes a clinically and genetically 
heterogeneous group of muscular disorders characterized by proximal muscle 
weakness and wasting, inherited in a dominant (LGMD1) or recessive (LGMD2) 
manner (Muchir, Bonne et al. 2000). 
LGMD1B is caused by various mutations in the LMNA gene and is characterized by 
mild muscular dystrophy affecting first proximal lower limb muscle and later upper 
limbs. Rigid spine and stiff neck are absent, distinguishing this disorder from 
EDMD, as well as the minimal or late joint contractures. Skeletal muscle 
involvement in LGMDB1 is associated with cardiac abnormalities including 
atrioventricular conduction disturbances and dysrhythmias (van der Kooi, Ledderhof 
et al. 1996). 
 
Congenital muscular dystrophy (CMD or L-CMD) 
Most mutations in LMNA causing muscle disorders manifest during childhood or 
early adulthood, yet some rare subjects present with congenital muscular 
dystrophy, which represents the most severe form of muscular involvement among 
laminopathies to date. It is typified by an earlier onset and a more severe 
phenotype than their later-onset counterparts, with uncertain heart involvement 
(Quijano-Roy, Mbieleu et al. 2008). 
While most cases of CMD are caused by de novo mutations, also cases of germinal 
mosaicism have been reported (Makri, Clarke et al. 2009).   
 
“Heart-hand” syndrome 
Heart-hand syndromes are a heterogeneous group of genetic disorders 
characterized by a combination of congenital cardiac disease and limb deformities, 
more precisely adult onset progressive conduction system disease, atrial and 
ventricular tachyarrhythmias, sudden death, dilated cardiomyopathy, and 
brachydactyly with predominant foot involvement.  
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A unique mutation in LMNA, creating a new cryptic splice site with the retention of 
11 intronic nucleotides in the mRNA, was reported to segregate with this disease 
type (Renou, Stora et al. 2008). 
 
Adipose tissue involvement 
Dunnigan-type familial partial lipodystrophy (FPLD2) 
FPLD was the second laminopathy to be reported in patients. Interestingly, the 
majority of disease causing mutations is confined to residue R482 in LMNA (Cao 
and Hegele 2000).  As with most other diseases described here, also the 
lipodystrophies represent a heterogeneous group, of either genetic or acquired 
origin, characterized by generalized or partial loss of body fat and in most cases, 
insulin resistance. The other cardinal signs are acanthosis nigricans (velvety 
hyperpigmentation of the skin), hyperandrogenism in females, muscular 
hypertrophy, hepatomegaly, altered glucose tolerance, and hypertriglyceridemia.  
Patients with the autosomal dominant disorder Dunnigan-type familial partial 
lipodystrophy are born with normal fat distribution, but after puberty experience 
regional and progressive adipocyte degeneration, often associated with profound 
insulin resistance and diabetes. The neck and face are often spared and fat can 
accumulate, giving an appearance resembling Cushing’s syndrome to the patients 
(Cao and Hegele 2000; Shackleton, Lloyd et al. 2000; Speckman, Garg et al. 2000). 
Next to the most common mutation of R482 in LMNA, missense mutations in exon 
11 of LMNA leading to R582H and R584H amino acid substitutions in lamin A, but 
not lamin C, were identified in some atypical cases (Vigouroux, Magre et al. 2000). 
Also, a few reports of patients with other LMNA mutations with atypical 
lipodystrophy syndromes, sometimes in combination with muscle abnormalities 
have been described (Vigouroux and Capeau 2005) (reviewed in (Worman, Ostlund 
et al. 2010)). 
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Mandibuloacral dysplasia (MAD) 
Mandibuloacral dysplasia (MAD) is a rare autosomal recessive disorder, 
characterized by postnatal growth retardation, mandibular and clavicular 
acroosteolysis (destructive changes in bone), delayed closure of the cranial suture, 
joint contractures, partial lipodystrophy, extreme insulin resistance, marked 
hypermetabolism and mottled cutaneous pigmentation.  In five consanguineous 
Italian families it is linked to a homozygous mutation (R527H) in the LMNA gene 
(Novelli, Muchir et al. 2002).  
Several other heterologous mutations in LMNA and in the ZMPSTE24 gene have 
also been reported to be linked to MAD (Agarwal, Fryns et al. 2003). 
Mandibuloacral dysplasia has features of both lipodystrophy and progeria, and is 
therefore sometimes considered to be part of the progeroid syndromes. 
 
Peripheral nerve involvement 
Charcot-Marie-Tooth disease type 2B1 (CMT) 
Charcot-Marie-Tooth disease constitutes a genetically heterogeneous group of 
hereditary motor and sensory peripheral neuropathies. The axonal type of Charcot-
Marie-Tooth is designated type 2.  
The disease can be inherited in an autosomal dominant or recessive way, 
mutations in LMNA being the first ones reported to cause the recessive form of 
CMT in a large Moroccan family. All affected individuals had weakness and wasting 
of the distal lower limb muscles and lower limb areflexia starting in the second 
decade of life (Bouhouche, Benomar et al. 1999). In a separate study, three 
consanguineous Algerian families with autosomal recessive CMT2 featured the 
same homozygous mutation in the LMNA gene (R298C), showing marked 
variability of the phenotype in terms of age of onset, of severity and of the groups of 
muscles involved (De Sandre-Giovannoli, Chaouch et al. 2002). 
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Systemic laminopathies- Progeria phenotypes 
Hutchinson-Gilford progeria syndrome (HGPS) 
Hutchinson-Gilford Progeria Syndrome (HGPS) is the most dramatic of the 
laminopathies, characterized by appearance of an ageing phenotype of an 
outstanding extent in children. It was first described in the early nineteenth century 
by Hutchinson and Gilford, the name-givers.  
Children with HGPS appear healthy at birth. While mental and emotional 
developments continue to stay unaltered, the first of a wide range of clinical 
features appear after two years of life. Amongst them are growth retardation, 
delayed closure of the anterior fontanel, incomplete sexual maturation, widespread 
atherosclerosis of aorta, coronary, and cerebral arteries, loss of subcutaneous fat, 
craniofacial abnormalities with micrognathism (undersized jaws), prominent eyes, a 
beaked nose, alopecia and reduced joint mobility. Other skeletal abnormalities 
include coxa valga (hip displacement), delayed and crowded dentition, thin and high 
pitched voice, pyriform thorax, short dystrophic clavicles, prominent scalp veins and 
dystrophic nails. Bone fractures are frequent due to a generalized low bone density. 
Children’s age of death ranges between 7 and 27.5 years, with a median age of 
13.4 years and is usually caused by myocardial infarction due to severe coronary 
artery disease. Reviewed in (DeBusk 1972; Burke and Stewart 2006) 
Both positional cloning and candidate gene approaches led to the identification of a 
HGPS causing de novo single-base substitution within exon 11 of LMNA 
(c.1824C>T). Although the mutation results in a silent change on protein level 
(p.G608G), a cryptic splice site within exon 11 in LMNA is activated, resulting in an 
in-frame deletion in the mRNA eliminating 50 amino acids from the C-terminal tail of 
prelamin A protein (De Sandre-Giovannoli, Bernard et al. 2003; Eriksson, Brown et 
al. 2003). 
This abnormal prelamin A, also called “progerin”, which retains the CAAX box but 
lacks the site for the second endoproteolytic cleavage, is only partially processed 
and accumulates in nuclei as a stably farnesylated lamin A variant, where it exerts 
concentration-dependent dominant negative toxic effects like lobulation of the 
nuclear envelope, thickening of the nuclear lamina, loss of peripheral 
heterochromatin, and clustering of nuclear pores (Goldman, Shumaker et al. 2004).  
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Most typical HGPS cases are due to a de novo dominant mutation usually occurring 
on the paternal allele often linked to advanced paternal age (D'Apice, Tenconi et al. 
2004), the mutation can nevertheless also be transmitted by the mother showing 
somatic and germline mosaicism (Wuyts, Biervliet et al. 2005). 
 
Atypical Werner Syndrome 
Werner syndrome is clinically characterized by premature aging and cancer 
predisposition, and was first reported as an autosomal-recessive trait due to 
mutations in the DNA helicase-like gene RECQL2 (WRN), an enzyme unwinding 
DNA and cleaving nucleotides from DNA termini, suggesting a defective DNA 
metabolism and DNA damage repair in these patients (Yu, Oshima et al. 1996). 
Several of these patients could not be diagnosed with a mutation in the RECQL2 
gene and were thus classified as "atypical Werner Syndrome". Interestingly, they 
presented with a more severe phenotype than previously observed. DNA 
sequencing of the LMNA gene identified heterozygous missense mutations in four 
patients in conserved residues. Fibroblasts showed a substantially enhanced 
proportion of nuclei with altered morphology and mislocalized lamins (Chen, Lee et 
al. 2003), (Bonne and Levy 2003). 
Werner syndrome manifests in the second to third decade of life in otherwise 
normally developing individuals. The observable and striking clinical features of 
Werner Syndrome are a prematurely aged face, premature graying and/or thinning 
of scalp hair, abnormal voice, sclerodermal-like skin changes especially in the 
extremities, bilateral cataract, short stature, subcutaneous calcification, premature 
arteriosclerosis, diabetes mellitus, hypogonadism, osteoporosis, soft tissue 
calcification, osteosclerosis of distal phalanges of fingers and/or toes and 
sarcomas. Early death, usually in the late 40s due to myocardial infarction, follows. 
(For review, see (DeBusk 1972) and (Worman, Ostlund et al. 2010)). 
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Restrictive Dermopathy (RD) 
Restrictive Dermopathy (RD), also known as tight skin contracture syndrome, is a 
very rare and severe disease leading to early neonatal death within the first hours 
or weeks of life.  RD is mainly characterized by intrauterine growth retardation, tight 
and rigid skin with erosions, prominent superficial vasculature and epidermal 
hyperkeratosis as well as mineralization defects of the skull, thin dysplastic 
clavicles, pulmonary hypoplasia and multiple joint contractures. The facial features 
include a small mouth, a small pinched nose, an undersized jaw and sparse or 
absent eyelashes and eyebrows (Morais, Magina et al. 2009). 
As with MAD, both de novo mutations in LMNA (dominant splicing mutations 
resulting in the complete or partial loss of exon 11) as well as recessive null 
mutations in ZMPSTE24 can be disease causing (Navarro, De Sandre-Giovannoli 
et al. 2004). The accumulation of truncated or normal length prelamin A has been 
shown to be a shared pathophysiological feature of recessive and dominant RD, 
tightly linking this disease to Progeria.  
 
Overlapping laminopathies 
There are an increasing number of publications reporting isolated or familial cases 
harboring several tissue involvements in lamin-linked diseases, like the combination 
of striated muscle involvement with partial lipodystrophy, striated muscles and 
peripheral nerves, peripheral nerves, striated muscles and lipodystrophy and 
association of myopathy and progeroid features. For review, see (Broers, 
Ramaekers et al. 2006). 
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Mouse models of laminopathies 
Given the fact that the striated muscle diseases represent the majority of 
laminopathies and were reported first to be linked to emerin and lamin, it is not 
surprising that in the first laminopathies-related mouse models the disease causing 
genes LMNA (Sullivan, Escalante-Alcalde et al. 1999) and EMD (Melcon, Kozlov et 
al. 2006) were targeted. Complete loss of emerin is the hallmark of X-linked EDMD; 
up to date, however, there is no report of a human patient featuring a complete 
absence of lamins A/C. The only reported case of a homozygous nonsense 
mutation introducing a premature stop codon in LMNA caused prenatal lethality 
(van Engelen, Muchir et al. 2005).  
Later, knock-in mice featuring disease-causing point mutations in Lmna, as well as 
mice deficient for the B-type lamins or Zmspte24, the enzyme responsible for lamin 
A maturation, followed and were reviewed in (Stewart, Kozlov et al. 2007). 
 
The Lmna-/- mouse model 
Homozygous mice lacking A-type lamins develop to term with no overt 
abnormalities. However, their postnatal growth is severely retarded and is 
characterized by the appearance of muscular dystrophy associated with 
ultrastructural perturbations of the nuclear envelope, including the mislocalization of 
emerin. These mice die at 6–7 weeks of age from muscular dystrophy and 
cardiomyopathy (Sullivan, Escalante-Alcalde et al. 1999). 
The lethal heart phenotype is caused by a rapidly progressive dilated 
cardiomyopathy (DCM) characterized by left ventricular dilation and reduced 
systolic contraction. Myocyte nuclei isolated from the left ventricle showed marked 
alterations of shape and size with central displacement and fragmentation of 
heterochromatin. Moreover, disorganization and detachment of desmin filaments 
from the nuclear surface was reported, together with progressive disruption of the 
cytoskeletal desmin network in cardiomyocytes. The import of SREBP1 to the 
nucleus was reduced, as well as PPARγ expression and subsequent hypertrophic 
gene activation. This means that despite severe DCM, cardiomyocytes fail to 
develop compensatory hypertrophy (Nikolova, Leimena et al. 2004). 
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The molecular mechanism of the lamin-linked muscular dystrophy phenotype is still 
unclear: Surprisingly, muscles of Lmna-/- mice regenerated normally after treatment 
with cardiotoxin, and primary Lmna-/- myoblast cultures did not show any 
impairment in their differentiation to myotubes (Melcon, Kozlov et al. 2006). On the 
contrary, immortalized Lmna-/- myoblasts were reported to be impaired in their in 
vitro differentiation potential, presumably due to decreased levels of proteins 
important for muscle differentiation including pRb, MyoD, desmin, and M-cadherin. 
Interestingly, Myf5 was up-regulated, pointing towards a compensatory mechanism 
for the loss of MyoD (Frock, Kudlow et al. 2006). 
It is noteworthy that also heterozygous mice develop disease phenotypes; Lamin 
haploinsufficiency caused early-onset programmed cell death of atrioventricular 
nodal myocytes and progressive electrophysiologic disease. Eventually also non-
conducting myocytes succumbed to diminished lamin levels leading to dilated 
cardiomyopathy, analogous to those observed in humans with heterozygous LMNA 
mutations. However, neither histopathology nor serum CK levels indicated skeletal 
muscle pathology in these mice (Wolf, Wang et al. 2008). 
Furthermore, sciatic nerves of the Lmna-/- mice showed a strong reduction in axon 
density, axonal enlargement and the presence of nonmyelinated axons, being 
highly similar to the phenotypes of human peripheral nerve laminopathies (De 
Sandre-Giovannoli, Chaouch et al. 2002). 
 
The Lmna LCO/LCO mouse model  
This mouse model produces lamin C, but no lamin A or prelamin A and was 
reported to be entirely healthy during a 2 year observation period, suggesting that 
prelamin A and lamin A are apparently dispensable in mouse. Necropsy and 
histological studies did not uncover any histological abnormalities. Lmna LCO/LCO 
cells displayed normal emerin targeting and exhibited only very minimal alterations 
in nuclear shape and deformability (Fong, Ng et al. 2006).  
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The Emd -/- mouse model 
In an attempt to model X-linked EDMD, the Emd gene was targeted by two different 
approaches, one using a conditional knockout approach deleting exons 2-6 of the 
Emd gene (Melcon, Kozlov et al. 2006), the other by insertion of a neomycin 
resistance gene into exon 6 of the coding gene, resulting in lack of most of exon 6 
of the gene, including the part encoding the transmembrane domain at the C-
terminal end of emerin (Ozawa, Hayashi et al. 2006). 
Neither mouse model showed an overt phenotype; Emd-/- mice are healthy and 
fertile with minimal motor and cardiac dysfunctions. This difference between human 
and mouse phenotype may be a result of interspecies differences in possible 
overlapping and/or redundant functions of inner nuclear membrane proteins. 
Electron microscopic analysis of skeletal and cardiac muscles showed vacuoles 
mostly associated with myonuclei but no dystrophic changes or joint contractures 
could be observed (Ozawa, Hayashi et al. 2006).  
Nonetheless, in vivo muscle degeneration and in vitro differentiation of primary 
myoblasts revealed evidence for temporal abnormalities in gene expression and 
synchronization of differentiation pathways early during muscle regeneration. 
Specifically, inappropriate phosphorylation of pRb was reported to result in a 
temporal failure to transcriptionally repress mitotic programs via the pRb/E2F 
pathway. Simultaneously, induction of myogenesis via the pRb/MyoD pathway was 
delayed (Melcon, Kozlov et al. 2006). 
 
Lamin B deficient mouse models 
Lamin B1 knockout mice were generated by introducing an insertional mutation in 
Lmnb1, which resulted in the synthesis of a mutant and truncated lamin B1 protein 
lacking several key functional domains, including a portion of the rod domain, the 
nuclear localization signal, and the CAAX motif. Homozygous Lmnb1-/- mice 
survived embryonic development but died at birth with defects in lung and bone; 
heterozygous mice were viable. Fibroblasts from mutant embryos grew under 
standard cell-culture conditions but displayed grossly misshapen nuclei, impaired 
differentiation, increased polyploidy, and premature senescence (Vergnes, Peterfy 
et al. 2004). Previous siRNA studies suggested that LMNB1 was an essential gene 
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in humans, so the fact that Lmnb1-/- mice survived until birth was astonishing, 
suggesting a potential compensation by lamin B2.  
Lamin B2 knockout mice were normal in size and appearance at birth, but died 
within 15–60 min postnatally. Histopathological studies did not uncover 
abnormalities in any organ system, except for the brain, where lissencephaly-like 
irregularities like abnormal layering of neurons in the cerebral cortex and 
cerebellum were detected (Coffinier, Chang et al. 2010). 
In forebrain-specific Lmnb1/Lmnb2 double-knockout mice, an even more severe 
phenotype, namely complete atrophy of the cortex was reported, demonstrating that 
both lamin B1 and lamin B2 are essential for brain development, with lamin B1 
being required for the integrity of the nuclear lamina, and lamin B2 being important 
for resistance to nuclear elongation in neurons (Coffinier, Jung et al. 2011). 
 
The LmnaGT -/- mouse model 
In a novel approach focusing on the potential role of lamin A in early-post natal 
development, a Lmna null mouse model was created by interruption of the 
endogenous lamin A/C locus by a promoter-trap construct in intron 2, generating an 
in-frame fusion of the lamin A N-terminus with βgeo and allowing visualization of 
Lmna promoter activity (Kubben, Voncken et al. 2011). 
Although LmnaGT -/- mice were apparently normal at birth, severe and widespread 
defects in post-natal tissue maturation soon became obvious, including impaired 
post-natal hypertrophy of cardiac myocytes, skeletal muscle hypotrophy, decreased 
subcutaneous adipose tissue deposits, decreased adipogenic differentiation of 
MEFs (mouse embryonic fibroblasts) and metabolic derangements. Death occurred 
extremely early at postnatal day 16 to 18 due to combined muscle weakness and 
metabolic complications, and the fact that it occurred in the absence of a dilated 
cardiomyopathy or obvious progeroid phenotype made this model the most severe 
up to date. 
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The Lmna Δ9/Δ9 mouse model 
The first progeria mouse model was created by the introduction of a splicing defect, 
leading to an in-frame deletion of exon 9 of Lmna, resulting in the removal of amino 
acids from the carboxyl-terminal globular domain.  
Homozygous mice displayed a marked reduction in growth rate and death by 4 
weeks of age. Pathologies in bone, muscle and skin resembled progeroid 
syndromes. Also fibroblasts isolated from homozygous LmnaΔ9/Δ9 mice showed 
nuclear morphology defects and a decreased lifespan (Mounkes, Kozlov et al. 
2003). 
 
The Lmna HG/HG mouse model 
In this HGPS mouse model, A-type lamins were replaced by progerin, a 
farnesylated prelamin A that lacks 50 amino acids and can thus not be further 
processed to mature lamin A. Furthermore, no lamin C could be produced due to 
deletion of intron 10 of Lmna, leading to the sole production of progerin (Yang, 
Bergo et al. 2005).  
Homozygous mice were reported to die early, before weaning, and to have severe 
osteoporosis and spontaneous bone fractures. Heterozygotes (LmnaHG/+) were 
normal at birth but developed retarded growth, osteoporosis, alopecia, 
micrognathia, reduced subcutaneous fat, and osteolysis of the clavicle, mimicking 
the phenotypes children with HGPS endure. These phenotypes were progressive, 
and the mice died by 6–7 months of age, interestingly in the absence of noticeable 
muscle weakness (Yang, Bergo et al. 2005). 
 
The Lmna BAC G608G mouse model 
In an approach to over-express human LMNA G608G, a transgenic mouse model 
carrying a human bacterial artificial chromosome (BAC) harboring the common 
HGPS G608G mutation in LMNA was created. 
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 A classical HGPS phenotype was absent; but like human progeria patients, the 
G608G transgenic mice were reported to suffer from severe vascular smooth 
muscle cell loss, accumulation of acellular material and calcification of the vessel 
wall, closely resembling the most lethal aspect of the human HGPS phenotype 
(Varga, Eriksson et al. 2006). 
 
The epidermal specific HGPS mouse model 
In this tissue specific transgenic mouse model of HGPS, human progerin is 
expressed exclusively in the epidermis by a keratin 14 promoter-driven progerin 
cDNA (Wang, Panteleyev et al. 2008). The mice exhibited severe abnormalities in 
the morphology of skin keratinocytes, including abnormally shaped nuclei and 
nuclear envelope lobulations that could be improved by treatment with 
farnesyltransferase inhibitors (FTIs). Hair growth and wound healing were however 
not affected; epidermal expression of human progerin in mice did not lead to 
alopecia or other skin abnormalities typically seen in human HGPS patient. 
 
The inducible Lmna G608G HGPS mouse model  
In this alternative approach, a tetracycline-inducible transgenic line was created that 
carries a minigene of human LMNA G608G under the control of a tet-operon with 
K5 promoter (Sagelius, Rosengardten et al. 2008). Targeted expression of this 
transgene in keratin-5-expressing tissues after weaning led to abnormalities in skin 
and teeth. Structural defects in the hair follicles and sebaceous glands, fibrosis, loss 
of hypodermal adipocytes and abnormal incisors were reported. The severity of the 
defects was related to the expression level of the transgene; Most interestingly, a 
rapid improvement of the already established skin phenotype was noted when the 
transgenic expression was suppressed (Sagelius, Rosengardten et al. 2008), 
nurturing hopes for an HGPS treatment as it was shown that a reversal of disease 
phenotype is indeed possible. 
Later, it was reported that induced expression of this transgene leads to a 
decreased epidermal population of adult stem cells and impaired wound healing in 
mice, most likely caused by downregulation of the epidermal stem cell maintenance 
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protein p63, ensuing activation of DNA repair and premature senescence. 
Additionally, upregulation of multiple genes in major inflammatory pathways 
indicated an activated inflammatory response, which has been also associated with 
normal aging (Rosengardten, McKenna et al. 2011).  
 
Other approaches to model HGPS 
Last year, two groups reported the use of induced pluripotent stem cells (iPSCs) 
created from human HGPS patient fibroblasts (Liu, Barkho et al. 2011; Zhang, Lian 
et al. 2011). Interestingly, HGPS-iPSCs show absence of progerin, and lack the 
nuclear envelope and epigenetic alterations normally associated with premature 
ageing. Upon differentiation, progerin and its ageing-associated phenotypic 
consequences are restored (Liu, Barkho et al. 2011). 
The iPSCs were differentiated into neural progenitors, endothelial cells, fibroblasts, 
vascular smooth muscle cells (VSMCs), and mesenchymal stem cells (MSCs). 
Progerin levels were highest in MSCs, VSMCs, and fibroblasts, displaying 
increased DNA damage and nuclear abnormalities, viability being compromised by 
stress and hypoxia (Zhang, Lian et al. 2011). 
In smooth muscle cells, progerin leads to the appearance of premature senescence 
phenotypes associated with vascular ageing. A DNA-dependent protein kinase 
catalytic subunit (DNAPK) was identified as a downstream target of progerin. The 
absence of nuclear DNAPK holoenzyme as well as the presence of progerin 
correlates with premature as well as physiological ageing (Liu, Barkho et al. 2011).  
 
The Zmpste24-/- mouse model 
In an attempt to model perinatally lethal restrictive dermopathy (RD), which is 
associated with a loss of ZMPSTE24 activity, two mouse models lacking Zmpste24 
were created (Leung, Schmidt et al. 2001; Pendas, Zhou et al. 2002). 
In Zmpste24-/- cells, no mature lamin A is produced; farnesylated prelamin A 
accumulates at the nuclear rim, where it interferes with the integrity of the nuclear 
lamina, resulting in an increased frequency of misshapen nuclei (Bergo, Gavino et 
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al. 2002). Still, the lethal RD phenotype was absent. Being normal and 
undistinguishable from their WT littermates at birth, Zmpste24-/- mice featured slow 
growth and develop incisor abnormalities, alopecia, kyphosis (curvature of the 
spine), and a slow arthritic gait. After 3–4 months of age, body weight began to 
decline, and age-related bone abnormalities manifested, as well as muscle 
weakness, leading to premature death (Pendas, Zhou et al. 2002).  
 
Excurse: FTIs and their therapeutic potential 
Studies on cells obtained from HGPS patients, as well as the Zmpste24-/- and the 
progerin mouse models, led to the hypothesis that the disease phenotypes may be 
ameliorated by reducing the levels of farnesylated prelamin A accumulating at the 
nuclear rim.  
A first proof of principle was obtained in 2005, when Scaffidi and Misteli showed 
that the cellular disease phenotype in HGPS patient fibroblasts could be efficiently 
eliminated by correction of the aberrant splicing event using a modified 
oligonucleotide targeted to the activated cryptic splice site, whereas introduction of 
WT lamin A did not rescue the phenotype (Scaffidi and Misteli 2005). 
When knockdown of the pre-lamin cleaving protease Zmpste  in mouse was found 
to cause accumulation of the farnesylated form of prelamin A and to lead to various 
progeroid phenotypes (Leung, Schmidt et al. 2001; Pendas, Zhou et al. 2002), it 
was hypothesized that blocking this modification by farnesyl-transferase inhibitors 
(FTIs) might ameliorate the disease phenotypes.  
In MEFs obtained from LmnaHG/HG mice, treatment with a farnesyl-transferase 
inhibitor caused localization of progerin away from the nuclear envelope to the 
nucleoplasm and resulted in a striking improvement of nuclear blebbing (Yang, 
Bergo et al. 2005). Other laboratories also reported that FTIs improved nuclear 
shape in Zmpste-/- mice, human HGPS fibroblasts or cells that had been transfected 
with a progerin cDNA (Fong, Frost et al. 2006), (Yang, Bergo et al. 2005), (Capell, 
Erdos et al. 2005), reviewed in (Stewart, Kozlov et al. 2007). 
These promising in vivo results lead to the clinical use of FTIs in children with 
HGPS. The FTI Lonafarnib, in a combination with zoledronic acid and pravastatin, 
is currently in phase II of investigation in the US. The study completion date is 
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estimated to be December 2014.  (ClinicalTrials.gov identifier: NCT00916747, 
Children's Hospital Boston, Massachusetts, United States, Principle investigator: 
Mark Kieran). Also in Europe, a combination of zoledronic acid and pravastatin is in 
phase II of clinical trial, the study completion date being fixed with March 2013. 
(ClinicalTrials.gov identifier: NCT00731016, Assistance Publique Hopitaux De 
Marseille Principle investigator: Nicholas Levy) 
 
The Lmna H222P/H222P mouse model 
The Lmna H222P missense mutation was identified in a family with autosomal 
dominant Emery-Dreifuss muscular dystrophy. In mice, the homozygous males 
(LmnaH222P/H222P) had normal embryonic development and sexual maturity but 
displayed reduced locomotion activity at adulthood. Later, they developed a cardiac 
phenotype characterized by chamber dilation and hypokinesia with conduction 
defects, leading to death at 9 months of age.  Female homozygotes also exhibited 
these pathologies but at a later stage and with a longer survival period. 
Degeneration of muscle associated with fibrosis and dislocation of heterochromatin, 
as well as activation of Smad signaling was observed, closely mimicking the human 
disease state (Arimura, Helbling-Leclerc et al. 2005). 
 
The Lmna N195K/N195K mouse model 
This missense mutation (N195K) acts in an autosomal dominant fashion and 
causes DCM in humans. A mouse line homozygous for the same mutation 
(LmnaN195K/N195K) shows characteristics consistent with DCM-CD1, with the mice 
dying at 3 months due to arrhythmia. Yet muscular dystrophy was absent. The 
transcription factor Hf1b/Sp4 and the gap junction proteins connexin 40 and 
connexin 43 were misexpressed and/or mislocalized in mutant hearts. Sarcomeres 
and intercalated disks were disorganized. These observations suggest that a 
disruption of the internal organization of cardiomyocytes combined with an 
alteration of expression of transcription factors essential to normal cardiac 
development, aging and function is most likely cardiomyopathy causing (Mounkes, 
Kozlov et al. 2005). 
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Transgenic line Lmna M371K 
In another approach using lamin A overexpression, the heart-selective alpha-
myosin heavy chain promoter was used to drive expression of human wild-type and 
M371K lamin A, a mutation shown to cause EDMD in patients. Mice expressing 
M371K lamin A were born at lower than expected frequency and those born 
typically died at 2-7 weeks of age, whereas their WT counterparts had normal life 
spans. Histological analysis of the hearts revealed extensive pathology; disruption 
of the cardiomyocytes and abnormal nuclei with extensively convoluted nuclear 
envelopes, intranuclear inclusions and chromatin clumps were reported. These 
results demonstrated that expression of a lamin A mutant that induces alterations in 
nuclear morphology can cause tissue and organ damage in mice that have a 
normal level of endogenous wild-type lamins (Wang, Herron et al. 2006). 
 
Transgenic line Lmna R482Q 
This mutation is the most common LMNA alteration found in FPLD2. Expression of 
the transgene was driven by the aP2 enhancer/promoter to ensure adipose tissue-
specific expression. 
The reported phenotype resembles many of the features of human FPLD2, 
including lack of fat accumulation, insulin resistance, and the presence of an 
enlarged, fatty liver. Transgenic mice appeared to develop normally, but after 
several weeks were unable to accumulate fat to the same extent as their wild-type 
littermates. It was reported that Lmna R482Q preadipocytes were unable to 
differentiate into mature and fully functional adipocytes, contradicting the current 
view that FPLD2 results in a loss of fat and suggesting that rather insufficient self-
renewal of adipose tissue can be held responsible (Wojtanik, Edgemon et al. 2009). 
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In this thesis, two mouse models are of particular interest, the LmnaΔK32/ΔK32 and the 
Lap2α-/- mouse model, as they were combined to assess specific functions of 
LAP2α in the CMD phenotype caused by the ΔK32 mutation in Lmna. 
 
The Lap2α-/- mouse model 
Cre-mediated germline deletion of the α-isoform specific exon 4 of the Lap2 gene 
resulted in the generation of a Lap2α-/- mouse. The expression of all other Lap2 
isoforms remained unaltered. (Naetar, Korbei et al. 2008) 
Lap2α-/- mice were stunningly indistinguishable from their wild-type littermates, not 
only at birth but throughout the whole life-span. Fertility was not impaired. Closer 
inspection of these mice on histological and molecular level, however, revealed a 
higher proliferation of progenitor cells in highly regenerative tissues like skin, 
intestine and hematopoietic system, as well as a more efficient tissue repair at early 
stages after treatment with stress-inducing agents. In these tissues, the 
phosphorylation status of the major cell-cycle regulator pRb was shown to be 
affected. The increased phosphorylation of pRb found in Lap2α-/- tissues is in 
accordance with the resulting higher number of proliferating cells (see also section 
“Lamins and LAP2α in cell cycle regulation”).  
In line with this finding, a higher number of skeletal muscle progenitor cells 
(SMPCs) were reported in muscle, although general muscle morphology, function, 
and regeneration were not detectably affected. Stunningly, loss of Lap2α shifted the 
myofiber-type ratios of adult slow muscles towards fast fiber types. When 
specifically eliminated in muscle (using Mck-Cre), loss of Lap2α affected early 
stages of in vitro myoblast differentiation and fiber-type determination (Gotic, 
Schmidt et al. 2010). 
In heart, Lap2α-/- knockout caused systolic dysfunction in young mice and sporadic 
fibrosis in old animals, as well as deregulation of major cardiac transcription factors 
GATA4 and myocyte enhancer factor 2c. In contrast to male mice, female Lap2α-/- 
mice did not develop any overt phenotype. A conditional mature cardiomyocyte-
specific Lap2α-/-  mouse was created in an attempt to find out whether the observed 
systolic dysfunction was due to a loss of LAP2α during early development or at later 
stages. Conditional Lap2α-/- mice did not develop any evident cardiac phenotype, 
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suggesting that the major role of LAP2α is restricted to early stages of cardiac 
development or during cardiac homeostasis later on in life (Gotic, Leschnik et al. 
2010), reviewed in (Verstraeten and Lammerding 2010).  
Alternatively, it was also hypothesized that the cardiac phenotype observed in the 
complete Lap2α-/- mouse is not caused by a cardiomyocyte-intrinsic mechanism, 
but may involve defects in non cardiac-cells. At molecular level, absence of LAP2α 
preserved the stem cell-like phenotype of primary Lap2α-/- myoblasts and caused 
delayed in vitro differentiation (Gotic, Schmidt et al. 2010). In cultured Lap2α-/- 
fibroblasts, a reduced nucleoplasmic lamin A pool coincided with a delayed cell 
cycle arrest, leading to the hypothesis that intranuclear lamin A-LAP2α complexes 
might be involved in the regulation of pRb activity (Naetar, Korbei et al. 2008).  
 
The Lmna ΔK32/ΔK32 mouse model 
This mouse model harboring the congenital muscular dystrophy (L-CMD) causing 
Lmna ΔK32 mutation was published most recently (Quijano-Roy, Mbieleu et al. 
2008; Bertrand, Renou et al. 2011; Bertrand, Renou et al. 2012). The mutation 
results in the loss of lysine at position 32 in the N-terminal domain of lamin A/C, 
which was previously proposed to be involved in the lateral assembly of head to tail 
polymers of lamin A/C (Bank, Ben-Harush et al. 2011). 
In homozygous mice, the level of mutant protein was markedly lower than wild-type 
lamin A/C. Furthermore, mutant proteins were maintained in nucleoplasmic foci 
while wild-type lamin A/C proteins were progressively relocated from nucleoplasmic 
foci to the nuclear rim during embryonic development. LmnaΔK32/ΔK32 mice were 
indistinguishable from their wild-type littermates at birth but soon exhibited striated 
muscle maturation delay and metabolic defects. More specifically, expression of 
ΔK32-lamin A/C altered SREBP-1 maturation and transcriptional activities in liver 
and during adipocyte differentiation (Bertrand, Renou et al. 2012).   
The consequential reduction in adipose tissue and hypoglycemia led to premature 
death during the third week of life. Based on the phenotype of these mice, the 
authors suggest a model in which lamin A/C relocation to the nuclear lamina during 
maturation causes the release of its inhibitory function on transcriptional factors (not 
restricted to SREBP-1). 
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The expression of the orthologous ΔK46 mutation in C. elegans (GFP:DeltaK46) 
resulted in motility defects and muscle structure abnormalities. In vitro filament 
assembly revealed alterations in the lateral assembly of dimeric head-to-tail lamin 
polymers, which led to abnormal organization of tetrameric protofilaments. 
Moreover, the capacity of GFP:DeltaK46 to bind to emerin was reduced, and it was 
found mislocalized in nuclear aggregates together with LEM-2 (Bank, Ben-Harush 
et al. 2011). 
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Proposed disease mechanisms of laminopathies 
How mutations in a single, universally expressed gene can cause such a myriad of 
different diseases, many of them tissue specific, is one of the biggest puzzles in the 
field and has been an area of intense research and discussions for many years. It is 
believed that progerin is a toxic version of lamin that causes the pathologies in 
HGPS due to its tight membrane attachment, while the effect of single point 
mutations in the LMNA gene found in most other laminopathies is less clear. Two 
models were proposed, the structural weakness model and the gene expression 
model. It is understood, however, that those models are not mutually exclusive and 
that multiple mechanisms in both hypotheses may account for the various 
pathologies. (For reviews, see (Broers, Ramaekers et al. 2006), (Gotzmann and 
Foisner 2006), (Bridger, Foeger et al. 2007) and (Zaremba-Czogalla, Dubinska-
Magiera et al. 2011)) 
 
The structural weakness model 
A major function of the nuclear lamina is to provide structural support for the 
nuclear envelope. Consequently, it has been proposed that mutations in lamins 
may affect their atomic structure and interfere with a proper lamina assembly after 
mitosis or during nuclear growth in interphase. These alterations in the lamin 
network also result in a compromised integrity of the nuclear envelope and an 
impaired nucleo-cytoskeleton link, leading to structural weakness of the nucleus 
and susceptibility to mechanical stress. This model is particularly intriguing for 
laminopathies that involve muscle and heart tissues, as those are subjected to 
constant mechanical stress. 
In line with this hypothesis, MEFs obtained from Lmna-/- mice were unable to resist 
forces of compression and ruptured more easily when subjected to physical loads, 
showing a direct correlation between absence of A-type lamins and nuclear fragility 
(Broers, Peeters et al. 2004).  Another group found not only that Lmna-/- cells had 
increased nuclear deformation, defective mechanotransduction, and impaired 
viability under mechanical strain, but also that NF-κB-regulated transcription in 
response to mechanical or cytokine stimulation was abrogated (Lammerding, 
Schulze et al. 2004). This suggests that varying degrees of impaired nuclear 
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mechanics and stress response-mediated transcriptional activation may contribute 
to tissue-specific effects of lamin A/C mutations observed in laminopathies. 
Interestingly, emerin-deficient MEFs were reported to have normal nuclear 
mechanics but impaired expression of mechanosensitive genes in response to 
strain, suggesting that emerin mutations may act primarily through altered 
transcriptional regulation but do not increase nuclear fragility (Lammerding, Hsiao et 
al. 2005).  
 
The gene expression model 
The changes in transcriptional regulation in Lmna-/- cells upon mechanical stress,  
in addition to the fact that A-type lamins play an important role in the general control 
of gene expression - by associating with transcription factors, regulatory proteins 
and chromatin - led to the postulation of the gene expression model. This model 
argues that defects or mutations in lamins may alter lamin interactions with 
signaling molecules and transcriptional regulators, resulting in pathogenic and 
tissue-specific de-regulation of respective signaling pathways and gene expression 
(see also section “Lamins in gene expression and signaling”). This model was 
proposed to explain laminopathies where mechanical stress was unlikely to be a 
causative agent, like FPLD. 
In addition, several other models that have been proposed can be seen as a 
combination of and an addition to structural and gene expression defects: 
 
The cell proliferation theory 
This theory argues that many features of especially progeroid laminopathic 
diseases can be explained by abnormally regulated cell proliferation and 
differentiation, and is supported by the many findings of premature cellular 
senescence and apoptosis of patient and mouse model cells in culture (Mounkes, 
Kozlov et al. 2003), (Muchir, van Engelen et al. 2003; Bridger and Kill 2004).  
Expanding the findings of cultured cells to adult stem cells, it was argued that 
mutated lamins may prevent their self renewal and amplification by driving them 
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into senescence or by misbalancing the ratio of proliferation versus differentiation. 
These defects would clearly limit the capacity of any tissue for stem cell driven 
regeneration (Halaschek-Wiener and Brooks-Wilson 2007). The so called stem cell 
exhaustion theory is in line with this hypothesis, stating that an initial functional set 
of adult stem cells is lost over time due to the increased demand for regeneration 
during life time. Exhaustion of satellite cells has been shown for instance in mdx 
mice, a model of Duchenne Muscular Dystrophy (Sacco, Mourkioti et al. 2010). 
The applicability of this model to laminopathies others than progeroid syndromes is 
supported by findings that insufficient self-renewal of adipose tissue can be held 
responsible for the FPLD phenotype in the transgenic Lmna R482Q mouse model 
(Wojtanik, Edgemon et al. 2009). 
 
The defective DNA damage response theory  
This theory argues that the ageing phenotype in cells due to accumulation of 
prelamin A forms (like HGPS patient cells or Zmpste-/- cells), correlates with 
increased aneuploidy and DNA damage as well as an impaired DNA damage repair 
and activation of p53 signaling (Liu, Wang et al. 2005), (Varela, Cadinanos et al. 
2005). 
Defects in DNA repair pathways are believed to be caused by a combination of 
factors like abnormal epigenetic modifications of chromatin that are required to 
recruit DNA repair pathway components to sites of DNA damage, abnormal 
recruitment of DNA excision repair proteins to sites of DNA double-strand breaks, 
and unrepairable DNA damage, induced by reactive oxygen species or other DNA 
damaging agents (Hutchison 2011). In line with this former mechanism, progeria 
cells failed to recruit p53-binding protein 1 and RAD51 to sites of DNA lesions, 
resulting in delayed checkpoint response and defective DNA repair (Liu, Wang et al. 
2005). In addition, the upregulation of p53 target genes was shown to be 
accompanied by a senescence phenotype at the cellular level and accelerated 
ageing at the organismal level in Zpmste-/- cells and mice. Interestingly, these 
phenotypes were largely rescued when prelamin A was lost in a double mutant 
Zmpste24-/-, Lmna+/- mouse (Varela, Cadinanos et al. 2005). 
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Skeletal Muscle 
In this thesis, the effects of mutations of Lmna and LAP2α were examined 
particularly in skeletal muscle. In order to attempt to comprehend muscular 
dystrophies, the structure, anatomy and regulation of muscle tissue need to be 
elaborated on. 
 
Skeletal muscle formation in the embryo- development 
In higher vertebrae, formation of skeletal muscle starts around mid-gestation 
(around embryonic day 9 to 12 in mice) from three different locations in the middle 
cell layer of the embryo: the segmented paraxial mesoderm known as somites, the 
unsegmented cranial paraxial mesoderm and the prechordal mesoderm. Skeletal 
muscles of the trunk and limbs arise from the somites that are formed on both sides 
of the neural tube of the embryo. Muscle groups from the head (tongue, laryngeal 
and extraocular muscles as well as branchial arches) are derived from occipital 
somites, cranial paraxial mesoderm, splanchnic mesoderm and prechordal 
mesoderm. (Reviewed in (Buckingham 1992; Braun and Gautel 2011)) 
Independent of the location, cell-autonomous activation of myogenesis is controlled 
by complex transcriptional regulatory networks resulting in the expression of the 
basic helix-loop-helix domain containing myogenic regulatory factors (MRFs), which 
include myogenic factor 5 (Myf5), myogenic differentiation 1 (Myod1, also known as 
MyoD), Myf6 (also known as Mrf4) and myogenin (Myog) in emerging and 
differentiating myoblasts. Muscle regulatory factors are transcription factors 
activating the expression of many downstream genes that are required to generate 
the contractile properties of a mature skeletal muscle cell, reviewed in (Bryson-
Richardson and Currie 2008; Braun and Gautel 2011).  
Loss of both MyoD and Myf5 results in a complete absence of skeletal muscle 
fibers or myoblasts, underlining their role as determination genes,  whereas 
myogenin is required for the terminal differentiation of committed myoblasts (Berkes 
and Tapscott 2005). Myf6 (Mrf4) acts as a differentiation gene in postmitotic 
maturating cells, but it is also expressed by undifferentiated proliferating cells in 
which it might act as a determination gene (Kassar-Duchossoy, Gayraud-Morel et 
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al. 2004). The upstream factors regulating the MRFs are different depending on the 
anatomical location and the muscle group in question (Figure 6). 
 
 
Figure 6: Activation of the muscle differentiation program in different anatomical locations 
(adapted from (Braun and Gautel 2011)) 
 
In muscle groups of the head, pituitary homeobox 2 (PITX2) predominantly controls 
the myogenic hierarchy, leading to the activation of Myf5 and MyoD and 
subsequent terminal differentiation induced by myogenin (Shih, Gross et al. 2008). 
In primary myogenesis of the limb, expression of paired box protein 3 (Pax3) is 
regulated by the activity of members of the sine oculis homeobox (SIX) and eyes 
absent homologue (EYA) protein families (Grifone, Demignon et al. 2005; Grifone, 
Demignon et al. 2007).  Pax3 in turn regulates a myogenic program consisting of a 
cascade of MyoD, Myf5, Mrf4 and myogenin (Bajard, Relaix et al. 2006). In trunk 
muscles, however, Myf5 or Mrf4 can cause parallel activation of MyoD and 
myogenin; Pax3 acts upstream of MyoD.  
Besides cell-autonomous regulation, embryonic myogenesis is also determined by 
signaling molecules secreted from surrounding tissues like the neural tube, 
notochord, surface ectoderm and lateral mesoderm.  Sonic Hedgehog (SHH) and 
WNT signaling are imperative to the induction of myogenesis, as well as the 
transforming growth factor- β (TGFβ) superfamily (activated by bone morphogenic 
proteins (BMPs) and inactivated by the signaling molecule Noggin).  
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Skeletal muscle anatomy 
Following completion of the first phase of myogenesis, the generation of the primary 
myotome, the adult skeletomuscular system, is believed to be generated from this 
initial structure in a second phase characterized by growth of individual fibers 
(hypertrophy) rather than by an increase of number of muscle fibers (hyperplasia).  
In the human adults, skeletal muscle makes up a considerable proportion of the 
body accounting for around 38% of body weight in men and 30% in women. 
Moreover, skeletal muscle exhibits major metabolic activity by contributing up to 
40% of the resting metabolic rate in adults and serves as the largest body protein 
pool (Matsakas and Patel 2009). Its basic cellular units are myofibers, also called 
myocytes. Next to myocyctes, muscle also contains satellite cells, which are the 
stem cells of the muscle and are key factors in regeneration and adult myogenesis 
(see below). Muscle fibers are formed by fusion of progenitor cells and are 
therefore multinucleated; their size ranges from 10 to 120 µm. The endomysium, a 
network of connective tissue, surrounds each fiber.  Moreover, bundles of adjacent 
fibers surrounded by the perimysium form the fasciculi, which in turn associate with 
each other to form the complete muscle. The outside connective tissue, the 
epimysium, contains neurovascular structures and provides continuity with tendons 
through its collagen fibers.  
Each muscle fiber is surrounded by the plasmalemma and is composed of 
thousands of myofibrils which consist of sarcomers joined end-to-end. The 
sarcomere is the basic unit of the contractile apparatus of the muscle, constructed 
from antiparallel actin and myosin filaments, elastic tintin filaments and  crosslinker 
proteins for actin filaments (myosin, myomesin and α-actinin). Skeletal muscle 
appears striated in standard histological procedures due to the presence of different 
bands (Figure 7).  
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Figure 7: Striated muscle structure 
adapted from (Burke and Stewart 2006; Braun and Gautel 2011) 
The A band appears dark in histochemistry and consists of thick filaments made of 
myosin, attached end-to-end at the M-line situated in the center. Adjacent to the A 
band is the lighter I band consisting of thin actin, troponin and tropomyosin 
filaments. The dark Z-line in the middle of the I band indicates the place where thin 
filaments are attached end to end. When muscle is stretched, an H-band appears 
along the middle of the A-band, between the free ends of the thin filaments.    
The sarcomere contains a range of accessory proteins for transcriptional regulation 
and turnover control. Amongst the former are the transcription factor CLOCK, the 
transcriptional cofactors muscle LIM protein, muscle ankyrin-repeat proteins and 
LIM domain-binding protein 3, amongst the latter are sequestosome 1, NBR1 and 
the muscle-upregulated RING finger proteins (Braun and Gautel 2011). 
An elaborate system of tubules and vesicles ensures the delivery of substances, 
removal of waste products and transmission of nerve impulses to the myofibrils. 
One component of this communication network is the T-system consisting of 
invaginations of the plasmalemma, running perpendicular to the myofibrils. Another 
major part is the sarcoplasmic reticulum running parallel to the myofibrils (reviewed 
in (Exeter and Connell 2010)). 
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Muscle contraction 
Muscle contraction is dependent on a neural signal generated by the brain or the 
spinal cord. Conduction of this signal is ensured by depolarization along the length 
of an α-motor neuron to the axon terminals, where vesicles rich in the 
neurotransmitter acetylcholine are located.  
The neuromuscular junction is a modified synapse between the motor end plate of 
the muscle membrane and the neuron termini. It allows propagation of an action 
potential through the calcium mediated release of acetylcholine and its subsequent 
binding to receptors on the plasmalemma, which in turn triggers the opening of 
sodium channels on the motor end plate.  This local impulse (the end-plate 
potential) leads to subsequent depolarization of the plasmalemma on either side of 
the end plate, including the invaginated extensions known as the T-system. 
Voltage-gated calcium channels lying within the T-tubule membrane (the 
dihydropyridine receptors) respond to the propagated action potential by release of 
calcium from the nearby sarcoplasmic reticulum, thereby exposing the binding sites 
of thin filaments for interaction with their thick filament counterparts (reviewed in 
(Exeter and Connell 2010)). 
Thick and thin filaments create muscle contraction in a process called the sliding 
filament model (Huxley and Niedergerke 1954; Huxley and Hanson 1954). Thick 
filaments contain myosin heads exhibiting a binding site for ATP and actin 
molecules in the thin filaments. After creation of a first bond and initial drawing of 
the thin filament past the thick filament, further sliding is achieved by breaking and 
reestablishing the myosin-actin bond in an ATP dependent manner, without 
shortening, thickening or folding of the individual filament. Both muscle contraction 
and relaxation are energy consuming processes. 
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Muscle fiber types 
Muscle fibers can be classified according to the major isoform of myosin heavy 
chain (MyHC) they express. Eight isoforms are known in mammals (IIa, IIx, IIb, 
embryonic, perinatal, slow/I, extraocular, and α), each encoded by a distinct gene 
and featuring its own myosin ATPase activity. In muscles of adult rodents, four 
isoforms (slow/I, IIa, IIx, and IIb) are present, whereas in humans three isoforms 
(slow, IIA, and IIX) predominate (Weiss and Leinwand 1996). 
The slow oxidative or red fibers are characterized by slow isoform contractile 
proteins, high levels of myoglobin, high oxidative capacity and volume of 
mitochondria, as well as high lipid content and capillary density. They are used in 
low-intensity exercise or endurance events, produce less force than their type II 
counterparts, but are more resistant to fatigue. Transcriptionally, they are 
determined by BLIMP1, a transcriptional repressor targeting the transcription factor 
SOX6 (Baxendale, Davison et al. 2004). 
The other extreme are the fast glycolytic or white IIB fibers, featuring fast isoform 
contractile proteins, low levels of mitochondria and myoglobin, low lipid content and 
capillary density, but high glycolytic capacity. MyHC IIA and IIX fibers are 
intermediate fast oxidative-glycolytic fibers, IIA being more related to slow fibers 
and IIX being more similar to IIB fibers. Fast glycolytic fibers are used for short 
duration, high-intensity activities ranging from middle distance running (IIa fibers) to 
sprinting (IIx fibers), reviewed in (Mallinson, Meissner et al. 2009).  
Development of fast-twitch fibers is controlled by SIX1 and SIX4, transcription 
factors also playing a role postnatally in the often pathological adaptation of muscle 
to the fast-twitch muscle fiber phenotype (Niro, Demignon et al. 2010). Moreover, 
intrinsically different myogenic precursors or satellite cells are recruited during 
development as well as during regeneration of slow- or fast-twitch muscle fibers 
(Kalhovde, Jerkovic et al. 2005). 
Correct fiber type composition is imperative for normal muscle function; many 
pathological conditions are associated with an imbalance in fiber type, particularly 
loss of slow muscle fibers. In humans, clinical studies have shown that individuals 
with muscles that are rich in oxidative type I fibers tend to confer favorable 
metabolic health, and are less likely to predispose to obesity and insulin resistance 
(Marin, Hogh-Kristiansen et al. 1992; He, Watkins et al. 2001). 
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The satellite cell and its molecular signature 
Besides myocyctes, skeletal muscle also contains satellite cells (SCs), stem cells, 
residing beneath the basal lamina closely juxtaposed to the plasma membrane 
(Mauro 1961). At the time of discovery of satellite cells in the early sixties, skeletal 
muscle was known to be capable of regeneration, but the mechanisms involved and 
the relationship between muscle formation in the primary myotome and the role of 
satellite cells in adult muscle tissue was not yet established. SCs were later 
accepted to be the key players in skeletal muscle regeneration and adult 
myogenesis.   
SCs constitute around 2.5-6% of all nuclei of a given mammalian muscle fiber, but 
are quiescent in adult, healthy tissue. The molecular signature of these quiescent 
cells is not unique, but characteristic. Table 2 gives an overview of markers 
associated with SC characterization, published often in the context of obtaining 
“pure” SCs for transplantation and reviewed in (Tedesco, Dellavalle et al. 2010).  
Table 2: Satellite cell markers.  
Abbreviations: BM: bone marrow, HGF: hepatocyte growth factor, HSC: hematopoietic stem 
cells, IF: intermediate filament, SCs: satellite cells, SDF1: Stromal cell-derived factor 1, TF: 
transcription factor, figure adapted from (Tedesco, Dellavalle et al. 2010) 
Marker SC expression Localization Function 
Expression in 
other cells 
Reference 
Pax7 
100% of quiescent 
and activated SCs 
Nucleus TF Absent 
(Zammit, 
Relaix et al. 
2006) 
Pax3 
Quiescent SCs 
(subset of muscles) 
 
Nucleus TF 
Melanocyte 
stem cells 
(Relaix, 
Montarras et 
al. 2006) 
Myf5 
 
Most quiescent 
SCs; All 
proliferating SCs 
and myoblasts 
Nucleus 
 
TF 
 
Absent 
 
 
(Tajbakhsh, 
Bober et al. 
1996) 
 
Foxk1 
Quiescent & 
Activated  SCs 
Nucleus 
Nuclear 
factor 
Neurons 
 
 
 
(Garry, 
Meeson et 
al. 2000) 
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Marker SC expression Localization Function 
Expression in 
other cells 
Reference 
Syndecan-3 
and -4 
Quiescent & 
Activated  SCs 
Membrane 
Trans- 
membrane 
heparan 
sulfate 
proteogly-
can 
Brain, dermis, 
BM, bone, 
smooth 
muscle, 
tumors 
(Cornelison, 
Filla et al. 
2001) 
VCAM-1 
Quiescent & 
Activated  SCs 
Membrane 
Adhesion 
molecule 
Activated 
endothelial 
cells 
(Rosen, 
Sanes et al. 
1992) 
c-met 
Quiescent & 
Activated  SCs 
Membrane 
HGF 
receptor 
Many tissues 
and tumors 
(Cornelison 
and Wold 
1997) 
CD34 
Quiescent & 
Activated  SCs 
Membrane 
Membrane 
protein 
Hematopoietic, 
endothelial, 
mast and 
dendritic cells 
(Beauchamp
, Heslop et 
al. 2000) 
CD56 
Quiescent & 
Activated  SCs: 
myoblasts 
Membrane 
Homophilic 
binding 
glycol- 
protein 
Glia, neurons 
and natural 
killer cells 
(Betsholtz 
2004) 
M-cadherin 
Quiescent & 
Activated  SCs; 
Myoblasts 
Membrane 
Adhesion 
molecule 
Absent 
 
(Irintchev, 
Zeschnigk et 
al. 1994) 
Calveolin-1 
Quiescent & 
Activated  SCs; 
myoblasts 
Membrane 
Membrane 
protein 
Endothelial 
fibrous and 
adipose tissue 
(Gnocchi, 
White et al. 
2009) 
α7 Integrin 
Quiescent & 
Activated  SCs; 
myoblasts 
Membrane 
Adhesion 
molecule 
Vessel-
associated 
cells 
 
(Blanco-
Bose, Yao et 
al. 2001) 
 
β1 Integrin 
Quiescent & 
Activated  SCs 
Membrane 
Adhesion 
molecule 
Many tissues 
(Kuang, 
Kuroda et al. 
2007) 
 
Cxcr4 
Subset of quiescent  
SCs 
Membrane 
SDF1 
receptor 
HSC, vascular 
endothelial 
and neuronal 
cells 
(Sherwood, 
Christensen 
et al. 2004) 
Nestin 
Around 98% of 
quiescent SCs and 
myoblasts 
IF IF protein 
Neuronal 
precursor cells 
(Day, Shefer 
et al. 2007) 
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The most prominent and uniformly expressed marker of SCs is the transcription 
factor paired box 7 (Pax7) which is essential for satellite cell specification and 
survival (Kuang, Charge et al. 2006). In contrast, its family member Pax3, playing a 
fundamental role in embryonic myogenesis, is expressed in a more restricted 
fashion by special muscle groups, especially the diaphragm. Furthermore, the large 
majority of murine SCs express the helix-loop-helix gene myogenic regulatory factor 
5 (Myf5) and the surface marker cluster of differentiation 34 (CD34) (Beauchamp, 
Heslop et al. 2000). However, CD34 does not mark SCs in human muscle. M-
cadherin, on the other hand, is just a consistent marker for human SCs, while in 
mouse this consistency is lost.  
It is still a heavily debated topic which markers exactly constitute a satellite cell, and 
the safest way to classify a cell as satellite cell is still to determine its anatomical 
location. The set of markers expressed during activation and subsequent 
differentiation will be discussed below. 
 
Skeletal Muscle Repair 
Satellite cells are the main players in skeletal muscle repair and regeneration, 
which can be  characterized by three overlapping, yet distinct phases (Ciciliot and 
Schiaffino 2010) occurring in around seven days in mice (Zammit, Heslop et al. 
2002) and around two weeks in humans (Chambers and McDermott 1996): 
 
The immediate inflammatory response 
Upon trauma of the muscle fiber characterized by fiber necrosis, plasma membrane 
dissolution and calcium influx, myofibrils and other cell constituents are readily 
degraded by calcium-dependent proteases such as the calpains. The initial 
inflammatory response is a characteristic Th1 (T helper cell type 1) response, first 
dominated by neutrophils and subsequently by macrophages (Tidball and Villalta 
2010).  
Two distinct populations fulfill important functions in this response (Chazaud, 
Brigitte et al. 2009). Initially, about 24 hours after injury, inflammatory macrophages 
expressing the surface marker CD68 secrete pro-inflammatory cytokines such as 
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tumor necrosis factor alpha (TNFα) and interleukin 1 beta (IL-1β), thereby 
promoting the phagocytic removal of necrotic debris, but also causing  further tissue 
damage by the release of nitric oxide (Tidball and Villalta 2010).  
Later, around 2-4 days after injury, a second population of anti-inflammatory 
macrophages takes over: These CD163 positive cells not only terminate the 
inflammation by secreting anti-inflammatory cytokines such as interleukin 10 (IL-10) 
but also promote muscle regeneration (Tidball and Wehling-Henricks 2007).  It is 
believed that pro-inflammatory cytokines like TNFα promote SC proliferation, 
whereas anti-inflammatory signals like IL-10 an IL-4 promote their differentiation 
and fusion (Horsley, Jansen et al. 2003; Mann, Perdiguero et al. 2011). 
At the same time, scar tissue is built up at the site of rupture. The base provided by 
fibrin and fibronectin allows fibroblastic invasion and subsequent synthesis of 
collagen (initially type III, then type I) as well as other components of the 
extracellular matrix (Jarvinen, Kaariainen et al. 2000). 
 
Activation, differentiation and fusion of satellite cells 
After two days following injury, satellite cells massively expand and rapidly 
proliferate, triggered by activating stimuli. One of them is sphingosine-1-phosphate 
on the inner membrane of satellite cells crucial for SC cell cycle entry (Nagata, 
Partridge et al. 2006), but also insulin-like growth factor (IGF), fibroblast growth 
factor (FGF) and nitric oxide (NO) play important roles. NO works through activation 
of matrix metalloproteases which in turn release hepatocyte growth factor (HGF) 
from the extracellular matrix (Tatsumi, Liu et al. 2006). Satellite cells express the 
HGF receptor c-Met and thereby receive a proliferation stimulus (Tatsumi, 
Anderson et al. 1998). At the same time differentiation is inhibited (Miller, Thaloor et 
al. 2000), so that other signaling pathways need to drive muscle regeneration 
forward.   
Proliferating satellite cells give rise to two progenies depicted in Figure 8. One 
minor fraction retains the undifferentiated Pax7+ MyoD- satellite- cell state and 
returns to quiescence, many others become committed myogenic precursors 
(Pax7+ MyoD+) and subsequently express muscle regulatory factors, MRFs, 
including MyoD, Myf5, Mrf4 and myogenin. 
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Figure 8: Activation of SCs giving rise to different populations by asymmetric cell division 
adapted from (Tedesco, Dellavalle et al. 2010) 
 
A fine-tuning between Wnt- and Notch signaling pathways is considered to be 
accountable for this asymmetric cell division (Brack, Conboy et al. 2008): Whereas 
Notch is prevalent during the proliferation phase and boosts expansion of satellite 
cell progeny, canonical Wnt drives differentiation. If Wnt is expressed too early, 
differentiation starts prematurely without sufficient myoblasts present to repair a 
given damage. 
 
Differentiation occurs very soon after activation and is marked by expression of 
myosin heavy chain and formation of myotubes by fusion of myoblasts. These 
newly formed myotubes express developmental markers such as embryonic myosin 
heavy chain and the cardiac factor troponin T that are also expressed in embryonic 
skeletal muscle. The newly formed fibers invade the scar tissue that has formed at 
the site of injury, creating minute myotendious junctions. The muscular side of 
these newly formed junctions remains the weakest spot of the injured muscle. 
(Reviewed in (Exeter and Connell 2010) and (Ciciliot and Schiaffino 2010)) 
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Maturation of newly formed myofibers and remodeling of muscle 
The extent to which regenerated muscle grows and regains function depends on a 
variety of factors, such as the type of muscle injury, the involvement of blood 
vessels and the reestablishment of neuromuscular and myotendious junctions. 
The integrity of the basal lamina during injury and the formation of new 
neuromuscular junctions (ensuring innervation of the muscle) are imperative for 
successful regeneration.  The former is essential, as myoblasts can readily 
proliferate and fuse with existing myofibers beneath an intact basal lamina; the 
latter, as muscles that fail to reestablish neuromuscular junctions remain atrophic 
(Rantanen, Ranne et al. 1995). 
Another hallmark of continuing regeneration is the switch from embryonic to adult 
forms of myosin heavy chain in newly formed myotubes (Jirmanova and Thesleff 
1972). This step can occur even in the absence of functional innervations whereas 
a second, equally important switch to slow myosin heavy chain clearly requires the 
activity of slow motor neurons (Jerkovic, Argentini et al. 1997).  
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The satellite cells in disease-muscular dystrophies 
Muscular dystrophies (MD) are a clinically and genetically heterogeneous group of 
muscle diseases characterized by progressive skeletal weakness. They can be 
inherited in an autosomal dominant, recessive, or X-linked fashion and can result 
from mutations affecting either structural proteins that localize to the sarcolemma, 
nuclear membrane, basement membrane, sarcomere, or nonstructural enzymatic 
proteins. Clinical variability manifests in age of onset, strength and progression of 
the muscle weakness as well as the presence of other symptoms, as reviewed in 
(Amato and Griggs 2011).  
Next to Emery-Dreifuss MD, Congenital MD and Limb-Girdle MD that are part of the 
laminopathies and therefore described earlier, the disease group also encomprises 
Duchenne and Becker MD (caused by mutations in the DMD gene), distal MD 
(DYSF and many other genes), facioscapulohumerfal MD (Cromosone 4q35, D4Z4 
unit contraction), myotonic MD (DMPK or ZNF9 gene) and oculopharyngeal MD 
(PABN1 gene), reviewed in (Morgan and Zammit 2010). 
Duchenne Muscular Dystrophy, which is not only the most common MD but also the 
most common lethal genetic pediatric disorder, is caused by nonsense and frame-
shifting mutations in the dystrophin gene (DMD) resulting in failure to produce a 
functional dystrophin protein. In the case of mutations that maintain an open 
reading frame and thus produce a functional but truncated dystrophin protein, a 
milder variant of the disease (Becker Muscular Dystrophy) arises. When completely 
functional dystrophin is lost, muscles become susceptible to mechanical injury 
which results in the disruption of muscle tissue architecture, chronic inflammation, 
and replacement of functional muscle tissue by adipose and fibrous connective 
tissue (reviewed in (Guglieri and Bushby 2010)).  
An interesting aspect of disease progression is the fact that the repaired and 
regenerated myofibers still contain the mutated proteins and therefore also become 
subject to the same damages, leading to chronic rounds of degeneration and repair. 
Ongoing regeneration can be determined on an histological level by the presence of 
developmental myosin heavy chain isoforms, variable fiber sizes and central 
nucleation (Morgan and Zammit 2010). This constant repair is mediated by satellite 
cells that are not directly affected by the pathogenic dystrophin mutation as they do 
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not express this protein or other components of the affected dystrophin-associated 
protein complex (DAPC).  
Still, over time, their proliferative potential gets lost, accelerated in comparison to 
normal aging,  causing a failure to maintain muscle homeostasis (Webster and Blau 
1990; Luz, Marques et al. 2002; Wagers and Conboy 2005). Satellite-cell 
exhaustion may at least partly be caused by shortening of telomere ends after 
repeated rounds of DNA replication, by the hostile environment due to inflammatory 
conditions and oxidative stress, or by an accumulation of mutations in key satellite-
cell regulatory genes and subsequent transcriptional dysregulation (Decary, 
Hamida et al. 2000) and (Renault, Thornell et al. 2002). 
In other muscular dystrophies like EDMD or OPMD (Brais 2009), the mutated 
protein is expressed in both muscle fibers and satellite cell, adding – to the already 
existing stem cell exhaustion mentioned before- the possibility of more direct effects 
on satellite cell function, such as failure to enter cell cycle from quiescence, 
proliferate and expand the SC pool, withdraw from cell cycle and differentiate or 
failure to fuse with already existing myotubes (reviewed in (Morgan and Zammit 
2010).  
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The aim of the study 
LAP2α and intranuclear lamins were reported to function in the regulation of the 
pRb-pathway, likely independent from the peripheral lamina.  A complex of A-type 
lamins and LAP2α in the nuclear interior was suggested to regulate the proliferation 
and differentiation of tissue progenitor cells during tissue homeostasis. Given that 
mutations in both LAP2α and Lamin A/C have been linked to tissue-specific 
disorders with overlapping pathologies, it was tempting to speculate that an 
impairment of the function of the lamin A/C-LAP2α complex by disease causing 
mutations may affect the regulation of tissue progenitor cells, which may contribute 
to some of the observed pathologies at cellular or tissue level. The aim of this study 
was to assess the impact of different disease causing mutations on the formation 
and regulation of the lamin - LAP2α interaction and to elucidate the role of 
intranuclear lamin complexes in muscular dystrophies.  
To this end, a previously generated CMD- mouse model featuring a mutation in 
lamin A (LmnaΔK32/ΔK32) was crossed to mice lacking LAP2α protein.  
This CMD mouse model was chosen particularly for the reported defective 
assembly of lamin ΔK32, expected to result in an increased pool of lamins in the 
nuclear interior. The Lap2α-/- mouse model, on the other hand, is to this date the 
only mouse model specifically affecting intranuclear lamins without interfering with 
the peripheral lamina. The resulting double mutant mice (LmnaΔK32/ΔK32, Lap2α-/-) 
were analyzed on a general phenotypical level to determine a possible 
improvement in survival ability and/or disease severity. Muscle, being the tissue 
primarily affected in CMD, was analyzed on a histological level and the behavior of 
primary muscle cells in vitro (in response to induced differentiation) was examined.  
We particularly emphasized the analysis of muscle specific progenitor cells. 
In a second approach, the first reported EDMD–causing mutation in LAP2α (P426L) 
was characterized in molecular detail. We first confirmed the pathology at tissue 
level by histochemical analyses and aimed particularly at the identification of 
potential disease mechanisms. As this mutation may affect the previously reported 
function of LAP2α in the pRb-mediated cell cycle control of tissue progenitor cells, 
the cell cycle properties of primary patient cells were investigated. In addition, the 
effects of the mutation on the interaction of LAP2α and lamin A/C were analyzed. 
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Materials and Methods 
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Specific materials and methods can also be found in the submitted 
manuscripts! 
Transgenic mouse models 
Mice were maintained in accordance with the procedures outlined in the Guide for 
the Care and Use of Laboratory Animals. Animal experiments were performed 
according to permissions from Austrian authorities. Data acquisition was done by 
observers blinded for the genotype of the animal. 
Our group generated LAP2α-deficient mice (Naetar, Korbei et al. 2008) by deleting 
the LAP2α-specific exon 4 in the Lap2 gene (also known as thymopoietin, Tmpo). 
Homozygous mice containing exon 4 flanked by loxP sites were crossed with Cre-
recombinase expressing mice (Schwenk, Baron et al. 1995) and a subsequent loss 
of LAP2α, but not other LAP2 isoforms was confirmed. LmnaΔK32/ΔK32 mice were 
generated by G. Bonne by deleting lysine at position 32 (delAAG) in exon 1 of the 
Lmna gene using PCR mutagenesis and are described in detail in (Bertrand, Renou 
et al. 2012) and Submitted Manuscript I. In order to obtain double mutants and 
littermate controls, mice heterozygous for both LAP2α and Lmna ΔK32 (Lap2α+/-, 
Lmna+/ΔK32) were crossed. All experiments were performed in a mixed genetic 
background (C57BL/6, B6129F1, BALB/c) on postnatal day 15 to 18 animals (same 
age within an experiment), killed by cervical dislocation. 
 
Genotyping 
For determination of the genotype, a small piece (2mm) of mouse tail was clipped 
as soon as possible after birth and dissolved in 70 µl ready-to-use tail-extraction 
buffer (recipe below) at 55°C for at least four hours shaking at 300 rpm. After that, 
the proteinase was inactivated by incubating the sample for 10 min at 96°C and 
1300 rpm shaking. The samples were spun down for 15 min at 13200 rpm and 0.5 
µl (LAP2α) or 1 µl (ΔK32) of tail suspension were utilized in a total volume of 25µl 
for PCR analysis using PuReTaq Ready-To-Go™ PCR Beads (GE Heathcare) 
according to the manufacturer’s protocol. After PCR using the primers and 
programs indicated below, 2.7µl of DNA loading buffer where added before loading 
the sample onto a 0.8% (LAP2α) or 1,5% (ΔK32) TAE-agarose gel substituted with 
0.05µl/ml ethidium bromide. Gel electrophoresis at 75V for 1 hour in a Subcell-GT 
electrophoresis chamber (BIORAD) was followed by UV-illumination on a GelDoc-
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It™TS Imaging System (UVP). All mice used in experiments were re-genotyped 
after extermination. 
Table 3: Genotyping Primers.  
All primers for genotyping were ordered from MWG-Biotech AG and used in working 
solutions of 10 pm/µl. 
  LAP2α 
Exon3sense: 
Exon4antisense: 
IntAfterEx4 antisense: 
5’- CAG GGA ACT GAA TCG AGA TCC TCT AC-3’ 
5’- CAC AAT CCC TAG CGG ACT TCA CTT-3’ 
5’- CTG TGA CTT TGC TGG CCT TCC AGT CTA-3’ 
ΔK32 
delk_F 
delk_R 
5’- CAA AGT GCG TGA GGA GTT CA-3’ 
5’- TGA CAG CAT AGG CCC TGT CAC-3’ 
 
Table 4: Genotyping PCR Program.   
For PCR, the PTC-2000 Peltier Thermal Cycler by MJ Reasearch or its equivalent by 
BIORAD were used. 
LAP2α - DD1 program 
Expected bands:  838 bp (WT), 695 bp (KO), both (HET) 
95°C  2 min 
95°C  30 sec   
62°C  45 sec   37  cycles 
72°C  1 min 
72°C  7 min 
10°C  forever 
ΔK32- DelK321 program 
Expected bands: 263 bp (WT), 336 bp (KI), both (HET) 
94°C  3 min 
94°C  30 sec   
62°C  40 sec   32 cycles 
72°C  40 sec 
72°C  3 min 
10°C  forever 
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Tail-extraction buffer: 
500 mM KCl 
100 mM Tris pH 8.3 
0.2 mg/ml Gelatine 
1% NP40 
1% Tween 20 
Proteinase K solution added 1:25: 
2.5 mg/ml Proteinase K 
50% glycerol 
10 mM Tris pH 7.5 
20 mM CaCl2 
 
Necroscopy 
The mouse was subjected to CO2 until no breathing or movement could be 
observed. Vital signs as checked by paw pinch and leg movement were absent. 
The thorax was opened and venous blood was taken from the right ventricle of the 
still beating heart using a 1ml Injekt®-F single use syringe and a 100 Sterican® 26 
G x 1’’ Size 18 disposable hypodermic needle (B. Braun Melsungen AG) rinsed with 
0,5 M EDTA to avoid coagulation of the blood. 100-300 µl blood were obtained and 
transferred to 0,5 ml MiniCollect collection tubes containing EDTA (Greiner Bio-
One). 
Organs (Liver, kidney, heart, colon, ileum) and muscles (tibialis anterior (TA), 
gastrocnemius and soleus (GC&SOL), diaphragm, extensor digitorum longus 
(EDL)) were collected or immediately used. For cryosections, organs and muscles 
were frozen in ice-cold 2-methyl-butane stored at -80°C. In case of tissues 
embedded in paraffin following procedure was followed: Overnight incubation in 
Roti® Histofix (4% formaldehyde solution, Roth), followed by 3x wash in PBS, 1 h 
incubation in 50% EtOH followed by storage in 70% EtOH at 4°C until processing of 
the sample in a Shandon Excelsor Tissue Processor (Thermo Electron Corporation) 
and embedding in paraffin.  
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Blood analysis 
Blood was obtained by terminal cardiac puncture as the small size of the animals 
ruled out the more common tail bleeding. Therefore, blood analysis could only be 
performed once in every animal. Blood was analyzed within 2 hours of withdrawal 
by the ABC™ Animal Blood Counter (Vet) for standard blood parameters.  
For determination of cholesterol, glucose and creatinine kinase blood levels 32µl of 
blood were pipetted onto the red pad of Reflovet® Cholesterol, Glucose or CK 
strips respectively, which were analyzed by the Reflovet® Plus System (Roche). 
Reference values for each parameter can be found in Table 5. 
Table 5: Reference values for laboratory animals.  
Values for mouse adopted from the Roche Reflovet® manual, the University of Minnesota 
Research Animal Resources (http://www.ahc.umn.edu/rar/refvalues.html) and the Jackson’s 
lab Biology of the Laboratory Mouse. Note: The great range may be accounted for by 
variation in age, sex, breed or strain, sampling technique and testing methodology. As such, 
the range limits are not firm boundaries and should be used as guidelines. 
 Reference value 
Hematocrit (%) 39-49 
Hemoglobin (g/dl) 10.2-16.6 
White Blood Cells (x1000) 6-15 
Red Blood Cells (106 per mm³) 9-11 
Platelets (x1000) 160-410 
Glucose (mg/dl) 62-175 
Cholesterol (mg/dl) 80 – 140 
Creatine Kinase (U/l at 37°C) > 20 
 
Histology 
Hematoxylin & Eosin (HE) staining: 
Staining with hematoxylin/eosin was done using the tissue-processing system Pat 
Histo ASS-1 staining unit according to the (standard) protocol given below. Stained 
sections were transferred to Xylene for 15 minutes, air-dried and mounted in 
Entellan. Microscopic analysis was done on a Zeiss Axio Imager M1 equipped with 
a Zeiss AxioCAm MRc5 and Axiovision LE software (version 4.5) 
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Protocol: 
Xylene substitute   2x 10 min 
100% Ethanol   2x 5 min 
90% Ethanol    2x 2 min 
H20    2 min 
Hematoxylin (Harris)  6 minutes 
H20    10 min 
1% HCl/Ethanol  5 seconds 
H20    10 min 
70% Ethanol    30 seconds 
80% Ethanol    30 seconds 
Eosin     2 seconds 
90% Ethanol    2x 1 min 
100% Ethanol   2x 1 min 
Xylene substitute   2x 5 min 
 
Sirius Red Collagen staining of tissue sections: 
Frozen sections were air-dried and fixed for 5 minutes in 3,7% formaldehyde 
solution, washed in dH20 and stained in Picro-Sirius red for 1 hour (0,1% Sirius red 
in picric acid).  Two washes in 0,5% glacial acetic acid in water followed. Physical 
removal of water was followed by dehydration in 3 changes of 100% ethanol. 
Stained sections were transferred to Xylene for 15 minutes, air-dried and mounted 
in Entellan (Merck).  
 
Periodic Acid-Schiff (PAS) staining of tissue sections: 
Frozen sections were air-dried and fixed in Carnoy’s solution (10% glacial acetic 
acid, 60% Ethanol, 30% Chloroform) for 5 minutes, washed in dH20 and incubated 
in 0,5% periodic acid for 10 min. After washing of the samples incubation in Schiff’s 
reagent (Merck) was allowed to proceed for 30 minutes. The samples were washed 
for 10 min in running tap water before nuclei were counterstained in filtered Mayer’s 
hematoxylin (ROTH) for 10 seconds to one minute. The samples were washed in 
running tap water for another 5 minutes, air-dried and mounted in Mowiol® 4-88 
mounting medium (ROTH).  
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Oil-Red O (ORO) staining of tissue sections: 
Frozen sections were air-dried and fixed for 60 minutes in 3,7% formaldehyde 
solution, washed in dH20 and stained in 0,2% Oil-Red O (Sigma) in 
Triethylphosphate (Fluka) for 30 minutes. 3 washes with dH20 were followed by 10-
60 seconds of staining in Harris modified hematoxylin (Sigma). The samples were 
washed in running tap water for 10 minutes, air-dried and mounted in 10% glycerol 
in PBS or Mowiol® 4-88 mounting medium (ROTH). 
 
Immunohistochemical and immunofluorescence staining of tissue sections: 
For IHC, the paraffin-embedded sections were incubated o/n at 50° and 
deparaffinized using either program 2 of the Pat Histo ASS-1 staining unit (equal to 
steps 1-7 of HE staining) or performing these steps manually. Boiling in citrate 
working solution for 30-60 minutes was followed by a 5 minutes wash in dH20. 
Inactivation of endogenous peroxidases was achieved by incubation of the sections 
in 2% H202 for 15-30 minutes. 3 five-minute washes in PBS and 5 minutes in 0,1% 
Tritin-X100 in PBS preceded the blocking step for 20-20 minutes in M.O.M Mouse 
Ig Blocking Reagent, goat serum  or Vectastain Rabbit IgG (Vector Laboratories 
Inc.) according to the manufacturer’s protocol.  
Primary antibodies were diluted in M.O.M protein diluent and incubated o/n at 4°. 
Sections were washed in PBS before the secondary (biotinylated) antibody was 
applied for 1 hour at room temperature. Vectastain Elite ABC reagent was prepared 
and sections were developed in DAB substrate solution according to the 
manufacturer’s protocol. Nuclei were visualized by Harris modified Hemtoxylin, 
sections were washed in running tap water for 10 minutes, dehydrated for 2 
minutes in 60%, 70%, 80% and 96% Ethanol, followed by incubation in Xylene, and 
mounted in Entellan (Merck).  
In the case of IF, the protocol was followed until the application of the fluorochrome-
coupled secondary antibody, which was applied in the dark and incubated for 1h at 
RT. Sections were washed for 3 times 5 minutes in PBS and 1 time in H20 before 
counterstained with DAPI or Hoechst solution. After rinsing in distilled water, slides 
were mounted in Mowiol® 4-88 mounting medium (ROTH). 
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Frozen sections were treated differently, in so much as freshly obtained cuts were 
allowed to air-dry for 10 minutes, followed by a 20 minute fixation in 3, 7% 
formaldehyde-solution in PBS. After washing in PBS sections were incubated in a 
freshly prepared 50mM NH4Cl solution for 5 minutes, followed by washing and 
permeabilization in 0,5% Triton X-100/PBS for 5 minutes. After another washing 
cycle in PBS, cells were blocked for 30 minutes in goat serum, MOM blocking 
reagent or MOM protein diluent. Primary antibodies were diluted in blocking solution 
and applied o/n at 4°. After that, either the before-mentioned protocol for IHC or IF 
was followed. 
For visualization by confocal microscopy, a Zeiss Axiovert 200M microscope 
equipped with a Zeiss LSM510META confocal laser-scanning unit, and a Plan-
Apochromat 63x/1.40 Oil DIC MC27 objective (Zeiss) was used. For other 
analyses, like counting centrally located nuclei or measuring epidermal thickness, 
the sections were viewed in a Zeiss Axiovision light microscope equipped with a 
camera and analyzed using Axiovision Rel4.7 software (Zeiss). 
 
Cell Culture 
Primary human fibroblasts 
Primary patient fibroblasts (G-11340) and control cells (TD) were kindly provided by 
Manfred Wehnert and cultured at 37°C, in an atmosphere containing 7,5% CO2 in 
DMEM supplemented with 20% fetal calf serum, 50 U/ml penicillin, 50 µg/ml 
streptomycin and 2 µM l-glutamine (all from Invitrogen). Experiments were 
performed between passages 11 and 21.  For analysis of cell growth, 105 cells per 
well were seeded on 6-well plates and cumulative cell numbers were determined 
daily using a CASY counter Model TTC (Schärfe System). For synchronization, 
cells were serum starved (DMEM supplemented with 0,5% FCS, 50 U/ml penicillin, 
50 µg/ml streptomycin and 2 µM l-glutamine) for 5 days. After restimulation with 
20% FCS medium propidium iodide staining was done following standard protocols 
and cells were sorted on a BD Biosciences FACSCalibur system. Data were 
quantified using FlowJo software (Tree Star). SDS-PAGE and immunoblot were 
performed as described (Dechat, Gotzmann et al. 1998). 
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Immortalized human myoblasts 
Immortalized human myoblasts (using the E6E7 region of papillomavirus, a kind gift 
of M. Wehnert, Greifswald) were cultivated at 37°C and 8,5% CO2 in Skeletal 
Muscle Cell Growth Medium® (Promocell, 5% FCS, 50 µg/ml Fetuin, 1 ng/ml Basic 
Fibroblast factor, 10 ng/ml Epidermal Growth Factor, 10 µg/ml Insulin, 0.4 µg/ml 
Dexamethasone) supplemented with 400 µg/ml G-418 and 250 ng/ml Gentamycin. 
Cells were trypsinized when 80% confluence was reached. Cells are not entirely 
immortalized but exhibit a significantly increased lifespan. In order to keep the 
immortalization vector stably integrated, G-418 has to be added to the culture 
medium. 
 
Primary fibroblast isolation 
Primary fibroblasts were isolated on day 1-3 pn from back skin of newborn mice as 
described (Andra, Nikolic et al. 1998; Naetar, Korbei et al. 2008). Cells were 
cultivated in high glucose DMEM, 10% fetal calf serum (FCS), 50 U/ml Penicillin, 50 
µg/ml Streptomycin and 0.2 µM L-Glutamine (all from Invitrogen) at 37°C and 5% 
CO2, with medium change every other day and split when 80% confluence was 
reached.  Experiments were performed between passage 1 and 4. 
 
Primary myoblast isolation 
Primary myoblasts were obtained from de-skinned front and hind limbs of neonatal 
mice (2 days old) as described in great detail in (Gotic, Schmidt et al. 2010). 
Proliferating cultures were maintained at low confluence and medium change every 
other day.  
For splitting, cells were washed in PBS and trypsinized for 5minutes at 37°C, then 
collected in medium, centrifuged for 3 minutes at 1100 rpm in a Heraeus centrifuge 
and recollected in growth medium. Before transferring them to collagen-coated 
plates, cells were pre-plated for 2-3 hours on uncovered cell culture Petri dishes to 
remove contaminating fibroblasts.  
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To induce muscle differentiation, growth medium (20% FCS / 2.5 ng/ml basic FGF / 
Hams’ F-10 / Pen-Strep) was substituted by DMEM containing 5% horse serum 
containing penicillin and streptomycin. All cells were kept on collagen coated dishes 
or cover slips in a humidified atmosphere at 37°C and 5% CO2. 
  
Isolation of skeletal muscle progenitor cells (SMPCs) 
Mice were euthanized and single fibers from particular muscles (Tibialis anterior 
(TA), Extensor digitorum longus (EDL), Soleus (SOL), Gastrocnemius (GC), 
Quadriceps (QC), Triceps and Biceps Brachii) were isolated according to a modified 
protocol described in previous studies (Gotic, Schmidt et al. 2010), (Shefer and 
Yablonka-Reuveni 2005). Shortly, muscles were collected in PBS and subsequently 
incubated in sterile 0.2% collagenase I (Gibco)/DMEM solution (3 ml/50 mg of 
tissue) for 1.5 – 2 hours (young and old animals respectively) in a shaking water 
bath at 37ºC. Muscle digestion was stopped by transferring samples to a series of 
DMEM containing Petri dishes coated with filtered horse serum. Single fibers were 
released by gentle trituration, collected in DMEM and pelleted by centrifugation at 
17 g for 5 min. After washing twice in PBS, fibers were resuspended in 0.01% 
collagense II (Gibco)/0.15 U/ml dispase II (Roche Applied Science)/PBS and 
incubated for 30 min at 37ºC shaking. Samples were filtered through 40 μm pore 
cell strainers and cells were pelleted by 5 min centrifugation at 210 g. After washing 
twice in PBS, samples were stained on ice for 30 min in 2% FCS/PBS containing 
following antibody cocktail: 
anti-CD45:  APC conjugated anti mouse CD45 (Ly-5), eBioscience 
anti-Sca1: PerCP-Cy5.5 conjugated anti mouse Sca-1 (Ly-6A/E), eBioscience 
anti-Mac1: APC conjugated anti mouse CD11b, eBioscience 
anti-CXCR4: FITCS rat-anti mouse  CD184 (CXCR4), BD Pharmingen™ 
anti-β1-integrin: PE anti mouse/rat CD29, eBioscience 
Cells were washed and analyzed using FASCAria equipped with DIVA acquisition 
software (BD Biosciences) as described in (Cerletti, Jurga et al. 2008). In brief, 
viable cells were first analyzed on the basis of size and granulation. Subsequently, 
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a population of cells homogenous in size was tested for the expression of CD45, 
Mac1 and Sca1 surface markers and a subpopulation of CD45-Sca1-Mac1- cells 
was selected for CXCR4 and β1-integrin expression analysis. The number of CD45-
Sca1-Mac1-CXCR4+β1-integrin+ cells in each mouse sample was presented as 
percentage within the parent CD45-Sca1-Mac1- population. After sorting, SMPCs 
were allowed to settle on adhesion slides (Biorad) before following a standard 
protocol for immunofluorescence. 
 
Propidium iodide staining for flow cytrometry 
Cells were trypsinized, resuspended in 1ml PBS and fixed by letting drop into 4 ml 
of 85% ethanol under vortexing. They were stored at -20°C for at least 24 h before 
being spun for 5 minutes at 1200 rpm. The supernatant was discarded; pellets were 
washed once in PBS and subsequently resuspended in a 4 µl/ml propidium iodide 
solution supplemented with 10 µl/ml RNaseA. After incubating at 37 °C (shaking) for 
30 min, cells were transferred into FACS tubes equipped with a meshed lid. 
 
Immunofluorescence of fixed cells 
For immunofluorescence, cells were trypsinized and plated on to dishes or wells 
containing poly-lysin coated glass cover-slips. The next day, the medium was 
aspirated, cells were washed twice in PBS and fixed either in 4% paraformaldehyde 
for 10 minutes at room temperature or chilled methanol for 1 minute at -20°C.  After 
washing in PBS, cells were incubated in a freshly prepared 50 mM NH4Cl solution 
for 5 minutes, followed by washing and permeabilization in 0,5% Triton X-100/PBS 
for 5 minutes. After another washing cycle in PBS, cells were blocked for 30 
minutes using 0,5% gelatin/PBS and subsequently incubated with primary 
antibodies diluted in blocking buffer. After washing 3 times 5-15 minutes secondary 
antibodies were added and cells were incubated in the dark for 30-45 minutes. After 
washing with PBS, nuclei were visualized using DAPI or Hoechst solutions. Cells 
were washed in distilled water and mounted in Mowiol® 4-88 mounting medium 
(ROTH). 
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Western Blot 
Cell lysates for Western blotting were obtained by direct lysis in the cell culture dish 
by addition of a standard protein sample after washing twice with PBS, followed by 
cooking for 5 minutes at 96°C. 
For tissue lysates, frozen tissue was homogenized in a lysis buffer (25mM HEPES 
pH7.5, 25mM TrisHCl pH7.5, 100mM NaCl, 5mM MgCl2, 10mM EGTA 1x Protease 
Inhibitor Cocktail Complete© EDTA free (Roche), 1mM DTT, 0.5mg/ml DNAseI, 
0.5mM β-G-P) using a Precellys 24 homogenizer (PeqLab Biotechnology) with 
programs 6500 rpm 2x15 sec (heart and muscle) or 5000 rpm 2x10 sec (liver, 
kidney, spleen) with appropriate beads. Following homogenization, lysates were 
incubated for 1 h at 4° shaking end-over-end with 0.4% TritonX-100, 0.5% NP-40, 
0.1%Tween-20 and 0.5% SDS. Lysates were centrifuged for 15 minutes at 13000g, 
diluted in standard protein sample buffer and cooked at 96°C for 5 minutes. 
SDS-PAGE and immunoblotting was performed according to standard protocols, 
using antibodies stated below. 
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Antibodies 
Following antibodies were used in IF, IHC or Western Blotting: 
Table 6: List of antibodies used in IF, IHC and Western Blotting 
Antigen Name 
Lamin A/C: Goat polyclonal anti Lamin A/C antibody (N18, 
Santa Cruz), or mouse monoclonal Lamin A/C 3A6-
4C11 Active Motif, provided by E. Ogris (Roblek, 
Schuchner et al. 2010) 
LAP2α: Rabbit antiserum to LAP2α (245) (Vlcek, Korbei et 
al. 2002) and mouse monoclonal to LAP2α 
(Dechat, Gotzmann et al. 1998) 
Emerin: Mouse monoclonal anti Emerin MANEM 5 provided 
by Glenn Morris and NCL-Emerin, Novocastro 
Lamin B : C20, Santa Cruz 
Total pRb: G3-245, BD Biosciences and IF8, Santa Cruz 
pRb S780 and  
pRb S807/811: 
Cell Signaling Technologies 
 
KI67: NCL-KI67p, Novocastra 
eMyHC: F1.652,  Developmental Studies Hybridoma Bank 
γ-tubulin: B-5-1-2, Sigma 
Actin: A-2066, Sigma 
 
Quantitative real time PCR 
Total RNA was isolated from muscle tissue and cultured cells using TRIzol® 
reagent (Invitrogen) or RNeasy® Plus Micro Kit (Qiagen) according to 
manufacturer’s instructions. cDNA was synthesized by First Strand cDNA Synthesis 
Kit for RT-PCR (Roche) and specific sequences were subsequently amplified on an 
Mastercycler® ep realplex (Eppendorf) using  MESA GREEN qPCR MasterMix Plus 
for SYBR Assay I TTP (Eurogentec) for quantitative PCR. Specific primers are 
listed in Table 7. Primer efficiency for each primer pair was tested using serial 
dilutions of WT mRNA. 
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Data were documented using Mastercycler® ep realplex software (Eppendorf) and 
processed by Microsoft Excel XP. Endogenous levels of Hprt (Hypoxanthine-
Guanine Phosphoribosyltransferase) in quantitative PCR were used for data 
normalization according to the Pfaffl method (Pfaffl 2001). Alternatively, the Relative 
Expression Software Tool (REST) 2009 was used (QIAGEN). 
Table 7: Primers used in qRT-PCR 
Name/Target Sequence Tm °C Source 
Hprt_forward TGATTAGCGATGATGAACCAGG 58,4 
(Gotic, Schmidt 
et al. 2010) 
Hprt_reverse CTTTCATGACATCTCGAGCAAG 60,3 
LaminA_reverse TGAGCGCAGGTTGTACT 52,8 
LaminC_reverse TAGGCTGGCAGGGCTAC 57,6 
LaminA/C_forward GCACCGCTCTCATCAACT 56 
Dystrophin_forward GACACTTTACCACCAATGCG 57,3 
Dystrophin_reverse CTCAGATAGTTGAAGCCATTTTA 55,3 
MyHC2b_forward ACAAGCTGCGGGTGAAGAGC 61,4 (Usami, Abe et 
al. 2003) MyHC2b_reverse CAGGACAGTGACAAAGAACG 57,3 
Emerin_forward GTTATTTGACCACCAAGACATACGGG 63,2 (Ozawa, Hayashi 
et al. 2006) Emerin_reverse GGTGATGGAAGGTATCAGCATCTACA 63,2 
RB1_forward TACACTCTGTGCACGCCTTC 59,4 
(Frock, Kudlow 
et al. 2006) 
RB1_reverse TCACCTTGCAGATGCCATAC 57,3 
MyoD_forward CATCCGCTACATCGAAGGTC 59,4 
MyoD_reverse TAGTAGGCGGTGTCGTAGCC 61,4 
Desmin_forward TACACCTGCGAGATTGATGC 57,3 
Desmin_reverse ACATCCAAGGCCATCTTCAC 57,3 
Crebbp-1 forward TCTCTCCCACACTGTCGAACC 66,7 (Pasini, 
Malatesta et al. 
2010) 
Crebbp-1 reverse AGAGATGATTTGTCGTGAAGATGC 65,4 
MEF2C-RT2-1 GTATGTCTCCTGGTGTAACA 55,3 (Azmi, Ozog et 
al. 2004) MEF2C-RT2-2 GGATATCCTCCCATTCCTTG 57,3 
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Vectors 
Vectors featuring prelamin A ΔK32 
The ΔK32 mutation was introduced in all vectors by in vitro mutagenesis of the 
prelamin A cDNA using a QuikChange™ Site-Directed Mutagenesis Kit 
(Stratagene), following manufacturer’s instructions and following primers: 
FOR: 5’-AGGAGGAGGACCTGCAGGAGCTCAATG-3’,  
REV:5’-AGGTCCTCCTCCTGCAGCCGGGTGA-3’.  
All constructs were sequenced (LGC genomics) to confirm mutagenesis and 
integrity. 
 
Table 8: List of created vectors featuring Lamin ΔK32 
Name of 
Construct 
Vector 
Backbone 
Insert 
Selection 
Markers 
Expression 
Pro-
moter 
Tag-
Epitope 
Gateway 
entry 
vector 
Cloning 
Strategy 
pUP3 
pENTR/ 
SD/D-
Topo 
prelamin 
A full 
length, 
ΔK32 
Kan 
(bac) 
entry 
vector 
pUC; 
T7 
none yes 
SDM of 
pRK1 
pUP21 PET24 
prelamin 
A full 
length, 
ΔK32 
Kan 
bacterial 
expressio
n 
T7 T7 tag no 
SDM  of 
205 TD 
pUP23 pSVK3 
prelamin 
A full 
length, 
ΔK32 
Amp 
eukaryotic  
/in vitro 
SV4
0/T7 
N-
term. 
FLAG 
no 
SDM of 
pSVK3 
lamin A 
 
Vectors featuring LAP2α P426L 
The P426L mutation was introduced in all vectors by in vitro mutagenesis of the 
LAP2α cDNA using a QuikChange™ Site-Directed Mutagenesis (SDM) Kit 
(Stratagene), following manufacturer’s instructions and following primers: 
 
FOR: 5’-CCTGTCTCCTCTAAGAAAAGTCCCTA-3’, 
REV: 5’-CTAGGGACTTTTCTTAGAGGAGACAGGA-3’.  
All constructs were sequenced (LGC genomics) to confirm mutagenesis and 
integrity. 
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Table 9: List of created vectors featuring LAP2α P426L 
Name of 
Construct 
Vector 
Backbone 
Insert 
Selection 
Markers 
Expression 
Pro-
moter 
Tag-
Epitope 
Gateway 
entry 
vector 
Cloning 
Strategy 
pUP6 
pENTR
D-Topo 
hLAP2α 
P426L 
with 
stop 
Kan 
(bac) 
entry 
vector 
T10 none yes 
SDM of 
gAG41 
pUP11 
pENTR
D-Topo 
hLAP2α 
P426L 
wo  stop 
Kan 
(bac) 
entry 
vector 
CMV none yes 
SDM of 
gAG42 
pUP24 pSVK3 
LAP2α 
P426L 
Amp 
eukaryotic 
expressio
n /in vitro 
SV4
0/T7 
? no 
SDM of 
pOK2 
pUP25 pET23a 
LAP2α 
P426L 
Amp in vitro T7 Flag no 
SDM of 
pSV5 
 
In vitro binding assay 
In order to create the vector pUP21, the ΔK32 mutation was introduced into 
prelamin A cDNA, in the pET24-LA construct (Goldman, Shumaker et al. 2004) by 
in vitro mutagenesis using a QuikChange™ Site-Directed Mutagenesis Kit 
(Stratagene), following manufacturer’s instructions and following primers: 
FOR: 5’-AGGAGGAGGACCTGCAGGAGCTCAATG-3’,  
REV:5’-AGGTCCTCCTCCTGCAGCCGGGTGA-3’.  
The construct was sequenced before use.  
BCL21 Star bacteria were transformed with pET24-LA WT or pET24-LA ΔK32 
(pUP21), expression of which was induced in a 30 ml culture at OD 0.6 by addition 
of 1 mM IPTG. Hourly samples as well as an un-induced control were taken and 
analyzed by Western Blotting. Expression was best after four hours; Bacterial cells 
were lysed in 5 ml lysis buffer (recipe below) and shook for 30 minutes end-over-
end, followed by centrifugation for 15min at 4000 rpm at 4° in a Heraeus centrifuge. 
A sample of the supernatant was taken for further analysis (SN1). The pellets were 
resuspended in lysis buffer containing 7M urea and an additional 0,2% Triton X-
100, shook for 1 hour end-over-end at room temperature, then homogenized in a 
glass homogenizer, followed by centrifugation for one hour at 14000 rpm at 4°C in 
an Eppendorf Table Top centrifuge. The supernatant was aliquoted and a sample 
was taken for later analysis (SN2), Remaining pellets were resuspended in 400µl of 
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urea containing buffer (sample P), mixed with 200µl sample buffer and frozen 
directly. (Also described in (Dechat, Korbei et al. 2000)) 
For the in-vitro binding assay, sample P of bacterially expressed WT and ΔK32 
prelamin A were resolved on a 10% SDS-PAGE and transferred to a nitrocellulose 
membrane. Purified rat vimentin was used as a negative control (Foisner, 
Leichtfried et al. 1988). Nitrocellulose membranes were stained with PonceauS, 
washed in PBST (PBS, 0.05% Tween 20) and incubated in overlay buffer (10 mM 
Hepes, pH 7.4, 100 mM NaCl, 5 mM MgCl2, 2 mM EGTA, 0.1% Triton X-100, 1 mM 
DTT) for 1 hour with three changes.  
After blocking with 2% BSA in overlay buffer, membranes were probed overnight at 
4°C with in vitro-translated, radioactively labeled FLAG - tagged LAP2α, diluted 
1:50 in overlay buffer plus 1% BSA (w/v) and 1 mM PMSF. For this, a plasmid 
containing FLAG - tagged LAP2α cDNA (pSV5) (Vlcek, Just et al. 1999) was in vitro 
translated using the TnT® T7 Quick Coupled Transcription/Translation System 
(Promega) according to the manufacturer’s instructions using 35S-labelled 
Methionine (Hartmann Analytic).  
After extensive washing in overlay buffer, nitrocellulose was air dried, and bound 
proteins were detected by autoradiography. 
A plasmid containing FLAG - tagged LAP2α (Vlcek, Just et al. 1999), was altered to 
contain the P426L mutation by site directed mutagenesis using following primers 
(yielding pUP25):  
FOR: 5’-CCTGTCTCCTCTAAGAAAAGTCCCTA-3’, 
REV: 5’-CTAGGGACTTTTCTTAGAGGAGACAGGA-3’.  
The construct was sequenced before use. 
Lysis buffer: Supplemented with: 
20 mM Tris-HCl at pH 8 
500 mM NaCl 
2 mM EGTA 
5mM DTT 
Aprotinin (10µg/ml buffer) 
1mM MgCl2 
20 µg/ml RNAse 
50 µg/ml DNAse 
100 µg/ml Lysozyme 
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Statistical analysis 
Data are presented as the mean of n individual experiments (n being indicated at 
each figure), the error bars denote standard error. Log-Rank tests for survival 
curves, Chi-square test, Student’s t-test and one-way ANOVA were applied using 
Microsoft Excel HP. Statistical significance was assumed at a p-value < 0,05 and is 
highlighted in graphs using a star. Three stars are indicating a p-value < 0,01. 
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Results and Discussion 
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Summary 
A-type lamins are components of the nuclear lamina, a filamentous network of the 
nuclear envelope in metazoans that supports nuclear architecture. In addition, a 
subfraction of lamin A/C can be found in the nuclear interior. This nucleoplasmic 
lamin pool depends on the presence of the lamin-binding protein, Lamina-
associated polypeptide 2 (LAP2) and regulates cell cycle progression in tissue 
progenitor cells. K32 mutations in A-type lamins cause severe congenital muscle 
disease in humans and a muscle maturation defect in LmnaΔK32/ΔK32 knock-in mice. 
At molecular level, mutant K32 lamin A/C protein levels were reduced and all 
mutant lamin A/C mislocalized to the nucleoplasm. To test the effects of K32 lamin 
A/C on the regulation and functions of the nucleoplasmic lamin-LAP2 complexes 
and the potential involvement in disease pathology we deleted LAP2 in 
LmnaΔK32/ΔK32 knock-in mice. In double mutant mice the LmnaΔK32/ΔK32- linked muscle 
defect was unaffected. LAP2 interacted with mutant lamin A/C, but unlike wild-type 
lamin A/C, the intranuclear localization of K32 lamin A/C was not affected by loss 
of LAP2. In contrast, loss of LAP2 in LmnaΔK32/ΔK32 mice impaired the regulation 
of tissue progenitor cells like in wild type animals. These data indicate that a 
LAP2-independent assembly defect of K32 lamin A/C is predominant for the 
mouse pathology, while the LAP2-linked functions of nucleoplasmic lamin A/C in 
the regulation of tissue progenitor cells are not affected in LmnaΔK32/ΔK32 mice.   
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Introduction 
Lamins are intermediate filament proteins in metazoan cells that form the lamina, a 
scaffold structure tightly associated with the inner nuclear membrane (Dechat, 
Pfleghaar et al. 2008). They provide mechanical stability for the nuclear envelope 
and the nucleus and help to organize higher order chromatin structure. Lamins are 
grouped into A- and B-type, based on biochemical, structural and dynamic 
properties, sequence homologies and expression patterns. While B-type lamins are 
ubiquitously expressed throughout development, the major A-type lamins (lamin A 
and C) encoded by Lmna are expressed at later stages during development 
(Stewart and Burke 1987; Rober, Weber et al. 1989). Lamin A and B-type lamins 
undergo posttranslational processing at their C-terminal CAAX motif, including 
farnesylation and carboxy-methylation (Rusinol and Sinensky 2006). The 
hydrophobic farnesyl-group at the C-terminal cysteine facilitates tight interaction 
with the inner nuclear membrane. While mature B-type lamins remain farnesylated, 
lamin A undergoes an additional endoproteolytic processing step that removes 15 
from the C-terminus including the farnesyl-group (Bertrand, Renou et al. 2012). 
Thus mature lamin A and also lamin C, which is not processed post-translationally, 
lack a farnesyl group and are less tightly bound to membranes than B-type lamins. 
Consequently, a fraction of A-type lamins is also found in the nucleoplasma 
(Dechat, Gesson et al. 2010).  
The physiological relevance and functions of the nucleoplasmic lamin A/C pool are 
poorly understood, but they are likely involved in many of the reported functions of 
lamins in cell signaling and gene expression (Ozaki, Saijo et al. 1994; Heessen and 
Fornerod 2007; Andres and Gonzalez 2009; Dechat, Gesson et al. 2010). Our 
recent studies showed that Lamina-associated polypeptide 2 (LAP2) regulates 
the localization and functions of nucleoplasmic A-type lamins (Naetar, Korbei et al. 
2008). LAP2 is a unique member of the LAP2 protein family (Wilson and Foisner 
2010). While most LAP2 proteins are integral membrane proteins of the inner 
nuclear membrane and associate with lamins in the peripheral lamina, LAP2α lacks 
a transmembrane domain, localizes to the nuclear interior and interacts with 
nucleoplasmic lamins A and C (Dechat, Korbei et al. 2000). Interestingly, when 
LAP2α is genetically eliminated in mice, lamins A and C are lost from the nuclear 
interior and localize exclusively at the peripheral lamina in dermal fibroblasts and 
proliferating tissue progenitor cells (Naetar, Korbei et al. 2008). Similarly, human 
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fibroblasts lose nucleoplasmic lamins following RNA-interference-mediated knock-
down of LAP2α (Pekovic, Harborth et al. 2007). Moreover, during myoblast 
differentiation, LAP2α expression is downregulated and nucleoplasmic lamins are 
lost (Markiewicz, Ledran et al. 2005). Nucleoplasmic lamins and LAP2α were 
shown to bind directly to the tumor suppressor retinoblastoma protein (pRb) in its 
active, hypo-phosphorylated form (Markiewicz, Dechat et al. 2002) and to promote 
pRb repressor activity on pRb/E2F target gene promoters, mediating efficient cell 
cycle exit of proliferating cells (Dorner, Vlcek et al. 2006). Accordingly, LAP2α 
deletion in mice accompanied by loss of nucleoplasmic lamins results in 
hyperproliferation of tissue progenitor cells and tissue hyperplasia (Naetar, Korbei 
et al. 2008).  
Mutations in the LMNA gene and in several genes encoding lamin-associated 
proteins have been linked to phenotypically heterogeneous diseases generally 
termed laminopathies. The many disease variants range from muscular dystrophies 
over cardiomyopathies to lipodystrophies and systemic involvements of multiple 
tissues like the premature ageing disease Hutchinson-Gilford progeria syndrome 
(HGPS) (Worman and Bonne 2007). The molecular mechanisms underlying the 
laminopathies are still poorly understood. While one disease model proposes 
defects in mechanical properties of the lamina in laminopathic cells, leading to 
increased fragility of nuclei, other models have proposed impaired functions of 
mutated lamins in chromatin regulation and gene expression (Gotzmann and 
Foisner 2006). 
In a recent study we described a novel mouse model for a severe, striated muscle–
affecting laminopathy (Bertrand, Renou et al. 2011): LmnaΔK32/ΔK32 knock-in mice 
harbor a Lmna mutation that results in the loss of lysine 32 in the N-terminal domain 
of lamins A and C, and causes a severe form of Congenital Muscular Dystrophy 
(CMD) in humans (Quijano-Roy, Mbieleu et al. 2008). Homozygous LmnaΔK32/ΔK32 
mice were indistinguishable from their wild-type littermates at birth but soon 
exhibited striated muscle maturation delay and metabolic defects and died within 2-
3 weeks (Bertrand, Renou et al. 2011). Interestingly, the ΔK32 mutation was 
previously proposed to impair the lateral assembly of lamin A/C head to tail 
polymers (Bank, Ben-Harush et al. 2011). In line with this observation, mutant 
lamins failed to assemble at the lamina and localized predominantly in the 
nucleoplasm. In view of the emerging role of nucleoplasmic lamins in chromatin 
regulation and gene expression (Dechat, Gesson et al. 2010), a deregulated 
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nucleoplasmic lamin pool in LmnaΔK32/ΔK32 mice may contribute to the observed 
pathologies. Since deletion of LAP2 in wild-type mice was shown to decrease the 
nucleoplasmic pool of lamins (Naetar, Korbei et al. 2008), we wondered how loss of 
LAP2 in LmnaΔK32/ΔK32 mice affects both K32 lamin localization and tissue 
pathology. To address this question, we crossed LmnaΔK32/+ and LAP2α-/+ mice. In 
this manuscript we show that loss of LAP2 did not change the localization of 
mutated lamins, although LAP2 still bound ΔK32 lamin A/C. In contrast cellular 
phenotypes linked to the loss of the nucleoplasmic LAP2 - lamin A/C complex, 
such as hyperproliferation of epidermal progenitor cells and hyperplasia of 
epidermis were still detectable in LmnaΔK32/ΔK32 mice following depletion of LAP2. 
These data indicate that a LAP2-unrelated assembly defect of K32 lamin may be 
the predominant molecular defect in LmnaΔK32/ΔK32 mice, while its LAP2-dependent 
functions in the nucleoplasm are unaffected. 
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Results 
Loss of LAP2 does not affect protein levels and localization of K32 lamin 
A/C 
Mutant K32 lamin A/C in  LmnaΔK32/ΔK32 knock-in mice fails to assemble at the 
nuclear lamina and mislocalizes to the nucleoplasm (Bertrand, Renou et al. 2011). 
Since LAP2 has previously been found to regulate the nucleoplasmic pool of wild-
type lamins A and C (Naetar, Korbei et al. 2008), we wanted to examine the 
influence of LAP2 loss on K32 lamin A/C expression and cellular distribution. We 
generated double mutant mice by crossing Lmna+/ΔK32 mice with heterozygous 
Lap2-deficient mice and isolated fibroblasts and myoblasts from newborn 
littermates. Lamin A/C protein levels were massively reduced to 60% to 90% of 
wild-type lamin A/C levels in all LmnaΔK32/ΔK32 cells independent of the presence or 
absence of LAP2 (Fig. 1, Supplementary Fig. S1A). LAP2 and other nuclear 
envelope and/or lamina proteins, such as lamin B1 and emerin, were not affected in 
LmnaΔK32/ΔK32 cells.  Similar results were obtained in lysates of liver and diaphragm 
derived from mice of the four genotypes (Supplementary Fig. S1B). Thus, LAP2α 
loss did not affect the expression level of mutant K32 lamin A/C protein. Down-
regulation of mutant lamin A/C likely occurs post-transcriptionally, since lamin A 
mRNA levels in fibroblasts were similar in all genotypes (Fig. 1) in accordance with 
previous reports (Bertrand, Renou et al. 2011).  
Immunofluorescence analyses of primary mouse fibroblasts confirmed the reduction 
of lamin A/C protein levels in single and double mutant LmnaΔK32/ΔK32 mice. Co-
cultures of LmnaΔK32/ΔK32 / Lap2+/+ and Lmna+/+ / Lap2-/- cells allowed identifying 
LmnaΔK32/ΔK32 versus Lmna+/+cells in the co-culture (by the lack of LAP2 staining), 
in order to directly compare lamin A/C levels and localization in the different 
genotypes under identical experimental conditions. Similar experiments were done 
in co-cultures of Lmna+/+ / Lap2+/+ and LmnaΔK32/ΔK32 / Lap2-/- cells (Fig. 2A). While 
wild-type lamin A/C was predominantly found at the nuclear periphery with an 
additional weaker nucleoplasmic staining, K32 lamin A/C mutants were equally 
distributed throughout the entire nucleus without any clear nuclear rim staining, 
supporting previous reports on impaired assembly of K32 lamin A (Bank, Ben-
Harush et al. 2011).  LAP2 localization was unaffected by K32 lamin A.  
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Loss of LAP2 has previously been found to decrease lamin A and C levels in the 
nuclear interior (Naetar, Korbei et al. 2008). To test whether loss of LAP2 also 
affects the localization of K32 lamin A/C, we performed a quantitative analysis of 
lamin A/C localization at the nuclear periphery versus the nuclear interior by plotting 
lamin A/C staining intensity profiles across the nuclear diameter in confocal 
immunofluorescence images (Fig. 2B). Independent of LAP2 expression, K32 
lamin A/C staining was always uniformly distributed throughout the nucleus and 
never accumulated at the periphery like wild-type lamin A/C. Interestingly, while 
loss of LAP2 significantly reduced the level of nucleoplasmic wild-type lamin A/C, 
the uniform nucleoplasmic distribution of K32 mutant lamin A/C was not affected 
by loss of LAP2. In addition we calculated ratios of nucleoplasmic over peripheral 
mean A-type lamin fluorescence intensities for 25 to 30 fibroblasts for each 
genotype (Fig. 2C). In LmnaΔK32/ΔK32 fibroblasts, the ratios were significantly 
increased compared to Lmna+/+ cells (n=25, P-value< 0.05), reflecting the lack of 
accumulation of mutant lamin A/C at the periphery and its even distribution 
throughout the nucleus. Loss of LAP2α had no effect on the distribution of mutant 
lamin A/C (LmnaΔK32/ΔK32 background), while in the lamin A/C wild-type background 
loss of LAP2α caused a significant reduction of nucleoplasmic lamins (n=30, P-
value< 0.05).  
 
ΔK32 lamin A interacts with LAP2α like wild-type lamin A.  
Next we tested whether the mutated K32 lamin A is able to interact with LAP2α. 
Bacterially expressed ΔK32 and wild type pre-lamin A were transferred to 
nitrocellulose and probed with in vitro translated, [35S]-labeled LAP2α. 
Autoradiography of the blot revealed binding of LAP2 to both wild-type and K32 
lamin A, while binding to a related, cytoplasmic intermediate filament protein, 
vimentin was not detectable (Fig. 3). These data are in line with previous results, 
which revealed binding of LAP2α to the lamin A/C C-terminus (amino acids 319 to 
572 (Dechat, Korbei et al. 2000), which is likely not affected by the K32 mutation 
located in the N-terminal head domain of lamin A. Altogether, we conclude that 
LAP2 can still bind K32 lamin A; nonetheless, loss of LAP2 does not render the 
mutant lamin A assembly-competent. Thus the mutation in the N-terminal head 
domain most likely interferes with proper lamin assembly in a LAP2-independent 
manner. 
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The lethal postnatal phenotype of LmnaΔK32/ΔK32 mice is not affected by loss of 
LAP2α  
In order to test the effect of loss of LAP2 on the organismal and tissue phenotype 
of LmnaΔK32/ΔK32 mice, we analyzed litters of mice heterozygous for both LAP2α and 
ΔK32 lamin A/C (Lap2α+/-/Lmna+/ΔK32). The breedings produced genotypes 
according to Mendelian ratios (n=384; Lmna+/+/Lap2α+/+ = 4.7%; Lmna+/+/Lap2α-/- = 
7.5%; LmnaΔK32/ΔK32/Lap2α+/+ = 4.9%; LmnaΔK32/ΔK32/LAP2α-/- = 8.4%). All genotypes 
were indistinguishable from wild-type littermates at birth. From postnatal day six on, 
all mutant mice homozygous for LmnaΔK32/ΔK32, independent of the Lap2 genotype, 
started to present a generally smaller appearance, a kinked tail, progressive growth 
retardation and stagnation in weight gain, as well as atrophied muscles and 
reduced mobility. By post-natal day 15 for single LmnaΔK32/ΔK32 mutants and day 17 
for double LmnaΔK32/ΔK32/Lap2-/- mutants, only 50% of mice were alive, none 
survived longer than post-natal day 21 (Supplementary Fig. S2). Thus, double 
mutants for LmnaΔK32/ΔK32 and Lap2α-/- showed a slightly prolonged, though 
statistically insignificant survival in comparison to the single LmnaΔK32/ΔK32 
littermates, indicating that the LmnaΔK32/ΔK32 – linked phenotype was prominent. 
 
LAP2α-/- specific epidermal paw hyperplasia is not counteracted by K32 
lamin A/C 
Having shown that K32 lamin A/C fails to form a lamina at the nuclear periphery, 
but was still able to interact with LAP2 in the nucleoplasm, we sought to test 
whether K32 lamin A – LAP2 complexes can still function in tissue progenitor cell 
regulation. Loss of nucleoplasmic lamin A/C - LAP2 complexes by either deletion 
of Lap2 or deletion of  Lmna (causing loss of nucleoplasmic and peripheral 
lamina) was shown to cause hyperproliferation of epidermal progenitor cells and 
progressive hyperplasia of the paw epidermis during post-natal life (Naetar, Korbei 
et al. 2008). If the nucleoplasmic K32 lamin A/C – LAP2 complex is still 
functional in this pathway, LAP2 knock-down in LmnaΔK32/ΔK32 mice is expected to 
have a similar effect on epidermal progenitor cells and epidermal thickness as in 
wild type mice. Despite the young age of LmnaΔK32/ΔK32 single and double mutant 
mice, the paw epidermis was ~20% thicker in LmnaΔK32/ΔK32 / Lap2-/- versus 
LmnaΔK32/ΔK32 / Lap2+/+ littermates (Fig. 4A). Moreover, and in line with our previous 
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findings, a higher number of proliferating (KI67 positive) cells was detected in 
double mutant LmnaΔK32/ΔK32 / Lap2-/- versus LmnaΔK32/ΔK32 / Lap2+/+ mice (Fig. 
4B), pointing towards an increased proliferation of progenitor cells. Thus, we 
concluded that the K32 lamin A/C mutant is still active in regulating progenitor 
cells in conjunction with LAP2. 
 
Loss of LAP2α in LmnaΔK32/ΔK32 mice increased number of skeletal muscle 
progenitor cells  
LAP2 loss was previously shown to increase the number of skeletal muscle 
progenitor cells (Gotic, Schmidt et al. 2010). To test the number of satellite cells in 
LmnaΔK32/ΔK32 mice, we enriched skeletal muscle progenitor cells (SMPC) from an 
isolated pool of muscle fiber associated cells by flow cytometry, based on the 
expression of CXCR4 and β1-integrin and lack of expression of CD45, Sca1 or 
Mac1. Immunofluorescence microscopy of these cells confirmed mislocalization of 
K32 lamin A/C and unaltererd lamin B distribution in lamin mutant versus wild-type 
cells (Fig. 5). Importantly, in both Lmna+/+ and LmnaΔK32/ΔK32 mice the SMPC 
population was increased in Lap2α-/- versus Lap2+/+ background (Fig. 5), 
supporting the hypothesis that K32 lamin A/C in conjunction with LAP2α is equally 
well capable of regulating muscle progenitor cells as the wild-type protein. The 
increase in SMCP cells in LAP2-deficient versus LAP2-expressing LmnaΔK32/ΔK32 
mice may slightly improve growth capability of muscle, which may also contribute to 
the subtle increase in survival of LmnaΔK32/ΔK32 / Lap2-/- versus LmnaΔK32/ΔK32 / 
Lap2+/+ mice (see supplementary Fig. S2). 
Based on the reported muscle phenotype of LmnaΔK32/ΔK32 mice (Bertrand, Renou et 
al. 2011) we also compared SMPC cell numbers in LmnaΔK32/ΔK32 versus Lmna+/+ 
littermates. The number of muscle fiber associated SMPC cells was 
indistinguishable in these genotypes (Fig. 5), indicating that an exhaustion of the 
SMPC pool is unlikely to contribute to muscle disease in LmnaΔK32/ΔK32 mice.  
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Muscular atrophy in LmnaΔK32/ΔK32 mice is not affected by loss of LAP2α.  
Histological haematoxylin/eosin staining of gastrocnemius and soleus muscle 
sections of 16 day old LmnaΔK32/ΔK32 mice revealed a generally atrophied muscle, 
decreased fiber cross sectional area, variability in fiber size and a significantly 
increased proportion of muscle fibers with centrally located or internalized nuclei 
(Fig. 6). Other dystrophic changes like replacement of functional muscle fibers by 
connective tissue or fat, cellular infiltrates, increased endomysial space, ruptured 
fibers or an increase in serum levels of creatine kinase (CK) levels as reviewed in 
(Costanza and Moggio 2010) were not observed. This phenotype was 
predominantly caused by the lamin A/C mutant, as the presence or absence of 
LAP2α did not grossly affect this phenotype. However, one striking phenotype upon 
loss of LAP2α in LmnaΔK32/ΔK32 mice was a further increase in the number of fibers 
with centrally located nuclei (14.2% to 18.4%, n=7, P-value= 0.019) (Fig. 6C). This 
observation is consistent with a subtle increase in muscle growth in LAP2-deficient 
background probably due to the higher number of SMPCs (Fig. 5). The presence of 
central nuclei within muscle fibers may also be an indicator for a muscle maturation 
defect as reported (Bertrand, Renou et al. 2011). Indeed, the proportion of muscle 
fibers expressing the embryonic form of myosin heavy chain was significantly 
increased in LmnaΔK32/ΔK32 versus Lmna+/+ mice (Fig. 6D, n=4, P-value= 0.04), but 
was independent of LAP2α expression. 
 
In vitro differentiation of LmnaΔK32/ΔK32 myoblasts is massively delayed and 
insufficient  
When LmnaΔK32/ΔK32 myoblasts were cultivated in vitro and induced to differentiate 
by withdrawal of serum, we observed a reduction of cell number, a delayed onset of 
differentiation, an insufficient formation of myotubes and failure to upregulate MyHC 
compared to the wild-type littermates, pointing towards a reduction of both 
proliferation and differentiation potential of the LmnaΔK32/ΔK32 myoblasts. Additional 
loss of LAP2α did not noticeably aggravate or ameliorate this phenotype. Fig. 7A 
shows bright field images revealing a lag of LmnaΔK32/ΔK32 myoblast differentiation at 
day 3, irrespective of LAP2α expression, and a massive reduction of myotube 
formation at day 6 of in vitro muscle differentiation. In line with this, failure of MyHC 
upregulation during differentiation as determined by qRT PCR (Fig. 7B) or by 
Immunofluorescence (Fig. 7C) was observed.  
  
93 
 
  
Discussion 
In this manuscript we confirm and extend our previous findings showing that CMD-
linked ΔK32 lamin A/C mutants fail to accumulate at the nuclear lamina in primary 
fibroblasts of LmnaΔK32/ΔK32 knock-in mice. Mutant lamin A/C is expressed at 
significantly reduced protein level and localizes uniformly throughout the entire 
nucleus. A lamina-independent pool of lamins has also been described in wild-type 
cells and tissues and found to be highly dynamic and regulated during the cell cycle 
(Moir, Yoon et al. 2000; Naetar, Korbei et al. 2008). This nucleoplasmic pool of 
lamin A/C has been implicated in the regulation of proliferation and differentiation of 
tissue progenitor cells during tissue homeostasis (Naetar, Korbei et al. 2008). It was 
thus tempting to speculate that an abnormally regulated pool of nucleoplasmic 
lamins or a misbalance between lamina-associated and lamina-independent lamins 
were responsible for some of the pathologies described in the LmnaΔK32/ΔK32 mice 
(Bertrand, Renou et al. 2012). To test this hypothesis we investigated, whether any 
of the previously described functions and regulation mechanisms of nucleoplasmic 
lamins are impaired in ΔK32 lamin A/C knock-in mice.  
Although the regulation of the intranuclear, nucleoplasmic lamin A/C pool is not 
completely understood yet, our previous studies revealed one direct regulator of 
nucleoplasmic lamins A and C, a nucleoplasmic isoform of the Lamina-associated 
polypeptide 2 family, termed LAP2. While most other LAP2 isoforms are 
transmembrane proteins of the inner nuclear membrane and bind lamins in the 
nuclear lamina (Foisner and Gerace 1993), LAP2 lacks a transmembrane domain 
and localizes to the nuclear interior (Dechat, Gotzmann et al. 1998) and binds 
specifically A-type lamins (Dechat, Korbei et al. 2000). We also showed that loss of 
LAP2 in LAP2 knock-out mice reduced the levels of lamins A and C in the 
nuclear interior in proliferating epidermal progenitor cells and primary fibroblasts, 
while re-expression of LAP2 into LAP2-deficient fibroblasts rescued the 
nucleoplasmic lamin A/C pool (Naetar, Korbei et al. 2008). These data suggested 
that LAP2 is essential and sufficient for targeting and/or stabilizing nucleoplasmic 
lamins A and C. Since this activity of LAP2 required its C-terminal lamin A/C-
interaction domain, it was assumed that LAP2 regulates intranuclear lamin A/C by 
direct binding. Since we found here that LAP2 interacted with mutant K32 lamin 
A/C like with wild type lamin A/C, we reasoned that loss of LAP2 in LmnaΔK32/ΔK32 
mice may reduce the potentially abnormal nucleoplasmic K32 lamin A/C pool in 
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mutant mice and may allow mutant lamin to associate with the peripheral lamina. 
However, loss of LAP2 did neither affect the levels nor localization of K32 lamin 
A/C. Therefore we concluded that mutant lamin A/C is incapable of assembling at 
the nuclear lamina even in the absence of LAP2, supporting previous studies that 
suggested that the K32 mutation in lamin A/C impairs the lateral association of 
head-to-tail dimer protofilaments into anti-parallel tetrameric filaments (Bank, Ben-
Harush et al. 2011). These studies, which were performed in C. elegans did 
however not reveal a uniform nucleoplasmic distribution of mutant lamin but rather 
nucleoplasmic aggregates. This difference may be due to the fact that C. elegans 
contains only one lamin gene, which encodes a farnesylated B-type lamin. In any 
case, our studies reveal that mouse K32 lamin A shows a LAP2-independent 
assembly defect.  
Our binding analyses show that LAP2 and K32 lamin A/C can form complexes. 
Are these complexes functional? While lamins A and C at the nuclear lamina have 
been implicated in a number of functions, including nuclear architecture (Sullivan, 
Escalante-Alcalde et al. 1999), (hetero-) chromatin organization (Guelen, Pagie et 
al. 2008) and signaling (reviewed in (Heessen and Fornerod 2007; Andres and 
Gonzalez 2009)), we have previously shown that LAP2 and nucleoplasmic lamin 
A/C function in the regulation of the pRb-pathway (Dorner, Vlcek et al. 2006; 
Naetar, Korbei et al. 2008). This function, which is likely independent of the 
peripheral lamina, has been proposed to regulate the proliferation and 
differentiation of tissue progenitor cells during tissue homeostasis. Since classical 
gene knock-out or knock-in approaches in mouse by targeting the Lmna gene affect 
both the peripheral lamina and the nucleoplasmic lamin A/C pool, it has been 
difficult to distinguish and specifically test the activities of peripheral versus 
nucleoplasmic lamins. The LAP2 knock-out mouse is currently the only model that 
selectively affects the nucleoplasmic pool of lamin A/C, while the peripheral lamina 
remains unaffected (Naetar, Korbei et al. 2008). The fact that both the selective loss 
of nucleoplasmic lamins (by LAP2 deletion) and the complete loss of lamin A/C in 
Lmna-/- mice (affecting nucleoplasmic and peripheral lamins) show a similar 
hyperproliferation of progenitor cells in the paw epidermis and epidermal 
hyperplasia (Naetar, Korbei et al. 2008) indicates that the phenotype is directly 
linked to the loss of nucleoplasmic lamin-LAP2 complexes rather than the loss of 
lamin-independent functions of LAP2. If the nucleoplasmic K32 lamin A/C - 
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LAP2 complexes were still functional, we would expect similar consequences on 
tissue progenitor cells upon LAP2 loss in wild type and LmnaΔK32/ΔK32 mice. 
Indeed, we observed an increase in proliferating cells in paw epidermis and a 
thickening of the epidermis upon knocking out LAP2 in LmnaΔK32/ΔK32 mice. These 
data show i) that nucleoplasmic K32 lamin A/C still functions in the regulation of 
tissue progenitor cells and ii) that the nucleoplasmic lamins require LAP2 for this 
activity. Forcing lamin A/C into the nuclear interior by, for instance interfering with 
the assembly at the lamina (as done in LmnaΔK32/ΔK32 mice) is insufficient to 
generate “active” nucleoplasmic lamin complexes.  
Based on our results, it is likely that the pathologies described in the LmnaΔK32/ΔK32 
mice are primarily caused by loss of peripheral lamins and/or the downregulation of 
lamin protein levels. Can loss of LAP2 affect the mutant lamin A/C-linked 
phenotype? One of the most prominent phenotype described in the LmnaΔK32/ΔK32 
mice is an impaired peri- and postnatal muscle maturation, reflected by an 
increased number of muscle fibers with centrally located nuclei and increased 
embryonic myosin heavy chain expression.  Since LAP2 loss has been shown to 
increase the number of fiber-associated progenitor cells, we speculated that the 
larger pool of skeletal muscle progenitor cells might partially rescue the mutant 
lamin A/C-mediated muscle defect. Although we saw a LAP2 loss-mediated 
increase in muscle progenitor cells in LmnaΔK32/ΔK32 mice, which may theoretically 
contribute to regeneration of defective muscle, we did not see any significant 
rescue of muscle morphology and maturation in double mutant LmnaΔK32/ΔK32 / 
Lap2-/- versus LmnaΔK32/ΔK32 mice. The slight increase in muscle fibers with 
centrally located nuclei in muscle of LmnaΔK32/ΔK32 / Lap2-/- versus LmnaΔK32/ΔK32 
mice would be consistent with an increased regeneration/growth activity. However, 
the prominent lamin mutant-linked defect in myoblast differentiation in vitro may 
preclude any further improvement of the double mutant phenotype.  
Overall our studies show that a LAP2-independent defect of the assembly and 
stability of K32 lamin A/C and the accompanied loss of lamin A/C at the peripheral 
lamina are prominent in LmnaΔK32/ΔK32 mice and responsible for the pathologies. In 
contrast, the nucleoplasmic K32 lamin A/C is still able to bind LAP2 and function 
in the regulation of tissue progenitor cells.   
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Materials and Methods 
Mice 
Mice were maintained in accordance with the procedures outlined in the Guide for 
the Care and Use of Laboratory Animals. Animal experiments were performed 
according to permissions from Austrian authorities. Data acquisition was done by 
observers blinded for the genotype of the animal. Lap2α-deficient mice were 
generated by deleting the Lap2α-specific exon 4 in the Lap2 gene (also known as 
thymopoietin, Tmpo) using the Cre/loxP system (Naetar, Korbei et al. 2008). 
LmnaΔK32/ΔK32 mice were generated by a knock-in strategy replacing the wild-type 
Lmna exon 1 with an exon 1 where the lysine at position 32 (delAAG) is deleted 
(Bertrand, Renou et al. 2011). In order to obtain double mutants and littermate 
controls, mice heterozygous for both Lap2α and Lmna ΔK32 (Lap2α+/-, Lmna+/ΔK32) 
were crossed. All experiments were performed in a mixed genetic background 
(C57BL/6, B6129F1, BALB/c) on postnatal day 15 to 18, following cervical 
dislocation. For genotyping genomic DNA was prepared from tail tips and PCR 
analyses were performed using puRETaq Ready-To-Go PCR beads (GE 
Healthcare Biosciences, NJ, USA) in a PTC-200 Peltier Thermo Cycler (TJ 
Research). The used primers were: 
Lap2α: Exon 4: 5’-CACAATCCCTAGAGGACTTCACTT-3’,  
Intron 4: 5’-CTGTGACTTTGCTGGCCTTCCAGTCTA-3’ and  
Exon 3: 5’-CAGGGAACTGAATCGAGATCCTCTAC-3’;  
Lmna: intron 2 forward: 5’-CAAAGTGCGTGAGGAGTTCA-3’ and  
intron 2 reverse in: 5’-TGACAGCATAGGCCCTGTCAC-3’ 
 
Tissue sections, histology, immunohistochemistry and immuno-fluorescence 
Following isolation, organs were immediately dipped into pre-chilled 2-methyl-
butane and snap frozen in liquid nitrogen, embedded in TBS™ Tissue freezing 
medium (Triangle Biomedical Sciences, Durham, NC, USA) and 5 µm sections 
were cut using a Cryostat HM500 OM at -23°C. Alternatively, tissues were fixed in 
4% formaldehyde (Rotifix from Roth, Karlsruhe, Germany), dehydrated, cleared, 
embedded in paraffin and sectioned using a Leica RM 2155 microtome. 
Haematoxylin and eosin (H & E) staining was done according to standard protocol 
using an automated Ass-1 staining unit. Immunostainings for embryonic myosin 
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heavy chain were performed using mouse monoclonal antibody against embryonic 
myosin (F1.652; DSHB, University of Iowa, Iowa City, USA) and biotinylated anti-
mouse antibody. Stainings were developed using DAB (Vector Laboratories, 
Burlingame, CA, USA), nuclei were counterstained with Haematoxylin. The sections 
were dehydrated, mounted in Entellan (Merck, Darmstadt, Germany), and analyzed 
using a Zeiss Axio Imager.M1 microscope equipped with a Zeiss AxioCam MRc5 
and images processed by AxioVision Rel. 4.5 software.  
For immunofluorescence microscopy, cryosections were fixed either in 3.7% 
formaldehyde (Merck, Darmstadt, Germany) in PBS or in ice-cold acetone. Paraffin 
sections were incubated in xylene for 20 min, in isopropanol for 10 min, in 96%, 
80%, 70% and 60% ethanol for 2 min each, and in ddH2O for 5 min. Rehydrated 
sections were incubated for 60 min in citrate buffer (1.8 mM citric acid and 8.2 mM 
sodium citrate) at 100°C. After washing in PBS, sections were incubated in 0.1% 
Triton-X-100 / PBS for 30 min, blocked with goat serum (Vectastain; Vector Labs, 
Burlingame, CA, USA), and incubated with antibodies and Hoechst-dye as 
described (Naetar, Hutter et al. 2007). Samples were viewed in a Zeiss Axiovert 
200M microscope equipped with a Zeiss LSM510META confocal laser-scanning 
unit, an alpha Plan-Fluor 100x/1.45 Oil and a Plan-Apochromat 63x/1.40 Oil DIC 
MC27 objective (Zeiss). Images were prepared with Adobe Photoshop software.  
The following antibodies were used: goat polyclonal anti Lamin A/C antibody N18 
(Santa Cruz Biotecj Inc., Heidelberg, Germany), rabbit antiserum to LAP2α (Vlcek, 
Korbei et al. 2002), mouse monoclonal antibody to LAP2α (15/2) (Dechat, 
Gotzmann et al. 1998), and rabbit serum NCL-KI67p (Novocastra Lab., New Castle 
UK). DNA was stained with DAPI: (#32670, Sigma, St Loius, MO, USA). 
 
Primary cells, isolation and analyses 
Primary fibroblasts were isolated 1-3 days after birth from back skin of newborn 
mice as described (Andra, Nikolic et al. 1998). Cells were cultivated in high glucose 
DMEM, 10% fetal calf serum (FCS), 50 U/ml Penicillin, 50 µg/ml Streptomycin and 
0.2 µM L-Glutamine (all from Invitrogen, Carlsbad, CA, USA) at 37°C and 5% CO2. 
Experiments were performed between passage 1 and 4. For immunofluorescence, 
cells were seeded on coverslips and processed as previously described using 
following antibodies: goat polyclonal anti Lamin A/C antibody N18 (Santa Cruz), 
mouse monoclonal anti lamin A/C antibody, clone 4C11, provided by E. Ogris 
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(Roblek, Schuchner et al. 2010), rabbit antiserum to LAP2α (Vlcek, Korbei et al. 
2002), goat polyclonal anti lamin B antibody (C20, Santa Cruz) 
Fluorescence intensity measurements were done using the profile tool in Zeiss LSM  
Image Browser version 4.2.0.121 software. Ratios of nucleoplasmic to peripheral 
mean A-type lamin fluorescence intensities were calculated for 25 or 30 fibroblasts 
of each genotype. 
Primary myoblasts were obtained from de-skinned front and hind limbs of neonatal 
mice (2 days old) as described (Gotic, Schmidt et al. 2010). To induce muscle 
differentiation, proliferation medium (20% FCS / 2.5 ng/ml basic FGF / Hams’ F-10 / 
Penicillin and Streptomycin) was substituted by DMEM containing 5% horse serum 
containing penicillin and streptomycin. All cells were kept on collagen coated dishes 
in a humidified atmosphere at 37°C and 5% CO2.  
 
Isolation of myofiber-associated satellite cells 
Mice were euthanized and single fibers from particular muscles (tibialis anterior 
extensor digitorum longus, soleus, gastrocnemius, quadriceps, triceps and biceps 
brachii) were isolated according to (Shefer and Yablonka-Reuveni 2005) and 
modified as described in (Gotic, Schmidt et al. 2010). In brief, muscles were 
collected in PBS and subsequently incubated in sterile 0.2% collagenase I (Gibco 
Life Technol., Carlsbad, CA, USA) / DMEM solution (3 ml/50 mg of tissue) for 1.5 – 
2 hours in a shaking water bath at 37ºC. Muscle digestion was stopped by 
transferring samples to a series of DMEM containing Petri dishes coated with 
filtered horse serum. Single fibers were released by gentle trituration, collected in 
DMEM and pelleted by centrifugation at 17 g for 5 min. After washing twice in PBS, 
fibers were resuspended in 0.01% collagenase II (Gibco Life Technol., Carlsbad, 
CA, USA) / 0.15 U/ml dispase II (Roche Applied Science, Mannheim, Germany) / 
PBS and incubated for 30 min at 37ºC by shaking. Samples were filtered through 
40 μm pore cell strainers and cells were pelleted by 5 min centrifugation at 210 g. 
After two washes in PBS, samples were stained on ice for 30 min in 2% FCS/PBS 
containing following antibody cocktail: anti-CD45, APC conjugated anti mouse 
CD45 (Ly-5); anti-Sca1, PerCP-Cy5.5 conjugated anti mouse Sca-1 (Ly-6A/E); anti-
Mac1, APC conjugated anti mouse CD11b,; and anti-β1-integrin, PE anti mouse/rat 
CD29, (all from eBioscience, Frankfurt, Germany; and anti-CXCR4, FITCS rat-anti 
mouse CD184 (CXCR4) (BD Pharmingen™Heidelberg, Germany) . 
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Cells were washed and analyzed using a FASCAria equipped with DIVA acquisition 
software (BD Biosciences) as described in (Cerletti, Jurga et al. 2008). In brief, 
viable cells were first analyzed on the basis of size and granulation. Subsequently, 
a population of cells homogenous in size was tested for the expression of CD45, 
Mac1 and Sca1 surface markers and a subpopulation of CD45-/Sca1-/Mac1- cells 
was selected for CXCR4 and β1-integrin expression analysis. The number of CD45-
/Sca1-/Mac1-/CXCR4+/β1-integrin+ cells in each mouse sample was presented as 
percentage within the parent CD45-/Sca1-/Mac1- population. 
 
Immunoblot analyses 
Cells and tissues were lysed and analyzed by SDS-PAGE and immunoblotting as 
previously described (Naetar, Korbei et al. 2008) using the following antibodies: 
antiserum to LAP2α (Vlcek, Korbei et al. 2002), goat polyclonal anti-lamin A/C 
serum N18 (Santa Cruz), anti lamin B (C-20, Santa Cruz), anti-emerin (NCL-
Emerin, Novoscastra), rabbit polyclonal actin antiserum A-2066 (Sigma), anti γ-
tubulin (B-5-1-2, Sigma) and rabbit polyclonal antiserum to histone 3, (Abcam, 
Cambridge, MA, USA). Quantitation of protein levels was performed with LICOR 
Odyssee Infrared Imaging System, application software version 2.1.12. Band 
intensities of lamins A and C were combined and normalized to the band intensity 
of the actin or γ-tubulin or histone 3 as loading control. 
 
Quantitative real time PCR 
Total RNA was isolated from muscle tissue and cultured cells using TRIzol® 
reagent (Invitrogen, Carlsbad, CA, USA) or RNeasy® Plus Micro Kit (Qiagen, 
Hilden, Germany). cDNA was synthesized by First Strand cDNA Synthesis Kit for 
RT-PCR (Roche Applied Science, Mannheim, Germany) according to 
manufacturers’ instructions and specific sequences were subsequently amplified on 
an Mastercycler® ep realplex (Eppendorf, Hamburg, Germany) using  MESA 
GREEN qPCR MasterMix Plus for SYBR Assay I TTP (Eurogentec, Liege, Belgium) 
for quantitative PCR. Specific primers are listed in Supplementary Table 1 (see also 
(Usami, Abe et al. 2003; Ozawa, Hayashi et al. 2006; Gotic, Schmidt et al. 2010). 
Data were documented using Mastercycler® ep realplex software (Eppendorf, 
Hamburg, Germany) and processed by Microsoft Excel XP. Endogenous levels of 
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Hprt (Hypoxanthine-Guanine Phosphoribosyltransferase) in quantitative PCR were 
used for data normalization according to the Pfaffl method (Pfaffl 2001). 
 
In vitro binding assay 
The ΔK32 mutation was introduced into prelamin A cDNA, in the pET24-LA 
construct (Goldman, Shumaker et al. 2004) by in vitro mutagenesis using a 
QuikChange™ Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), 
using the following primers: 
FOR: 5’- AGGAGGAGGACCTGCAGGAGCTCAATG-3’, REV: 5’-
AGGTCCTCCTCCTGCAGCCGGGTGA-3’. The construct was sequenced before 
use. Wild-type and ΔK32 prelamin A were expressed in bacteria as described in 
(Dechat, Korbei et al. 2000) and resolved on a 10% SDS-PAGE and transferred to 
a nitrocellulose membrane. Purified rat Vimentin was used as a negative control 
(Foisner, Leichtfried et al. 1988). Nitrocellulose membranes were stained with 
PonceauS, washed in PBST (PBS, 0.05% Tween 20) and incubated in overlay 
buffer (10 mM Hepes, pH 7.4, 100 mM NaCl, 5 mM MgCl2, 2 mM EGTA, 0.1% 
Triton X-100, 1 mM DTT) for 1 hour with three changes. After blocking with 2% BSA 
in overlay buffer, membranes were probed overnight at 4°C with in vitro-translated, 
radioactively labeled FLAG - tagged LAP2α, diluted 1:50 in overlay buffer plus 1% 
BSA (w/v) and 1 mM PMSF. For this, a plasmid containing FLAG - tagged LAP2α 
cDNA (pSV5) (Vlcek, Just et al. 1999) was in vitro translated using the TnT® T7 
Quick Coupled Transcription/Translation System (Promega, Mannheim, Germany) 
according to the manufacturer’s instructions using 35S-labelled Methionine 
(Hartmann Analytic, Braunschweig, Germany). After extensive washing in overlay 
buffer, nitrocellulose was air dried, and bound proteins were detected by 
autoradiography. 
 
Statistical analysis 
Data are presented as the mean of n individual experiments (n being indicated in 
each figure), the error bars denote standard errors. Log-Rank tests for survival 
curves, Chi-square test, Student’s t-test and one-way ANOVA were applied using 
Microsoft Excel HP. Statistical significance was assumed at a P-value < 0.05 and is 
highlighted in graphs using a star. Three stars are indicating a P-value < 0.01.  
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Figure legends: 
Fig. 1: Lamin A/C expression is significantly reduced in ΔK32 Lamin A/C 
expressing cells independent of the presence and absence of LAP2. 
Immunoblots of lysates of primary fibroblast derived from single and double mutant 
LmnaΔK32/ΔK32, and Lap2α-/- mice and wild-type control littermates probed for 
indicated proteins are shown. The star indicates an unspecific band produced by 
the LAP2α antibody. For quantification of lamin protein levels, band intensities of 
lamins A and C were combined and normalized to the band intensity of the actin 
loading control and presented as % of the wild-type control. Protein levels of single 
mutant LmnaΔK32/ΔK32 and double mutant LmnaΔK32/ΔK32 / Lap2α-/- fibroblasts were 
significantly reduced (n=4, P-values=0.04 and 0.03, respectively as determined by 
Student’s t-Test against wild-type). Lower right panels show mRNA levels of lamin 
A and emerin as determined by real-time PCR. mRNA levels were normalized to 
the corresponding wild-type levels. Means and s.e. of 3-4 independent experiments 
are shown. mRNA levels of lamin A or emerin are not altered in single and double 
mutant fibroblasts compared to wild type as determined by Student’s t-test: 
LmnaΔK32/ΔK32: n=4, P-value 0.2 (lamin A) and 0.8 (emerin); Lap2α-/-: n=4, P-value 
0.4 (lamin) and 0.3 (emerin); LmnaΔK32/ΔK32 / Lap2α-/-: n=4, P-value 0.2 (lamin) and 
0.9 (emerin). 
 
Fig. 2: Lamin A/C protein is redistributed to the nuclear interior in 
LmnaΔK32/ΔK32 fibroblasts in a LAP2-independent manner. Co-cultures (A) or 
single cultures (B) of primary dermal fibroblasts with indicated genotypes isolated 
from new born littermates were processed for confocal immunofluorescence 
microscopy. Cells were stained with antibodies to lamin A/C and LAP2, with the 
latter allowing identification of the genotype in mixed cultures.. Scale bar denotes 
10 µm. (B) Quantitation of intranuclear lamin staining was done by fluorescence 
intensity measurements along the dashed line shown in image using the profile tool 
in Zeiss LSM Image Browser. (C) Ratios of nucleoplasmic over peripheral mean A-
type lamin fluorescence intensity were plotted in the histogram. In LmnaΔK32/ΔK32 
fibroblasts, the ratios are significantly increased versus wild-type controls (n=25, P-
value<0.05). In the Lmna+/+ background, nucleoplasmic lamins are lost and the ratio 
decreases significantly upon loss of LAP2α (n=30, P-value<0.05). 
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Fig. 3: Wild-type and ΔK32 lamin A bind LAP2 in vitro. (A) Ponceau protein 
staining of bacterially expressed and blotted recombinant wild-type prelamin A, 
ΔK32-prelamin A, or vimentin on nitrocellulose (upper panel), and autoradiogram of 
the same blot after probing with [35S] labelled LAP2α (lower panel) are shown. (B) 
Autoradiography of in vitro-translated [35S} labelled LAP2α separated by SDS-
PAGE. 
 
Fig. 4: Lap2α-/- -specific epidermal paw hyperplasia is not affected in 
LmnaΔK32/ΔK32 mice. 
(A) Paraffin-embedded paw sections of 18 day old single and double mutant 
LmnaΔK32/ΔK32 and Lap2α-/- mice and respective wild-type control littermates were 
stained with hematoxylin/eosin (HE). Scale bar denotes 50 µm. Epidermal thickness 
of the plantar region of the paw is shown. Upon loss of LAP2α, the thickness of the 
epidermis is increased irrespective of LmnaΔK32/ΔK32 (n=6, P-value<0.05). (B) 
Paraffin embedded paw sections were processed for immunofluorescence 
microscopy and stained for proliferation marker KI67. Scale bar is 20 µm. KI67-
positive nuclei, were quantified by counting and found to be increased upon loss of 
LAP2α (n=2). 
 
Fig. 5: Lap2α-/- -specific increase in SMPCs is not affected in LmnaΔK32/ΔK32 
mice.  
Skeletal muscle progenitor cells (SMPCs) (CD45-/Sca1-/Mac1-/CXCR4+/β1-
integrin+) were obtained from skeletal muscles (Gastrocnemius, Soleus, Tibialis 
anterior, Quadriceps, Triceps) and analyzed by flow cytometry or processed for 
confocal immunofluorescence microscopy. The number of CD45-Sca1-Mac1-
CXCR4+β1-integrin+ (SMPC) cells within the parent population (CD45-Sca1-Mac1-
) is presented in left panel. Lap2α-/- mice show a significant increase in SMPCs in 
comparison to their wild-type littermates (n=9, P-value=0.03 as determined by 
Student’s t-test). Similarly double mutant LmnaΔK32/ΔK32 / Lap2α-/- mice show an 
increase in SMPCs in comparison to their single mutant LmnaΔK32/ΔK32 littermates 
(n=9, P-value=0.02 as determined by Student’s t-test). (Right panel shows 
immunofluorescence microscopic confocal images of isolated SMPCs stained for 
lamin A/C, lamin B and LAP2α. Scale bar denotes 5 µm.  
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Fig. 6: Skeletal muscle phenotype of double mutant LmnaΔK32/ΔK32 / Lap2α-/- 
mice 
(A) Cross-sectional sections of cryo-preserved gastrocnemius muscles of 18 day 
old wild-type, and single and double mutant LmnaΔK32/ΔK32 I Lap2α-/- mice were 
stained with hematoxylin/eosin (HE). Arrows denote fibers exhibiting a central 
nucleus. Scale bar is 50 µm. (B) Fiber cross-sectional area (n=5) was measured. 
(C) Quantification of fibers with centrally located nuclei is shown (n=7, P-value= 9.9 
E-05 for Lmna+/+ against LmnaΔK32/ΔK32 / Lap2α+/+ and P-value=0.019 for 
LmnaΔK32/ΔK32 / Lap2α+/+ against LmnaΔK32/ΔK32 / Lap2α-/-) 
(D) Quantification of embryonic myosin heavy chain (eMHC) positive muscle fibers 
(n=4, P-value = 0.04 for Lmna+/+ against LmnaΔK32/ΔK32 / Lap2α+/+). 
 
Fig. 7: Primary LmnaΔK32/ΔK32 myoblasts exhibit delayed and insufficient in 
vitro differentiation irrespective of presence or absence of LAP2α. 
Primary murine myoblasts were isolated from newborn littermates and expanded 
and differentiated on collagen-coated dishes. At 1, 3 and 6 days after induction of 
differentiation, cultures were analyzed by various assays: (A) bright field images 
show a lag of LmnaΔK32/ΔK32 myoblasts differentiation irrespective of LAP2α at day 3 
and massive reduction of myotube formation at day 6 of in vitro muscle 
differentiation  (bar = 100 µm). (B) Real time PCR analyses of myosin heavy chain 
(MyHC) normalized to endogenous levels of Hprt showing an absence of MyHC 
upregulation upon LmnaΔK32/ΔK32 myoblast differentiation. Means of 5 independent 
experiments are shown and only positive standard errors are shown as error bars. 
(C) Confocal  immunofluorescence microscopic analyses of differentiating 
myoblasts at day 1 (upper) and 6 (lower) stained with antibodies to lamin A/C and 
Myosin heavy chain. DNA was stained with DAPI. Scale bar denotes 20 µm 
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Supplementary Table 1: Primers used in qRT-PCR 
Name/Target Sequence Tm Source 
Hprt_forward TGATTAGCGATGATGAACCAGG 58,4 
(Gotic, 
Schmidt et 
al. 2010) 
Hprt_reverse CTTTCATGACATCTCGAGCAAG 60,3 
laminA_reverse TGAGCGCAGGTTGTACT 52,8 
laminC_reverse TAGGCTGGCAGGGCTAC 57,6 
laminA/C_forward GCACCGCTCTCATCAACT 56 
MyHC2b_forward ACAAGCTGCGGGTGAAGAGC 61,4 (Usami, 
Abe et al. 
2003) 
MyHC2b_reverse CAGGACAGTGACAAAGAACG 57,3 
Emerin_forward GTTATTTGACCACCAAGACATACGGG 63,2 (Ozawa, 
Hayashi et 
al. 2006) 
Emerin_reverse GGTGATGGAAGGTATCAGCATCTACA 63,2 
 
Supplementary References: 
Gotic, I., W.M. Schmidt, K. Biadasiewicz, M. Leschnik, R. Spilka, J. Braun, C.L. Stewart, and 
R. Foisner. 2010. Loss of LAP2 alpha delays satellite cell differentiation and affects 
postnatal fiber-type determination. Stem Cells. 28:480-8. 
Ozawa, R., Y.K. Hayashi, M. Ogawa, R. Kurokawa, H. Matsumoto, S. Noguchi, I. Nonaka, 
and I. Nishino. 2006. Emerin-lacking mice show minimal motor and cardiac 
dysfunctions with nuclear-associated vacuoles. Am J Pathol. 168:907-17. 
Usami, A., S. Abe, and Y. Ide. 2003. Myosin heavy chain isoforms of the murine masseter 
muscle during pre- and post-natal development. Anat Histol Embryol. 32:244-8. 
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Supplementary Fig. S1: Lamin A/C expression is significantly reduced in 
ΔK32 Lamin A/C expressing myoblasts and tissues. (A) Immunoblot analyses of 
myoblast lysates of single and double mutant LmnaΔK32/ΔK32, and Lap2α-/- mice and 
wild-type control littermates probed for lamin A/C, and -tubulin. Protein levels were 
quantified using LICOR Odyssee Infrared Imaging System. Band intensities of 
lamins A and C were combined and normalized to the band intensity of the -tubulin 
loading control. (B) Immunoblot analyses of diaphragm and liver lysates of 16 day 
old single and double mutant LmnaΔK32/ΔK32 and Lap2-/- mice and wild type control 
littermates probed for lamin A/C and γ-tubulin protens. 
 
Supplementary Fig. S2: Loss of LAP2 in LmnaΔK32/ΔK32 does not significantly 
change life span. From post natal day 6 onward, LmnaΔK32/ΔK32 mice showed a 
delayed growth and increased lethality compared to wild-type, irrespective of 
LAP2α expression. LAP2α deficiency slightly but statistically insignificantly 
increases survival time (P-value <0.43 as determined by Log-rank test). 
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Abstract 
Emery-Dreifuss muscular dystrophy (EDMD) is a rare disorder characterized by 
early joint contractures, muscular dystrophy, and cardiac involvement with 
conduction defects and arrhythmias. 35% of EDMD cases are genetically defined 
and found to be associated with mutations in EMD or LMNA genes - encoding 
nuclear envelope components emerin and lamins A and C, respectively, but the 
existence of additional disease genes is very likely. Based on reported interactions 
of lamina associated polypeptide 2 (LAP2) with nucleoplasmic lamin A/C and its 
association to dilated cardiomyopathy, we tested LAP2 as a potential candidate 
disease gene for EDMD patients not associated to LMNA and EMD. We identified a 
P426L mutation in LAP2α in one out of 111 EDMD and 89 cardiomyopathy patients 
that segregated with the EDMD phenotype. The P426 residue of LAP2α is 
conserved in mammals and is located in a region previously mapped to bind the cell 
cycle regulator protein retinoblastoma (pRb). We show that P426L LAP2α does 
neither interfere with binding of the protein to lamin A/C nor did it affect lamin A/C 
expression and localization in primary patient fibroblasts and muscle biopsies. 
Interestingly patient fibroblasts contained less pRb protein level compared with 
control cells and showed impaired cell cycle regulation in vitro. These data indicate 
that the P426L LAP2α mutation may affect the previously reported function of 
LAP2α in the pRb-mediated cell cycle control of tissue progenitor cells, which may 
in turn contribute to the disease phenotype.  
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Introduction 
Emery Dreifuss muscular dystrophy (EDMD) was first described in 1966 as an 
independent muscular dystrophy (Emery and Dreifuss 1966), presenting symptoms 
of dilated cardiomyopathy (DCM) with a specific conduction defect usually not found 
in Becker or Duchenne muscular dystrophy patients (Ellis 2006). Hallmark EDMD 
pathologies are i) early joint contractures of Achilles tendons, elbows, and rigid 
spine, ii) childhood onset of muscle weakness and wasting, usually with a 
scapuloperoneal distribution, and iii) adult-onset cardiac disease characterized by 
conduction defects, arrhythmias, and cardiomyopathy (Ellis 2006).  
The gene locus associated with the X-linked form of EDMD was mapped to Xq28 
(EMD or STA), encoding a membrane spanning protein of the inner nuclear 
membrane, which was named emerin (Bione, Maestrini et al. 1994). A few years 
later, an autosomal form of EDMD was found to be associated with defects in the 
LMNA gene (Bonne, Di Barletta et al. 1999) encoding lamins A and C, components 
of the nuclear lamina. The LMNA gene has also been linked to a wide range of 
other rare diseases collectively termed laminopathies, which includes various 
striated muscle diseases, lipodystrophy and Hutchinson–Gilford progeria syndrome 
(Worman and Bonne 2007). Although the molecular disease mechanisms of EDMD 
are still unclear, the identified EDMD-associated genes suggested a functional 
impairment of nuclear organization in EDMD cells.  
Emerin is a type II integral protein of the inner nuclear membrane, and belongs to 
the LAP-Emerin-MAN1 (LEM) domain-containing protein family (Manilal, Nguyen et 
al. 1996; Lin, Blake et al. 2000; Wagner and Krohne 2007). The LEM domain is a 
40 residues long structural motif that mediates binding to the DNA-binding protein, 
Barrier-to-Autointegration Factor (BAF) (Laguri, Gilquin et al. 2001). Emerin has 
been implicated in higher order chromatin organization by anchoring chromatin 
fibers at the nuclear periphery (Holaska and Wilson 2007; Brachner and Foisner 
2011). In addition, emerin has been shown to bind lamins and may thus be involved 
in the mechanical integrity of the nuclear membrane by providing a physical link 
between the membrane and the underlying lamin scaffold. 
Lamins are nuclear intermediate filament proteins that form the lamina, a scaffold 
structure underneath the inner nuclear membrane that serves many structural roles, 
such as stabilizing nuclear morphology, providing mechanical stability for the 
  
126 
 
  
nucleus, positioning of nuclear pore complexes in the nuclear envelope and linking 
the nucleus to the cytoskeleton (reviewed in (Burke and Stewart 2006; Wilson and 
Foisner 2010)). The lamina has also been implicated in higher order chromatin 
organization, particularly in anchoring heterochromatin at the nuclear periphery 
(reviewed in (Dechat, Gesson et al. 2010)). While B-type lamins, encoded by 
LMNB1 and LMNB2 are expressed throughout development (Hoger, Zatloukal et al. 
1990), the LMNA-encoded A-type lamins lamin A and C are only expressed at later 
stages of development and appear to serve functions in tissue homeostasis 
(Stewart and Burke 1987; Constantinescu, Gray et al. 2006). In addition to their 
architectural and chromatin regulatory roles, emerin and lamins A and C have also 
been shown to regulate various signaling pathways (reviewed in (Zastrow, Vlcek et 
al. 2004; Wilson and Foisner 2010)). The significance of these diverse functions of 
emerin and lamins A and C for the EDMD phenotype is still unclear.  
Over 50% of EDMD patients could not be linked to mutations in the EMD and 
LMNA genes, suggesting the existence of other causative genes. One approach in 
the search for new EDMD-linked genes was to specifically test genes encoding 
lamin A/C and/or emerin-interacting proteins. This strategy identified EDMD-linked 
mutations in SYNE1 and SYNE2, genes encoding nuclear membrane proteins 
nesprin 1 and 2 (Zhang, Bethmann et al. 2007). These proteins bind emerin and 
lamin A/C and link the nucleoskeleton to the cytoskeleton (Mellad, Warren et al. 
2011). More recently, a genome-wide screen identified mutations in the FHL1 gene 
to be causative for the EDMD phenotype in six families (Gueneau, Bertrand et al. 
2009). FHL1 encodes LIM domain proteins which have not yet been shown to be 
related to lamins; similar to lamins, however, they serve dual roles in the 
maintenance of structural integrity and in signaling. 
We present here another lamin A-binding protein, Lamina associated polypeptide 2 
alpha (LAP2α) as a potential causative EDMD gene. Like emerin, LAP2α belongs to 
the LEM protein family and binds chromatin (Berger, Theodor et al. 1996), 
(Schirmer and Foisner 2007). However, in contrast to emerin and most other LEM 
proteins, LAP2α lacks a transmembrane domain and localizes to the nuclear 
interior. It has been found to stabilize a subfraction of lamin A in the nucleoplasm 
(Dechat, Korbei et al. 2000), which may be involved in an retinoblastoma-mediated 
regulation of tissue progenitor cells important for tissue homeostasis (Naetar, 
Korbei et al. 2008), (Dorner, Vlcek et al. 2006). Lack of LAP2α in mice caused loss 
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of the nucleoplasmic lamin A pool, leading to a deregulation of skeletal muscle 
progenitor cells (Gotic, Schmidt et al. 2010) and to dilated cardiomyopathy (Gotic, 
Leschnik et al. 2010).  Intriguingly, a mutation in LAP2α that impairs binding to A-
type lamins has previously been reported to cause dilated cardiomyopathy in 
humans (Taylor, Slavov et al. 2005), phenotypically similar to lamin A/C-linked 
cardiomyopathies (Worman and Bonne 2007), (Vytopil, Benedetti et al. 2003), 
pointing to a common disease mechanism of these two proteins. 
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Results 
 
P426L LAP2α is a mutation potentially associated to EDMD 
In order to identify novel EDMD-linked genes we performed a candidate gene 
approach using a collection of genomic DNA samples from a cohort of patients 
presenting EDMD-type pathologies and lacking mutations in either LMNA or EDM. 
We tested for potential disease-associated mutations in the LAP2 gene in 111 
EDMD and 87 dilated cardiomyopathy patients by heteroduplex analysis and direct 
sequencing. The LAP2 gene encodes six isoforms, LAP2, , , , , and  (Harris, 
Andryuk et al. 1994), among which the non-membrane bound LAP2 isoform has 
been shown to interact with lamins A and C in the nuclear interior (Dechat, Korbei 
et al. 2000). Among ten variations found in LAP2, four changes leading to single 
amino acid exchanges in the protein were unique for EDMD patients - p.P426L 
(c.1481C>T) in the LAP2 splice form, p.D271E (c.1054T>G) in LAP2, and 
p.V423L (c.1058G>C) and p.M381I (c.1387 G>A) in LAP2.  However, segregation 
analyses identified only p.P426L LAP2 as a mutation potentially associated with 
EDMD (Figure 1A). Proline P426 is highly conserved in mammals (Figure 1B). 
 
Phenotypic and histochemical description of patient G-11340  
The EDMD patient bearing the p.P426L LAP2 mutation is a 23 year old female 
presenting with progressive muscular dystrophy She had normal motor milestones 
during early childhood with a detectable disease onset at an age of 6 years, 
including frequent stumbling, impaired running and bilateral Pes equinus. Later, 
difficulty in climbing stairs, waddling gait, Gowers maneuvre and slowly progressive 
humero-peroneal muscular weakness and wasting were observed. No cardiac 
involvement occurred up to age 12. EMG confirmed advanced myopathic damage 
whereas electroneurography ruled out a neuropathic involvement. Moreover, 
massive fatty infiltrates were affecting both upper thighs. Creatine kinase serum 
levels were increased (152 U/l). Histopathology of a muscular biopsy obtained at 
age 12 showed unspecific dystrophic changes including variation in fiber size with 
hypertrophic, hypotrophic and degraded fibers, internalized nuclei und infiltration of 
inflammatory cells (Figure 2A). Sirius Red staining revealed a high degree of 
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fibrosis, with significant replacement of functional muscle tissue by fibrotic tissue 
(Figure 2B).  
 
P426L mutation in LAP2α neither affects lamin A/C localization nor lamin 
binding  
LAP2α has previously been shown to bind lamins A and C and to affect the 
nucleoplasmic localization of lamin A/C in proliferating cells (Vlcek, Korbei et al. 
2002; Pekovic, Harborth et al. 2007).  In order to get more insights into the potential 
disease mechanisms we analyzed the interaction of P426L LAP2α with lamin A/C 
and its effect on lamin A/C localization. In solid phase binding overlay assays, 
recombinantly expressed human lamin A and a previously described muscular 
dystrophy-linked ΔK32 lamin A variant (Bertrand, Renou et al. 2012) were 
transferred to nitrocellulose and overlaid with in vitro translated and radioactively 
labeled wild type or P426L LAP2α (Fig. 3). Autoradiography revealed strong binding 
of both LAP2α variants to both lamin A variants, whereas binding of the LAP2α 
variants to a transblotted lamin-related cytoplasmic intermediate filament protein 
vimentin was not detected (Fig 3). These data show that LAP2α binds specifically to 
nuclear (type V) intermediate filament proteins and that the P426L mutation in 
LAP2α did not affect its binding to lamin. This is in agreement with previous studies 
predicting the lamin A interaction domain of LAP2α to map to its extreme C-terminal 
domain (aa 615-693) (Dechat, Korbei et al. 2000). Similarly, the LAP2α interaction 
domain of lamin A was mapped to the C-terminal lamin A Ig-fold (Dechat, Korbei et 
al. 2000), explaining the unimpaired binding of the N-terminal lamin A mutant (ΔK32 
lamin A) to LAP2α.  
In order to investigate the effect of P426L LAP2α on lamin A/C expression and 
localization we analyzed lamin A/C in primary dermal fibroblasts and muscle tissue 
obtained from the patient or from sex-matched control samples. Western blot 
analyses of patient fibroblast cell lysates revealed identical expression levels of 
lamins A and C and of LAP2α in wild type versus mutant cells (Fig. 4 A). Also, the 
localization of lamins A and C, LAP2α and emerin (Fig. 4B) were unaffected in 
patient cells. Similarly lamin A/C localization was not detectably affected in patient 
muscle tissue (Fig. 4C). Thus the P426L mutation in LAP2α does not affect its 
interaction with lamin A/C and does not alter lamin A/C localization.   
 
  
130 
 
  
LAP2α P426L fibroblasts exhibit an impaired cell cycle regulation  
Having seen no difference in lamin A/C binding of P426L versus wild-type LAP2α 
we wanted to test whether the previously reported function of the LAP2α-lamin A/C 
complex in a retinoblastoma protein-mediated cell cycle control pathway was 
affected. Lack of lamin A/C in mouse cells has been shown to decrease pRb protein 
stability, reducing overall pRb levels (Johnson, Nitta et al. 2004). LAP2α deficiency 
was found to affect pRb repressor activity, promoting cell cycle progression, while 
overexpression of LAP2α caused accelerated cell cycle exit (Dorner, Vlcek et al. 
2006). Interestingly, total pRb protein levels were reduced in patient versus control 
fibroblasts, indicating a deregulation of the pRb-mediated cell cycle pathway (Figure 
4A). 
To test this in more detail we analyzed proliferation behavior of patient versus 
control cells. In standard cell culture conditions, patient cells exhibited reduced 
proliferation compared to wild type cells (Figure 5A). When cells were serum 
starved for 72h and subsequently re-stimulated with growth medium, proliferation of 
patient cells was significantly impaired in the first 24 hours following restimulation 
(Figure 5A), suggesting delayed cell cycle entry of patient cells from Go to G1/S 
phase. DNA flow cytometry supported these results, showing that 26% of wild type 
cells were in S phase 18 hours after serum restimulation, whereas only 7% of 
patient cells entered S-phase in the same period. Patient cells, however, were not 
permanently arrested, as at 24 hours a similar percentage of cells progressed to S-
phase compared to wild type control (Fig. 5B). Thus expression of mutated P426L 
LAP2α may impair the function of the LAP2α-Lamin A/C complex in pRb mediated 
cell cycle regulation.   
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Discussion 
In the present study we undertook a first description of a novel EDMD causing 
mutation in LAP2α. The described mutation (P426L) is located at the C-terminal 
domain of LAP2α and results in a single amino exchange from Proline 
(hydrophobic, bulky) to Leucine (hydrophobic, aliphatic). The - so far - only other 
published mutation in LAP2α associated to a pathological condition is the DCM-
causing mutation R690C (Taylor, Slavov et al. 2005), which resulted in impaired 
lamin binding, in line with the mutation being located in the lamin binding – region of 
LAP2α (Dechat, Korbei et al. 2000).  
In this study, the P426L mutation in LAP2α was the only LAP2 mutation found in 
EDMD patients that segregated with the disease phenotype.  However, due to the 
low number of patients a clear causal link of this mutation to the disease could not 
be unambiguously shown. Therefore, we set out to test how this mutation may 
affect LAP2α expression, localization, interaction and its potential functions in cell 
cycle regulation.  
LAP2α P426L was expressed at levels identical to those of WT and could be readily 
detected in muscle biopsies and in proliferating, primary fibroblasts derived from the 
patient or healthy control individuals. Also, the expression of its binding partner 
lamin A/C, mutations of which are associated to AD-EDMD, (Bonne, Di Barletta et 
al. 1999) was not altered in patient tissues and fibroblasts. Also emerin, another 
inner nuclear lamin protein involved with the pathology of X-linked EDMD (Bione, 
Maestrini et al. 1994), was not mislocalized or misexpressed in patient fibroblasts 
as determined by immunofluorescence studies. Since both lamin A/C and emerin 
were unaltered in fibroblasts, and cells did not present themselves as fragile or 
malformed, we consider it unlikely that nuclear fragility is a main disease cause.  
Thus, we aimed at testing potential effects of the mutation on the reported activity of 
LAP2α in establishing a nucleoplasmic pool of lamins A/C that may be involved in 
the regulation of pRb mediated cell cycle control. A prerequisite of LAP2α’s ability to 
stabilize a nucleoplasmic lamin A pool is its direct interaction with lamins A/C (Moir, 
Yoon et al. 2000; Dorner, Vlcek et al. 2006; Naetar, Korbei et al. 2008; Gotic, 
Schmidt et al. 2010). For this reason we were interested to see whether the 
mutation in LAP2α interfered with its binding to lamin A/C. Our in vitro binding 
studies clearly showed that the present mutation (P426L) did not interfere with 
lamin binding, leading us to conclude that intranuclear complexes of lamin A/C can 
  
132 
 
  
still be formed. This nucleoplasmic lamins in the nuclear interior have previously 
been found to affect pRb activity in cell cycle control of proliferating cells. Loss of 
LAP2α in mice leads to a deregulation of the pRb pathway and a hyperproliferation 
of tissue progenitor cells (Naetar, Korbei et al. 2008). 
A-type lamins have been found to interact with pRb (Ozaki, Saijo et al. 1994). 
Furthermore it was reported that in A-type lamin deficient cells, pRb is exposed to 
proteosomal degradation leading to reduced overall pRb levels (Johnson, Nitta et 
al. 2004). Interestingly, also LAP2α was shown to bind pRb directly in its 
hypophosphorylated form and to be necessary for its nuclear tethering (Markiewicz, 
Dechat et al. 2002), indicating a direct role of LAP2α in the regulation of pRb 
stability. Intriguingly, the disease-linked mutation in LAP2α mapped to the domain 
previously reported to mediate pRb interaction (Dorner, Vlcek et al. 2006). Indeed, 
we found that total pRb levels were reduced in patient fibroblasts compared to 
controls. Therefore, we tested the cell cycle behavior of proliferating primary cells in 
an unstressed environment and after serum starvation. LAP2α P426L fibroblasts 
exhibit an impaired cell cycle control, as characterized by reduced proliferation and 
delayed cell cycle entry of patient cells from Go to G1/S phase after serum 
starvation. Altogether, these findings hint towards a deregulation of the pRb-
mediated cell cycle pathway in cells expressing P426L LAP2α, and it is tempting to 
speculate that this may contribute to the disease pathology by impaired regulation 
of muscle progenitor cells. 
Our data also show that the primary molecular defects of the P426L mutation are 
different from that of the CMD-causing R690C mutation in LAP2α. While the latter 
one caused an impaired binding to lamin A/C (Taylor, Slavov et al. 2005) the P426L 
mutation showed no affect on the lamin A/C interaction. Despite this difference the 
downstream effects may be quite similar. Both mutations may impair the 
nucleoplasmic complex of LAP2α-lamin A/C and its function in the regulation of 
pRb.   
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Materials and Methods 
Mutational analysis  
We analyzed 111 EDMD and 87 DCM patients, who were negative for LMNA, EMD, 
SYNE1 or SYNE2 mutations. Screening for DNA variations in LAP2 was carried out 
by PCR using intronic primers flanking each of the LAP2 exons. The PCR products 
were tested for changes by heteroduplex analysis and directly sequenced by a 
cycle-sequencing procedure using a Big Dye Deoxy-terminator Cycle sequencing 
kit (PE/Applied Biosystems). Each DNA variation found was checked for its 
frequency in 384 chromosomes of an ethnically matched control population.  
 
Immunofluorescence and histology 
Cryomaterial in cut form was kindly provided by Ralf Schober (Institut für Pathologie 
der Universität Leipzig, Liebigstraße 26, 04103 Leipzig). Staining with 
hematoxylin/eosin was performed using the tissue-processing system Pat Histo 
ASS-1. Sirius Red staining was done following a standard protocol. A Zeiss Axio 
Imager.M1 equipped with a Zeiss AxioCam MRc5 and Axiovision LE software 
version 4.5 was used for microscopy. 
 
For immunofluorescence, microscopy cryosections were fixed in 3.7% 
formaldehyde (Merck, NJ, USA) in PBS.  After washing in PBS, sections were 
incubated in 0.1% Triton-X-100 / PBS for 30 min, blocked with goat serum or 
mouse IgG blocking reagent (Vectastain or MOM Immundetection Kit Vector Labs, 
Burlingame, CA, USA), and incubated with antibodies and Hoechst-dye as 
described (Naetar, Hutter et al. 2007). Immunofluorescence microscopy was done 
as described (Naetar, Hutter et al. 2007) and samples were viewed in a Zeiss 
Axiovert 200M microscope equipped with a Zeiss LSM510META confocal laser-
scanning unit, an alpha Plan-Fluor 100x/1,45 Oil (a=0,11mm) and a Plan-
Apochromat  63x/1.40 Oil DIC MC27 (a=0.19mm) objective (Zeiss). Fluorochromes 
used were either Texas Red or Cy5 (Jackson Immuno Research, West-Grove, 
USA), coupled to appropriate secondary antibodies. Fluorescence intensity 
measurement was performed with LSM Imaging software (Zeiss). Images were 
prepared with Adobe Photoshop and Adobe Illustrator software.  
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Cell culture 
Primary patient fibroblasts (G-11340) and control cells were cultured at 37°C, in an 
atmosphere containing 7,5% CO2 in DMEM supplemented with 20% fetal calf 
serum, 50 U/ml penicillin, 50 µg/ml streptomycin and 2 µM l-glutamine (all from 
Invitrogen, Carlsbad, CA, USA). Experiments were performed between passages 
11 and 21.  
For analysis of cell growth, 105 cells per well were seeded on 6-well plates and 
cumulative cell numbers were determined daily using a CASY counter Model TTC 
(Schärfe System, Reutlingen, Germany) For synchronization, cells were serum 
starved (DMEM supplemented with 0,5% FCS, 50 U/ml penicillin, 50 µg/ml 
streptomycin and 2 µM l-glutamine) for 5 days. After restimulation with 20% FCS 
medium propidium iodide staining was done following standard protocols and cells 
were sorted on a BD Biosciences FACSCalibur system. Data were quantified using 
FlowJo software (Tree Star). SDS-PAGE and immunoblot were performed as 
described (Dechat, Gotzmann et al. 1998). 
 
Antibodies 
The following antibodies were used: rabbit antiserum to LAP2α (Vlcek, Korbei et al. 
2002) and mouse monoclonal to LAP2α (Dechat, Gotzmann et al. 1998); Lamin A/C 
3A6-4C11 Active Motif, kindly provided by Egon Ogris, and  N18, Santa Cruz; 
Emerin (MANEM 5 provided by Glenn Morris and NCL-Emerin, Novocastro); γ-
tubulin (B-5-1-2, Sigma); Total pRb (G3-245, BD Biosciences and IF8, Santa Cruz); 
Actin (A-2066, Sigma);  
 
In vitro binding assay 
Bacterially expressed WT and ΔK32 prelamin A (Goldman, Shumaker et al. 2004), 
as well as Vimentin as negative control were resolved on a 10% SDS-PAGE and 
transferred on a nitrocellulose membrane.  
A plasmid containing FLAG - tagged LAP2α (Vlcek, Just et al. 1999) was altered to 
contain the P426L mutation by site directed mutagenesis using following primers:  
FOR: 5’-CCTGTCTCCTCTAAGAAAAGTCCCTA-3’ 
REV: REV: 5’-CTAGGGACTTTTCTTAGAGGAGACAGGA-3’ 
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LAP2α WT and P426L were in vitro translated using the TnT® T7 Quick Coupled 
Transcription/ Translation System (Promega) according to the manufacturer’s 
instructions using 35S-labelled Methionine (Hartmann Analytic). The in vitro-
translated, radioactively labeled product was used for probing overnight. An 
autoradiography of the washed membrane visualized binding of prelamin A to 
LAP2α.   
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Figure legends: 
Figure 1: Proline at position 426 in LAP2α is a conserved residue, mutation of 
which resulted in EDMD in a patient. Segregation analysis of a LAP2 mutation 
p.P426L in family Leipzig-EMD-1 (A) and evolutionary conservation of proline at 
position 426 in LAP2 (B)  
 
Figure 2: Muscle tissue of a patient carrying the LAP2α P426L mutation 
shows dystrophic changes. H&E (A) and Sirius Red (B) staining of control and 
patient muscle cryosections. Dystrophic features like replacement of functional 
muscle tissue by fibrotic tissue, variations of muscle fiber size, internalized nuclei 
und infiltration of inflammatory cells are observable. Scale bar denotes 50µm. 
 
Figure 3: Mutant P426L LAP2α binds to lamin A in vitro. Bacterially expressed 
recombinant wild-type prelamin A, prelamin A that features a mutation associated 
with EDMD (ΔK32), or Vimentin as negative control were resolved on a 10% SDS-
PAGE and transferred on a nitrocellulose membrane and probed with in vitro 
translated, 35S labelled LAP2α or LAP2α P426L. (A, B) Ponceau staining of the 
nitrocellulose membrane and autoradiography after probing with 35S labeled LAP2α 
WT (A) or LAP2α P426L are shown (B). Note that vimentin as negative control does 
not show binding to LAP2α while both WT and LAP2α P426L bound lamin A. (C) 
Autoradiography of in vitro- translated 35S labeled LAP2α WT and P246L used for 
overlay. 
 
Figure 4: P426L mutation in LAP2α neither affects lamin A/C nor LAP2α 
expression and localization. 
(A) Western Blot analysis of lysates from WT and LAP2α P426L-expressing primary 
patient fibroblasts probed for lamin A/C (N18), LAP2α (mAK15-2), Retinoblastoma 
protein pRb (IF8) or actin proteins. (B) Immunofluorescence of primary WT or 
LAP2α P426L fibroblasts stained with a polyclonal Lamin A/C antibody (N18), rabbit 
serum against LAP2α or emerin. Scale bar denotes 10µm. (C) Cryosections of 
control or patient muscle (LAP2α P426L) stained for Lamin A/C or LAP2α. Nuclei 
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were visualized by DAPI staining. Lower panel shows cells at higher magnification. 
Scale bars denote 20 µm. 
 
Figure 5: LAP2α P426L primary fibroblasts exhibit a proliferation delay and 
delayed cell cycle entry after serum starvation. (A) Growth curve of primary WT 
or LAP2α P426L fibroblasts in normal growth conditions (left panel) or after 5 days 
of serum starvation (right panel).  The fold increase of cell number in relation to day 
0 is shown for the indicated time points.  Means of four individual experiments are 
shown, error bars denote standard deviation. (B) After serum starvation, samples of 
primary WT or LAP2α P426L fibroblasts were taken for DNA flow cytometry. The 
percentage of total cells in a given cell cycle phase is depicted for each time point. 
Untreated proliferating cells were taken as a control. (Lower panel) Graphical 
representation of time point 24h by FlowJo.  
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Additional data on the ΔK32 lamin A/C mouse model 
Postnatal development and phenotype of LmnaΔK32/ΔK32 mice 
 
Mice heterozygous for both LAP2α (Lap2α+/-) and ΔK32 lamin A/C (Lmna+/ΔK32) 
were crossed to ensure the presence of both wild-type, single mutant and double 
mutant littermates. For pairings, mice were between 2 and 6 months old and did not 
originate from the same parents. No impairment of breeding capability was 
observed, heterozygous mice were fertile and healthy. Litters were of normal size 
and typically ranged from 4 to 10 pups. Single mutant LmnaΔK32/ΔK32 and double 
LmnaΔK32/ΔK32/Lap2α-/- mutant mice were born at expected Mendelian ratios and 
were impossible to tell apart from their wild-type littermates at birth. In general, a 
high variability of analyzed parameters was seen amongst and sometimes also 
within individual litters, likely due to the mixed genetic background, the litter size 
and other environmental factors.  
Figure U 1 shows photographs taken from wild-type, single and double mutant 
littermates at various time points. It is clearly visible that although initially 
indistinguishable, over time certain features in LmnaΔK32/ΔK32 were striking: a kinked 
tail as encircled in red (here around day 10 pn) and a slimmer and shorter figure. 
This visual phenotype is just attributable to the presence of the ΔK32 lamin 
mutation; additional loss of Lap2α did not influence these features. Moreover, 
LmnaΔK32/ΔK32 mice were observed to move less than their littermates at any age 
and did so in a waddling gait with repeated falling. 
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Figure U 1: Photographs of Lmna
ΔK32/ΔK32
 mice (1) and littermates 
 (Next to double mutant Lmna
ΔK32/ΔK32
, Lap2α
-/-
 (2) and wild-type control (WT)). Dashes on 
the paper are centimeter marks. Note: In the picture of day 13, the wild-type littermate is 
placed on the very left. 
 
Weight was monitored on a daily basis to assess and quantify growth retardation of 
LmnaΔK32/ΔK32 and double mutant mice. LmnaΔK32/ΔK32 gained weight slowly and 
insufficiently compared to Lmna+/+ mice, independent of the presence of Lap2. 
Between day 10 and time of death, a plateau was reached, followed by a slight loss 
of weight in the last days of life.  
Figure U 2 shows weight-gain of genotypes in percentage of the wild type control. 
While healthy littermates continued to gain weight, LmnaΔK32/ΔK32 mice had a clearly 
delayed growth showing 20% less weight than WT littermates on day 7, to around 
50% at day 18 (latest day of death). Double mutant LmnaΔK32/ΔK32, Lap2α-/- mice also 
exhibited growth retardation, but to slightly less dramatic extents. This may result in 
the slightly increased life span observed. Nonetheless, around the time of weaning 
(21 days pn), all LmnaΔK32/ΔK32 irrespective of presence or absence of Lap2α were 
dead. 
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Figure U 2: Stagnation and retardation of growth of Lmna
ΔK32/ΔK32 
mice 
(red; Double mutant Lmna
ΔK32/ΔK32
, LAP2α
-/-
: orange; wild-type control: black). 
Weight is presented as % of weight of wild-type control littermates. Error bars represent 
standard deviation. 
 
The fact that LmnaΔK32/ΔK32 pups were less mobile and generally weaker could be 
linked to insufficient feeding due to limited access to the mother (especially in large 
litters) or to swallowing difficulties. However, a filled belly was readily observed in 
pups at all times before fur growth. Whenever mice were used for harvest of tissues 
or other experiments, routine checking of the stomach was performed.  
Table 10 gives an overview of physiological values of representatives of each 
genotype at the time of extermination. At that time, LmnaΔK32/ΔK32 and double mutant 
pups were very weak, did not walk anymore and could hardly breathe. It can be 
noted that body and heart weight was dramatically reduced, although other organs 
like kidney were normal. The tibia length was reduced by several millimeters, 
indicating reduced bone length, although to a lesser degree than weight would 
suggest. Since no observable difference was seen between male and female pups, 
results were not discriminated according to sex in further experiments. 
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Table 10: Representative physiological values of Lmna 
ΔK32/ΔK32 
mice and littermates 
Genotype 
Age  
(days pn) 
Sex Weight Size Heart 
mg 
Kidneys 
mg 
Tibia length 
mm 
Fed 
Lmna
+/+
 18 m 6,81 5,6 70 120 12 y 
Lap2α 
-/-
 17 f 6,6 6,1 50 130 11 y 
Lmna
ΔK32/ΔK32
 18 m 4,11 4,9 20 120 9 y 
Lmna
ΔK32/ΔK32
; 
Lap2α 
-/-
 
18 f 3,59 5 30 120 8,5 y 
 
Blood analysis of LmnaΔK32/ΔK32 mice 
As part of the phenotypic description, blood obtained by cardiac puncture (terminal 
only, on day 18 pn) was analyzed for red and white blood cell count, platelet count 
as well as hematocrit and hemoglobin values. Published blood reference values 
(indicated in Table 5, Material and Methods) for laboratory animals and especially 
mice are always advised to be handled with care, as huge variations due to genetic 
variations and other factors are likely. Moreover, these values can further vary with 
age of the animal. Since published reference was not available for mice as young in 
age as day 18 postnatal, we compared values to the respective WT littermate. As 
shown in Figure U 3 (lower panel), standard blood parameters of mutant mice 
differed only statistically insignificantly from WT, indicating normal parameters and 
no sign of e.g. anemia.  
 
 
Figure U 3: Blood analysis for Glucose, CK and Cholesterol 
Using day 18 pn WT (black, n=2), LAP2α
-/-
 (grey, n=2), single mutant Lmna
ΔK32/ΔK32
 (dark 
red, n=3) and double mutant Lmna
ΔK32/ΔK32
, Lap2α
-/-
 (orange, n=4) mice by a ABC™ Animal 
Blood Counter (Vet) and Roche Reflovet
®
 strips. 
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Similarly, glucose, creatine kinase and cholesterol serum levels were similar in all 
genotypes, indicating no sign of hypo- or hypercholesterolemia, assuming normal 
lipid synthesis and cholesterol metabolism in LmnaΔK32/ΔK32 mice (Brown, Goldstein 
et al. 1973; Hasty, Shimano et al. 2001). Likewise, CK levels were not altered, 
ruling out massive dystrophic degradation and rupture of muscle fibers reported to 
cause an increase in serum CK levels  (Bulfield, Siller et al. 1984).  
The most striking and only statistically significant finding was that LmnaΔK32/ΔK32 
mice exhibited a massively decreased value of blood glucose levels irrespective of 
Lap2α (Figure U 3, upper panel, left). As LmnaΔK32/ΔK32 mice were extremely weak 
and moribund at the time of analysis, the presence of hypoglycemia is explainable.  
However, even moribund animals were observed to have been feeding normally, so 
this hypoglycemia could not have resulted from prolonged starving as initially 
assumed, but must have been due to a more general metabolic defect. As severe 
hypoglycemia can resemble respiratory failure in neonates and is moreover leading 
to brain damage and death (Cohen 1971), it is difficult to establish the cause and 
effect relationship in this case.  
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Expression levels of K32 lamin A/C are differently regulated in muscle versus non-
muscle cells  
In order to examine the effect of LAP2 loss on mutated K32 lamin A/C at cellular 
level we isolated fibroblasts and myoblasts from newborn littermates. Lamin A/C 
protein levels of single mutant LmnaΔK32/ΔK32 and double mutant LmnaΔK32/ΔK32 / 
Lap2α-/- cells were massively reduced to 60% to 90 % of wild-type lamin A/C level, 
whereas other nuclear envelope and/or lamina proteins, such as lamin B1 and 
emerin were not affected (Figure U 4 A left). Thus, LAP2α did not affect the 
expression level of mutant K32 lamin A/C protein.   
As shown previously (Bertrand, Renou et al. 2012) , down-regulation of mutant 
lamin A/C in fibroblasts occurred post-transcriptionally, since lamin A mRNA levels 
were similar in the 4 genotypes (Figure U 4 A right). 
However, and contrary to these published findings, lamin A transcript levels showed 
more variation in myoblasts. In single mutant LmnaΔK32/ΔK32 / Lap2+/+ mice, lamin A 
transcript levels were significantly reduced compared to wild-type (Figure U 4 B 
lower right panel, n=3, p-value < 0,01), while this reduction was less pronounced in 
double mutant LmnaΔK32/ΔK32 / Lap2-/- mice. Thus, it seems likely that fibroblasts 
and myoblasts may regulate lamin A/C expression by different pathways. 
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Figure U 4: Down-regulation of Lamin A ΔK32 protein in primary fibroblasts and myoblasts  
(A and B, left panel) Western Blot analysis of fibroblast (A) and myoblast (B) lysates of 
single mutant Lmna
ΔK32/ΔK32
, double mutant Lmna
ΔK32/ΔK32 
/ Lap2α
-/-
 as well as WT and 
Lap2α
-/-
 control littermates.  
(A and B, right upper panel) Quantitation of protein levels was performed with LICOR 
Odyssee Infrared Imaging System, application software version 2.1.12. Band intensities of 
lamins A and C were combined and normalized to the band intensity of the actin loading 
control. Protein levels of single mutant Lmna
ΔK32/ΔK32 
and double mutant Lmna
ΔK32/ΔK32 
/ 
Lap2α
-/-
 fibroblasts (A) and myoblasts (B) were significantly reduced (n=4, P-value =0,04 
and 0,03, respectively as determined by Student’s t-Test against WT, for B, no statistical 
significance could be determined as n=1).   
(A, lower right panels) mRNA levels of lamin A or emerin are not altered in single and 
double mutant fibroblasts compared to wild type as determined by Student’s t-test: 
Lmna
ΔK32/ΔK32
 , n=4, P-value 0,2 (lamin A) and n=3, P-value 0,4 (emerin); Lap2α
-/-
: n=4, P-
value 0,4 (lamin) and n=2, P-value 0,6 (emerin); Lmna
ΔK32/ΔK32
 / Lap2α
-/-
, n=4,  P-value 0,2 
(lamin) and 0,5 (emerin).  
(B, lower right panels) mRNA levels of lamin A are reduced in Lmna
ΔK32/ΔK32 
myoblasts in 
comparison to wild-type as determined by Student’s t-test:  Lmna
ΔK32/ΔK32
, n=3, P-value < 
0,01, whereas emerin mRNA levels stay unaltered n=3, P-value = 0,56. Lap2α
-/-
, n=3, P-
value 0,62 (lamin) and P-value 0,85 (emerin); Lmna
ΔK32/ΔK32
 / Lap2α
-/-
 , n=3,  P-value 0,15 
(lamin) and 0,6 (emerin).  
mRNA levels of each genotype were normalized to their corresponding WT. Endogenous 
levels of Hprt in quantitative PCR were used for data normalization according to the Pfaffl 
method (Pfaffl 2001).  
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In order to confirm the results obtained at cellular levels, we analyzed different 
tissues derived from single mutant LmnaΔK32/ΔK32, double mutant LmnaΔK32/ΔK32 / 
Lap2α-/- and wild-type as well as Lap2α-/- littermates. While liver and diaphragm 
tissues clearly showed significant reduction of lamin A/C protein levels in 
immunoblots of LmnaΔK32/ΔK32 versus wild-type tissue lysates (Figure U 5), reduction 
of lamin A/C protein levels in spleen were less dramatic. 
 
 
Figure U 5: Western Blot analysis of liver, diaphragm and spleen 
Lysates were prepared of organs of day 16-18 pn WT, Lap2α
-/-
, single mutant Lmna
ΔK32/ΔK32
 
and double mutant Lmna
ΔK32/ΔK32
, Lap2α
-/-
 littermates. 
 
The reduction of ΔK32 lamin A/C protein levels in LmnaΔK32/ΔK32 mice at tissue level 
was confirmed by immunofluorescence analysis in muscle and liver tissues (Figure 
U 6). LAP2α was expressed and localized normally, independent of the Lmna 
genotype. We also observed a difference in localization of lamin A. Whereas wild-
type lamin A/C localized prominently to the nuclear periphery and showed just little 
additional nucleoplasmic staining, ΔK32 lamin A/C was less clearly found at the 
periphery, localized rather diffusely throughout the nucleus (especially in muscle) or 
was found in aggregates (particularly in liver).   
This is consistent with our findings in cultured primary fibroblasts (Figure 2 of 
Submitted Manuscript 1), where mutated lamin A/C localized throughout the 
nucleoplasm, and findings reported earlier by (Bertrand, Renou et al. 2012), who 
  
157 
 
  
described the localization of ΔK32 lamin A/C in nuclear aggregates during 
embryonic development. We concluded that ΔK32 lamin A/C cannot integrate in the 
nuclear lamina and is found in a not yet known assembly state in the nuclear 
interior. 
 
Figure U 6: Lamin A ΔK32 is massively reduced and partly mislocalized in tissues. 
Cryosections (5µm) of gastrocnemius muscle (A) or liver (B) of 16 day old mice were 
stained with a goat-polyclonal Lamin A/C antibody (N18) or rabbit serum against LAP2α 
(Vlcek, Korbei et al. 2002) and a Texas-Red or Alexa 488 conjugated secondary antibody. 
Nuclei were visualized by DAPI staining and sections viewed in a Zeiss Axiovert 200M 
microscope equipped with a Zeiss LSM510META confocal laser-scanning unit, and a Plan-
Apochromat 63x/1.40 Oil DIC MC27 objective (Zeiss). Scale bar denotes 20 µm. 
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In view of the observed differences in transcriptional regulation of lamin A/C in 
LmnaΔK32/ΔK32 fibroblasts versus myoblasts (see Figure U 4 above), we tested lamin 
A mRNA expression in muscle (gastrocnemius and diaphragm) versus non-muscle 
(liver or spleen) tissues. qRT-PCR analysis revealed that lamin A mRNA levels 
were similar in liver and spleen in all genotypes, but significantly reduced in 
diaphragm of  LmnaΔK32/ΔK32 mice (n=7, p-value< 0,01) (Figure U 7). Interestingly in 
LAP2-deficient LmnaΔK32/ΔK32 muscle this phenotype was lost. Emerin mRNA 
transcript levels were not altered in any tested tissue. 
 
Figure U 7: qRT PCR analysis of tissues of Lmna
ΔK32/ΔK32 
mice 
Liver, diaphragm and spleen of day 16-18 pn WT, Lap2α
-/-
, single mutant Lmna
ΔK32/ΔK32
 and 
double mutant Lmna
ΔK32/ΔK32
, Lap2α
-/-
 littermates were used. mRNA levels of each genotype 
were normalized to their corresponding WT. Endogenous levels of Hprt in quantitative PCR 
were used for data normalization according to the Pfaffl method (Pfaffl 2001).  
Diaphragm: mRNA levels of lamin A C are reduced in Lmna
ΔK32/ΔK32 
diaphragm in 
comparison to wild-type as determined by Student’s t-test:  Lmna
ΔK32/ΔK32
, n=7, P-value < 
0,01 (lamin A) and P-value < 0,05  (lamin C), whereas emerin mRNA levels stay unaltered, 
P-value = 0,72; Lap2α
-/-
, n=7, P-values 0,92 (lamin A), 0,81 (lamin C) and 0,28 (emerin); 
Lmna
ΔK32/ΔK32 
/ Lap2α
-/-
 , n=7,  P-values 0,65 (lamin A), 0,87 (lamin C) and 0,94 (emerin). 
Liver: Lmna
ΔK32/ΔK32
, n=3, P-values 0,83 (lamin A)  , 0,56 (lamin C), 0,17 (emerin); Lap2α
-/-
, 
n=3, P-values 0,7 (lamin A), 0,09 (lamin C) and 0,82 (emerin); Lmna
ΔK32/ΔK32 
/ Lap2α
-/-
, n=3,  
P-values 0,17 (lamin A), 0,1 (lamin C) and 0,39 (emerin). 
Spleen: Lmna
ΔK32/ΔK32
, n=6, P-value 0,8 (lamin A) and n=4,  P-value 0,8 (lamin C), n=6, P-
value 0,85 (emerin); Lap2α
-/-
 ,n=6, P-value 0,35 (lamin A) and n=4,  P-value 0,64 (lamin C), 
n=6, P-value 0,85 (emerin); Lmna
ΔK32/ΔK32 
/ Lap2α
-/-
 , n=6, P-value 0,49 (lamin A) and n=4,  
P-value 0,73 (lamin C), n=6, P-value 0,29 (emerin); 
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The observed down-regulation of lamin A mRNA levels in LmnaΔK32/ΔK32 muscle 
tissue and cells (diaphragm and cultured primary myoblasts, see Figure U 4 and 
Figure U 7), but not in non-muscle tissues and cells (liver, fibroblasts), led us to the 
conclusion that mutant K32 lamin A/C expression is regulated differently in muscle 
versus non-muscle tissues and cells. The down-regulation or instability of lamin A 
mRNA specifically in muscle tissue may add to the muscle specific phenotype.  
 
In vitro differentiation of myoblasts 
We have shown that when cultured and in vitro differentiated, primary myoblasts 
obtained from LmnaΔK32/ΔK32 mice are rapidly reduced in cell number. In addition, an 
insufficient formation of myotubes and failure to up-regulate MyHC was observed 
(Figure 7 of Submitted Manuscript 1 and top right panel of Figure U 8).  
Expression of MyoD, the earliest myogenic marker, was downregulated shortly after 
induction of differentiation in all genotypes (Figure U 8). Interestingly, and in line 
with previous findings of our group, myoblasts obtained from Lap2α-/- mice 
expressed MyoD to a slightly higher level as their WT counterparts at day 1, 
indicating a delay of differentiation onset, most likely occurring at the point of 
myoblast cell cycle exit. In the following days, efficient downregulation occurred; 
visual examination as shown in Figure 7 of Submitted Manuscript I could not detect 
any difference or delay in differentiation in Lap2α-/- myoblasts. 
Mef2c, a later marker of ongoing myogenic differentiation (Edmondson, Lyons et al. 
1994), reached its maximum relative expression at day 1-3 in WT myoblasts, in 
contrast to all LmnaΔK32/ΔK32 cells, where the initial peak could be observed between 
days 3  and 6 after serum change. In Lap2α-/- cells, Mef2c has not surpassed its 
peak by day 6 when the time course experiment was stopped for practical reasons. 
 
  
160 
 
  
 
Figure U 8: Expression of myogenic markers in in vitro differentiated myoblasts 
mRNA obtained at different time points (proliferating or 0 days, 1, 3 and 6 days after 
induction of differentiation) from in vitro differentiated primary myoblasts was analyzed by 
qRT-PCR. Levels of each marker at each day were normalized to their corresponding levels 
at day 0 to visualize relative change. As internal control, endogenous levels of Hprt were 
used for data normalization according to the Pfaffl method (Pfaffl 2001).  
 
As for the time course of Crebbp (CBP) expression, an acetylase involved in 
activation of MyoD and acetylation of histones on downstream MyoD transcriptional 
targets (Puri, Iezzi et al. 2001; Magenta, Cenciarelli et al. 2003), expression was –
as expected- highest shortly after the MyoD peak in the WT control, around days 3 
to 6 of differentiation. The premature upregulation of Crebbp in Lap2α-/- cells could 
coincide with that of MyoD. In double mutant Lap2α-/- , LmnaΔK32/ΔK32 myoblasts, 
Crebbp expression stayed almost invariable during the course of differentiation, 
whereas single mutant LmnaΔK32/ΔK32 cells showed an upregulation close to WT 
levels over time. 
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The significance of these findings is not yet known. In a gene expression profiling 
study of 125 human muscle biopsies from 13 diagnostic groups, including EDMD 
patients with LMNA and EMD mutations, Bakay et al. reported induction of Crebbp 
at around day 3.5 in a regeneration setting, and a confirmed upregulation of Crebbp 
and other pRb-MyoD pathway members (p300, CRI-1 and NAP1L1) in EDMD 
muscle tissues  (Bakay, Wang et al. 2006). The authors of this study hypothesized 
this upregulation to be a response to a biochemical block of one or more pathways 
(involving MyoD and pRb) dealing with the withdrawal of proliferating myoblasts to 
differentiated myotubes during muscle regeneration. 
 
In view of these findings I tested relative levels of Crebbp at the start of 
differentiation in the different phenotypes. Figure U 9 shows that indeed Crebbp is 
about 2 fold upregulated in proliferating LmnaΔK32/ΔK32 myoblasts independent of 
LAP2α expression. 
 
 
 
Figure U 9: Expression of Crebbp in proliferating myoblasts 
mRNA obtained from proliferating primary myoblasts was analyzed by qRT-PCR. Levels of 
each genotype were normalized to the corresponding WT level to visualize relative change. 
As internal control, endogenous levels of Hprt were used for data normalization according to 
the Pfaffl method (Pfaffl 2001).  
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Double mutant Lmna+/ΔK32, Lap2α-/- mouse model  
Due to the fact that the homozygous presence of the lamin ΔK32 mutation 
produced a lethal and complex phenotype that was hardly influenced by the 
additional loss of Lap2α, we decided - early in the project - to also create a separate 
double mutant Lap2α-/- mouse model in which animals would be heterozygous for 
the lamin ΔK32 mutation.  
Lmna+/ΔK32 animals (further referred to as Lmna ΔK32 heterozygotes) were used 
beforehand in breeding and proved overtly fertile and healthy over the first 6 
months of life. We reasoned that a longer life span and a less drastic phenotype 
generated by the by the single mutant Lmna allele would allow the more subtle 
Lap2α-/- phenotype to manifest more strongly, and may reveal more conclusive 
results on the potential role of intranuclear lamin complexes in disease 
backgrounds. 
As a first assessment of phenotype, long-time survival was analyzed in littermates 
(male and female) not used for breeding or any other experiment. As presented in 
Figure U 10, Lmna+/ΔK32 animals lived shorter than their wild-type littermates, with a 
majority of the population dying between days 250 and 350. Additional loss of 
Lap2α increased the survival slightly. 50% of the population were dead at day 295 
pn for Lap2α+/+, Lmna+/ΔK32; day 347 pn for Lap2α-/-, Lmna+/ΔK32; and day 420 pn for 
Lap2α+/+, Lmna+/+. 
 
Figure U 10: Survival time of Lmna ΔK32 heterozygous mice  
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The fact that additional loss of Lap2α slightly increased survival of Lmna ΔK32 
heterozygotes mimics the situation of survival in Lmna ΔK32 homozygotes, 
indicating that loss of Lap2α and subsequent abolishment of the intranuclear lamin 
complex might have a beneficial effect in disease backgrounds caused by mutated 
lamins.  
However, and somewhat contradictory to this assumption, previous studies have 
shown that single mutant male Lap2α-/- mice develop cardiac phenotypes in the 
form of impaired heart function and an increased susceptibility of the myocardium to 
fibrosis with advanced age, although deterioration into cardiac failure was 
compensated for by activation of compensatory pathways, including the down-
regulation of beta-adrenergic receptor signaling (Gotic, Leschnik et al. 2010).  
Consequently, also single mutant Lap2α-/- littermates had survival times (n=8 due to 
later inclusion) differing from that of WT littermates and being almost identical to 
that of double mutant Lap2α-/-, Lmna+/ΔK32 mice (50% of the population were dead at 
day 368 pn). We concluded that single mutant Lmna+/ΔK32 mice have problems of 
yet unidentified nature that cause a quite sudden death starting from day 250 pn on, 
and that single mutant Lap2α-/- and double mutant Lap2α-/-, Lmna+/ΔK32 mice share a 
similar Lap2 -/- heart phenotype. 
Additionally, the presence of reported Lap2α-/- specific phenotypes like 
hyperproliferation of progenitor cells in the paw epidermis (causing an increase in 
plantar epidermal thickness) and muscle were analyzed in adult, 8 week old 
animals not suffering from any overt phenotype in the Lmna+/ΔK32 background (see 
Figure U 11). In double mutant Lap2α-/-, Lmna+/ΔK32 mice, the trend towards an 
increased epidermal thickness in the thickest, most mechanically used lower part of 
the paw could be seen, although not statistically confirmed due to the small sample 
size.  
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In muscle (Figure U 11, right), however, no higher percentage of skeletal muscle 
progenitors were observed. This is especially astonishing since in double mutant 
Lap2α-/-, LmnaΔK32/ΔK32, despite their young age, both of these factors were 
significantly increased (see Submitted Manuscript 1). Due to the small sample size 
of n=5 these data have still to be taken with caution.  
 
 
Figure U 11: Epidermal thickness and SMPC cell number of adult Lmna ΔK32 heterozygous 
mice 
Epidermal thickness of the plantar region of the paw (left) and quantitation of skeletal 
muscle progenitor cells (right) in adult Lmna ΔK32 heterozygous mice (white or grey bars 
dependent on Lap2α) in comparison to WT (black bar) littermates. Lmna ΔK32 does not 
have an effect on SMPC cell number. 
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Additional data on the P426L LAP2α mutant 
P426L LAP2α does not increase the nucleoplasmic pool of lamin A/C 
We have shown that LAP2α bearing a disease causing mutation (P426L) was still 
able to interact with lamins in an in vitro binding assay (see Manuscript in 
preparation for submission II, Figure 3) and did not influence lamin A/C expression 
levels. Since loss of LAP2 has previously been found to decrease lamin A and C 
levels in the nuclear interior (Naetar, Korbei et al. 2008), we wanted to quantitatively 
test whether LAP2 P426L may affects localization of lamin A/C.  
Independent of the presence of the P426L mutation in LAP2 , lamin A/C staining 
was always prominent at the nuclear rim and faint throughout the nucleus. For 
statistical analyses, ratios of nucleoplasmic over peripheral mean A-type lamin 
fluorescence intensities were calculated for 50 fibroblasts of patient and control 
fibroblasts. This analysis confirmed that patient versus control cells do not show 
any difference in lamin A/C localization or distribution (n=50, P-value 0,9,  Figure U 
12 lower panel). 
 
 
Figure U 12: LAP2α P426L does not change lamin A/C localization in fibroblasts. 
Primary dermal fibroblasts with indicated genotypes were processed for 
immunofluorescence microscopy using a lamin A/C antibody. Scale bar denotes 10 µm. 
Lower panel: Quantitation of intranuclear lamin staining was done by fluorescence intensity 
measurements along the dashed line shown in the upper image using the profile tool in 
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Zeiss LSM Image Browser. Ratios of nucleoplasmic over peripheral mean A-type lamin 
fluorescence intensity were plotted in the histogram. No difference in ratio could be 
observed between the two phenotypes (n=50, P-value 0,9). 
 
qRT-PCR analysis of LAP2α P426L patient fibroblasts  
In order to characterize the impact of LAP2α P426L on the transcriptional profile of 
patient fibroblasts, qRT-PCR analyses of selected genes was performed. In line 
with the findings above that LAP2α P426L does not influence lamin A/C expression 
or localization, lamin A mRNA levels were identical in patient and control cells. In 
contrast to this, cell cycle regulator genes E2F-1 and RB1 were more than 3 times, 
Crebbp/CBP (a transcriptional coactivator of many transcription factors, (He, Yu et 
al. 2011)),  around 1,5 times upregulated, as shown in Figure U 13.  
 
Figure U 13: qRT-PCR analysis of control and patient (LAP2α P426L) fibroblasts. 
Data are means of technical triplicates (n=1), and are presented as relative expression (WT 
being 1) normalized to HPRT levels according to the Pfaffl method. 
 
 
Further repeats and extension of target genes are paramount to confirm this 
preliminary result, which could point towards a transcriptional upregulation and 
therefore increased presence of cell cycle suppressor genes. This could explain the 
reduced proliferation of LAP2α P426L fibroblasts we previously described (Figure 
5A in Manuscript in preparation for submission II). Alternatively the transcriptional 
upregulation of these genes may be a compensatory response to the reduced 
protein levels of pRb and the impairment of the pRb/E2F1 pathway.   
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Concluding remarks  
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This study aimed at assessing the impact of different disease-causing mutations on 
the formation and regulation of the lamin - LAP2α complexes and at elucidating the 
potential role of intranuclear lamin complexes in muscular dystrophies. 
In the case of ΔK32 lamin A, the mutation has a detrimental effect on lamin 
assembly during tetrameric proto-filament organization as determined by in vitro 
assembly studies in C. elegans (Bank, Ben-Harush et al. 2011). We hypothesized 
that this irregularity would result in a higher presence of A-type lamins in the 
nuclear interior since integration of mutant lamin A/C into the peripheral lamina may 
be defective. Our studies revealed a significantly reduced expression of ΔK32 lamin 
A (down to 10-20% of WT levels) at the protein level (Figure 1 of Manuscript I). At 
the same time, immunofluorescence analysis in tissues and cells of LmnaΔK32/ ΔK32 
mice revealed that the normally prominent lamin A/C staining at the nuclear rim was 
largely lost and that ΔK32 lamin A accumulated in the nuclear interior (Figure 2 of 
Manuscript I and Figure U 6).  
In our working model, we hypothesized that an increased and/or abnormally 
regulated pool of nucleoplasmic lamins may contribute to the disease phenotype of 
LmnaΔK32/ΔK32 mice. We further assumed that nucleoplasmic ΔK32 lamin A may 
require the interaction with LAP2α to stably localize in the nuclear interior, as 
previously shown for WT lamin A/C. As expected, in vitro studies confirmed that the 
ΔK32 lamin A mutant was still capable of binding to LAP2α (Figure 3 of Manuscript 
I). We then reasoned that deletion of LAP2 in LmnaΔK32/ΔK32 mice may decrease 
the nucleoplasmic pool of K32 lamin A mutant and at least partially rescue the 
phenotype of LmnaΔK32/ΔK32 mice.  
The resulting double mutant LmnaΔK32/ΔK32, Lap2-/- mice, however, showed only a 
slightly prolonged, statistically insignificant survival in comparison to the single 
LmnaΔK32/ΔK32 littermates; double mutant mice suffered the same lethal myopathic 
conditions (Figure 6 and S2 of Manuscript I).  
Intriguingly, we found that loss of LAP2 does not affect localization of K32 lamin 
A mutant, like it had previously described for WT lamin A. This finding raised the 
interesting question as to whether nucleoplasmic K32 lamin A mutant alone (in the 
absence of LAP2) may still function in the regulation of tissue progenitor cells, as 
reported for the nucleoplasmic WT lamin A/C-LAP2 complex. To address this 
question we tested whether deletion of LAP2 in LmnaΔK32/ΔK32 mice would affect 
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tissue progenitor cells in the same way as deletion of the protein in WT lamin A 
mice. We observed both the Lap2-/--specific hyperplasia of the paw epidermis and 
the increased pool of SMPCs (Figures 4 and 6 of Manuscript I) in LmnaΔK32/ΔK32 
mice.   
These findings suggest that the function of intranuclear lamin complexes is not 
affected in LmnaΔK32/ΔK32 mice and does thus not contribute to the observed 
pathology. Instead, the K32 mutation may primarily affect peripheral lamins which 
constitute the vast majority of cellular lamins. Thus, the CMD-causing ΔK32 lamin 
A/C mutation may predominantly result in a LAP2-independent defect in the 
assembly and stability of K32 lamin A/C leading to loss of lamin A/C at the 
peripheral lamina. This LAP2α-independent effect is prominent in LmnaΔK32/ΔK32 
mice and may be mostly responsible for the pathologies.  
Another important conclusion that can be drawn from our study is that forcing 
lamins into the nuclear interior is insufficient to generate functional, active 
nucleoplasmic lamin complexes, serving in the regulation of tissue progenitor cells.  
In future studies, it will be indispensable to confirm the interaction of ΔK32 lamin 
and LAP2α in vivo, preferably in both cells and tissues. Also the interaction of ΔK32 
with other lamin interaction partners needs to be evaluated in order to get insights 
into the potential effects of the K32 mutation on LAP2-independent functions of 
lamin A as well as its assembly, stability and turnover. To this date, we neither 
know the exact assembly state of intranuclear lamins nor do we know which 
assembly state is required for efficient interaction with LAP2α and pRb. In this 
respect, the heterozygous Lmna+/ΔK32 mouse model may be an interesting tool and 
may provide valuable insight as to whether mutant lamins form homo- or 
heterodimers with WT lamins and whether one functional copy of Lmna suffices for 
stabilization of the total lamin protein pool.   
Due to the complexity of the double mutant mouse model, a lot of questions 
remained unsolved on organismal level, most importantly the potential 
developmental defect of LmnaΔK32/ΔK32 muscle and heart tissue. Also the reported 
metabolic syndrome and transcriptional alterations of SREBP-1 needs further 
investigation, especially in view of the fact that recent studies demonstrated that 
SREBP-1a and SREBP-1c inhibit myoblast-to-myotube differentiation and induce in 
vivo and in vitro muscle atrophy (Rome, Lecomte et al. 2008; Lecomte, Meugnier et 
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al. 2010), linking the control of muscle mass to metabolic pathways. In addition, it is 
still unclear whether other progenitor cells (in colon etc.) are affected in single lamin 
mutant or double mutant mice.  
In the second part of this thesis, I focused on the novel P426L mutation in LAP2α. 
We report the first LAP2α mutation to segregate with an EDMD phenotype. In view 
of the fact that this mutation was so far only reported in one patient, however, a 
certain caution regarding its causative effect for the disease has to be applied.  
Our studies also confirmed the dystrophic phenotype of patient derived muscle 
tissue expressing the P426L LAP2 mutant. At histological level, we observed the 
presence of variation in muscle fiber size, internalized nuclei and infiltration of 
inflammatory cells and fibrosis (Figure 2 of Manuscript II). On a molecular level, 
LAP2α P426L was neither downregulated, misexpressed or mislocalized, nor did it 
influence the expression, localization or distribution of its binding partner lamin A. 
We also found that the nucleoplasmic pool of lamin A was not altered (Figures 4 in 
Manuscript II and Figure U 12) and the interaction with lamin A was not affected by 
the mutation (Figure 3 in Manuscript II).  
In our working model, we hypothesized that the nucleoplasmic complex of P426L 
LAP2 and lamin A/C may have impaired function in the cell cycle control in tissue 
progenitor cells. This assumption was supported by the fact that the mutation 
mapped to the previously identified pRb interaction domain in LAP2. Therefore, 
we went on to analyze pRb regulation and its potential function in cell cycle control 
in patient fibroblasts. Indeed we found that primary LAP2α P426L patient fibroblasts 
contain less pRb protein than WT control cells (Figure 4 in Manuscript II). We also 
observed an upregulation of pRb mRNA levels and of E2F1 transcripts, another 
component of the cell cycle regulatory pathway (Figure U 13).  
These observations were exciting in view of our previous data showing that LAP2α 
affects pRb repressor activity – promoting cell cycle exit in case of LAP2 
overexpression and causing faster progression in case of LAP2 deficiency 
(Dorner, Vlcek et al. 2006).  
So far, unlike lamin A deficiency, LAP2α loss was not reported to reduce overall 
pRb levels (Johnson, Nitta et al. 2004). The authors of this latter study drew the 
conclusion that A-type lamins may alter phosphorylation of pRb at a specific site, 
  
172 
 
  
leading to pRb instability, since previous studies linked increased pRb 
phosphorylation to its degradation (Wang, Sampath et al. 2001; Higashitsuji, Liu et 
al. 2005).  
In our studies we found that P426L LAP2-expressing patient cells exhibited 
reduced proliferation under standard conditions and delayed cell cycle reentry after 
serum starvation (Figure 5 in Manuscript II), indicating a deregulation of the pRb-
mediated cell cycle pathway, most likely at the G0 to G1/S phase transition. This 
allows the conclusion that expression of mutated P426L LAP2α may impair the 
function of the LAP2α-Lamin A/C complex in pRb mediated cell cycle regulation. In 
view of the reduced level of total pRb one would have expected the opposite effect, 
i.e. a less efficient cell cycle arrest and increased proliferation. This discrepancy 
may be explained by the observation of an increased transcription of the pRb and 
E2F-1, which point towards a compensatory mechanism, causing activation of the 
pRb pathway and in turn more efficient cell cycle exit.   
Although our studies provided the first insight into potential mechanisms involved in 
LAP2-linked EDMD, many new questions were raised and remained unanswered. 
It is recommended that further research be undertaken in the following areas:  
One of the most pressing questions currently is whether P426L LAP2α can still 
interact with pRb. Furthermore, since pRb is a highly stable protein, regulated in 
large part through phosphorylation by cell cycle kinases, the reduced stability 
observed in P426L fibroblasts merits further investigation, especially in regard to 
phosphorylation changes. Intranuclear lamin complexes could play a role in this by 
providing a platform for further interaction partners and pRb regulators, determining 
pRb function that is important for initiation, if not maintenance, of muscle 
differentiation (Huh, Parker et al. 2004).  
For EDMD causing mutations in general, an extensive gene profiling study was 
undertaken (Bakay, Wang et al. 2006). The authors of this study proposed failure of 
key interactions between the nuclear envelope and pRb and MyoD at the point of 
myoblast exit from the cell cycle, leading to poorly coordinated phosphorylation and 
acetylation steps in EDMD.  
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This study depicts an interesting potential link to LAP2α, whose loss caused a delay 
in early differentiation and a hyperproliferation of satellite cells (Gotic, Schmidt et al. 
2010), indicating that there might be a finely tuned balance between the pRb-E2F 
pathway and the pRb-MyoD pathway in myoblast differentiation that is paramount 
for unhindered initialization of the muscle differentiation program. 
In order to assess the effects of the mutation more closely and to substantiate our 
earlier findings, introduction of mutated LAP2α into established cell lines, such as 
the myoblast C2C12 line may be considered, as they may allow more robust 
analyses of in vitro myoblast differentiation.  Some of the tools, such as expression 
vectors are available and listed in Table 9.  
In summary, the present study succeeds in giving a first insight into the role of 
intranuclear lamin complexes in muscular dystrophies by analyzing effects of 
different disease-causing mutations in the constituents of the LAP2α - lamin A 
complex - and provides the basis for further, complimentary research. 
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